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1. Ambulance will be equipped with oxygen, salbutamol and fluids.
2. If profound shock judged immediately life-threatening, give CPR if necessary.
3. If respiratory distress present, elevate head, provided BP adequate to prevent loss of consciousness.
4. Adrenaline maximum effect 10 minutes after IM injection.
Note: Microgram = µg
Consider anaphylaxis if signs of severe allergic-type reaction with respiratory 
difficulty and/or hypotension, especially if skin changes present.
Assess airway, breathing, circulation. 
Stridor, wheeze, respiratory distress or clinical signs of shock
2
For hypotension, lie patient flat with legs raised (unless 
respiratory distress increased)3
Inhaled ß agonist if 
brochospasm present 1
Child: Dose by weight (0.01ml/kg) or age
 <6 months  0.05 ml (50µg)
 7-18 months  0.1 ml (100µg)
 18-48 months  0.15 ml (150µg)
 4-7 years  0.2 ml (200µg)
 8-10 years  0.3 ml (300µg)
 11-12 years  0.4 ml (400µg)
 >12 years  0.5 ml (500µg)
 Adult:   0.5 ml (500µg)5
Those >100 kg can be given 1 mg IM (use green needle, 37 mm)
Repeat every 5-10 mins, up to 3 doses 
Remember urgency of hospital transfer 
Chlorpheniramine 
<1 year  0.25 mgs/kg 
Get help 
Call ambulance.1
Adrenaline (epinephrine) 1:1000 (1 mg (1000 microgram (µg)/ml)) IM4
<1 year  0.25 m /kg IM
1-5 years  2.5-5 mg IM
6-12 years  5-10 mg IM
>12 years and adult 10-20 mg IM
Anaphylactic Reactions: Treatment in the Community 
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Preface & Anaphylaxis
1.  If profound shock judged immediately life-threatening, give CPR/ALS if necessary. Consider slow IV 
 adrenaline (epinephrine) 1:10,000 solution if severe hypotension. Dose 10 microgram/kg., 
 max. 500 micrograms, over several minutes. This is hazardous and is recommended only for hospital 
 setting. Note the different strength for IV use.
2.  An inhaled beta2-agonist such as salbutamol may be used if bronchospasm is severe and does not 
 respond rapidly to other treatment.
3.  Adrenaline maximum effect 10 minutes after IM injection.
4.  
Assess airway, breathing, circulation
Get help 
Oxygen when available 
Stridor, wheeze, respiratory distress or 
clinical signs of shock1
Repeat in 5-10 mins if no improvement 
Max. 3 doses 
IN  ADDITION
For severe or recurrent reactions and patients with 
asthma give Hydrocortisone (4mgs/kg) 
<1 year    25 mg IM or slow IV 
1-5 years:    50 mg IM or slow IV  
6-12 years:  100 mg IM or slow IV 
>12 years: 100-500 mg IM or slowIV
If clinical manifestations of shock 
do not respond to drug treatment 
give 20 ml/kg IV fluid 
e.g. Normal saline.
Inhaled ß agonist if 
bronchospasm2
Consider anaphylaxis if signs of severe allergic-type reaction with respiratory difficulty 
and/or hypotension, especially if skin changes present..
      Adrenaline (epinephrine) 1:1000 (1 mg (1000µg)/ml)) IM3
Child: Dose by weight (0.01 ml/kg) or age
 <6 months 0.05 ml (50µg)
 7-18 months 0.1 ml (100µg)
 18-48 months 0.15 ml (150µg)
 4-7 years 0.2 ml (200µg)
 8-10 years 0.3 ml (300µg)
 11-12 years 0.4 ml (400µg)
 >12 years 0.5 ml (500µg)
 Adult:  0.5 ml (500µg)4
Those    100 kgs can be given 1 mg IM (use green needle, 37 mm)
  Chlorpheniramine
<1 year 0.25 mg/kg IM
1-5 years 2.5-5 mg IM
6-12 years 5-10 mg IM
>12 years and adult  10-20 mg IM
If a patient on beta-blockers has not improved after 2-3 doses of Adrenaline, consider giving 
Glucagon, 2-3 micrograms/kg (max.1-2mgs) IV over 5 minutes, IV salbutamol, and/or IV atropine.
Anaphylactic Reactions: Treatment Algorithm for 
First Medical Responders 
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Anaphylaxis
Anaphylaxis is a potentially life-threatening allergic reaction to foreign 
protein antigens such as food and bee stings. It is a very rare complication 
of immunisation (0.4-2 per million doses). Most episodes begin within 30 
minutes of vaccination. Shorter intervals to onset generally indicate more 
severe reactions. However, due to the unpredictable nature of anaphylactic 
reactions, it is not possible to define a particular time period over which 
all individuals should be observed following immunisation. When possible, 
patients should remain in the vicinity of the place of vaccination for up to 
15 minutes, as typically onset of anaphylaxis occurs within minutes.
Anaphylaxis must be distinguished from fainting (vasovagal episode), 
anxiety and breath-holding episodes, which are more common.
Table 1 shows features which may assist in differentiating fainting from 
anaphylaxis. Those experiencing an anxiety spell may appear fearful, pale 
and sweaty, and complain of light-headedness, dizziness and numbness or 
tingling of their hands or feet. Hyperventilation is usually present. During a 
breath-holding episode the child is suddenly silent but obviously agitated. 
Facial flushing or pallor can occur as breath-holding continues. Some 
episodes end with a resumption of crying, but others can be followed by a 
brief period of unconsciousness during which breathing resumes.
Swelling and an urticarial rash may appear at the injection site but are not 
always caused by an allergic reaction and may disappear without additional 
treatment. However, if any other symptoms occur, even if considered mild 
(sneezing, nasal congestion, coughing, etc.), Adrenaline should be given. 
There is little risk with the unnecessary use of Adrenaline, whereas delay 
in its administration in anaphylaxis may result in severe anaphylaxis and 
death. The features of severe disease include obstructive swelling of the 
upper airway, marked bronchospasm and hypotension.
A number of drugs may interfere either with the action of Adrenaline 
(Epinephrine) or with the compensatory mechanisms, which occur in 
anaphylaxis. These drugs include beta-blockers, tricyclic antidepressants, 
ACE inhibitors, and Angiotensin 2 receptor blockers. As anaphylaxis is a 
life-threatening event, the benefits of giving the recommended doses of 
Adrenaline outweigh potential risks. Adrenaline doses should be titrated 
according to their effect. If a patient on beta-blockers has not improved 
after 2-3 doses of Adrenaline, consider giving Glucagon, 2-3 micrograms/
kg (max. 1-2mgs) IV over 5 minutes, IV salbutamol, and/or IV atropine. 
These should only be used in hospital, preferably under the supervision of 
an intensivist.
P
reface &
A
nap
hylaxis
Preface & Anaphylaxis
V
Table 1 Vasovagal episode v. Anaphylaxis
Vasovagal 
episode
Anaphylaxis
Onset Immediate Usually within 5 
mins, but can occur 
within 1-2 hours
Symptoms/
signs
Skin Generalised pallor; 
cold, clammy skin
Itch, generalised 
erythema, urticaria 
or angio-oedema 
(localised swelling 
of face, mouth, 
etc.)
Respiratory Normal or shallow, 
not laboured
Cough, wheez e, 
stridor, tachypnoea, 
recession, cyanosis
Cardiovascular Bradycardia but 
strong carotid pulse
Hypotension 
corrected when lying 
down
Tachycardia, weak/
absent pulse
Sustained 
hypotension unless 
specific treatment
Neurological Light-headed
Possible loss of 
consciousness
Improves on lying 
down
Severe anxiety and 
distress
Loss of 
consciousness
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Preface
This revised report on immunisation guidelines for Ireland has been 
prepared with the assistance of an active Committee from associated 
disciplines in Paediatrics, Infectious Diseases, General Practice, Public Health, 
Microbiology, Occupational Health, Travel Medicine and the Irish Medicines 
Board. The report itself continues to be simple and concise in design and 
of course does not claim to contain all information on any pharmacological 
material. 
The report contains a considerable revision of chapters, reflecting updated 
epidemiological and vaccine information, and providing the current 
information and guidelines concerning immunisation. Since the last 
guidelines were issued in 2002 there has been an improvement in the uptake 
of childhood vaccines at 24 months, from 80% to 90% in 2006. There was 
a similar improvement for MMR vaccine uptake, from 70% to 85% over the 
same period. The health services have also undergone major reform and 
we have a new National Immunisation Office. There are exciting vaccine 
developments from the pharmaceutical industry and our guidelines will 
obviously change to reflect this.  
As Chairman of the Committee I sincerely thank all those who spent so much 
time and put so much effort into this document. I also wish to thank those 
who participated in the concerted process, in particular the Chairpersons of 
each section, Dr Karina Butler, Dr Mary Cafferkey, Dr Jeff Connell, Dr Kevin 
Connolly, Dr Brenda Corcoran, Dr E. Gallagher and Dr Darina O’Flanagan. 
These Committees carried out their tasks with much enthusiasm and 
efficiency. It was indeed a pleasure to work with them. In particular, we must 
thank our Committee Medical Secretary, Dr Helena Murray, and past medical 
secretaries, Dr Denise McCarthy, Dr Patricia McDonald and Dr Emer Feely 
and also Ms Karen Doyle from the College. We would also like to thank Dr 
Paul Kavanagh and Ms Stephanie Mulcair who proof-read the document for 
their patience and time in delivering the final manuscript.  
I would like to thank our many colleagues who made presentations to 
the committee, particularly Dr Michael Barry for his contributions to the 
economic evaluation of new vaccine programmes.
This document is not designed to be restricted to the medical profession 
alone and we hope it would be of interest to a broad section of our 
community involved in the medical, paramedical and tourist industry.  
Finally, I would wish to thank the Department of Health and Children for their 
valuable input and the Health Protection Surveillance Centre, Health Service 
Executive for their financial support in producing this report.
Brian Keogh, MD
Past President, RCPI
Chairman, NIAC
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The 2008 Edition
Principal changes to this document 
This publication continues to be A5 size but has changed to book format 
in the 2008 edition as this publication is larger. There is a folder in the 
back cover to hold additional information.
The year in which each of the principal childhood vaccines was 
introduced to Ireland is indicated at the start of the relevant chapter.
Changes to recommended immunisation schedule
Since the publication of the last version of these guidelines in 2002 there 
have been a number of changes to the recommended immunisation 
schedule:
•  Hepatitis B vaccine is added to the routine childhood immunisation 
schedule (Hep B).
•  Pneumococcal conjugate vaccine is added to the routine childhood 
immunisation schedule (PCV).
•  Low-dose acellular pertussis vaccine is added to the current tetanus and 
low-dose diphtheria at 11-14 years (Tdap).
•  A booster dose of Haemophilus influenzae type B (Hib) is to be given at 
13 months, rather than at 12 months as at present.
•  The Meningococcal C conjugate (MenC) vaccine is to be given at 4, 6 
and 13 months of age.
•  The indications for varicella vaccination have been updated for children 
and adults in the specified risk groups. All women of child-bearing 
age without a history of varicella infection should have their immunity 
checked. Women with negative serology should be vaccinated if no 
contraindications exist.
•  NIAC recommends annual influenza vaccination for people aged 50 
years or older. This may be implemented on a phased basis.
In addition, a catch-up schedule is set out for children aged 4 months to 
10 years and for children aged 10 to 18 years.
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Other chapters have been updated and expanded, particularly in relation 
to occupational risk from vaccine preventable disease. A new chapter on 
rabies was added because of occupational risk to this disease in Ireland.  
New sections
This document has a new chapter on
•  Rabies
Expanded sections
The following chapters have been expanded:
•  Chapter 6, Hepatitis B, to reflect new recommendations for inclusion in 
primary immunisation schedule
•  Chapter 12, Pneumococcal infection, to reflect new recommendations 
for inclusion in primary immunisation schedule
•  Chapter 17, Varicella-Zoster, to include VZIG algorithms for neonates, 
pregnant women and immunosuppressed people who are exposed 
to chickenpox. Recommendations about active immunisation with 
varicella vaccine are given with an algorithm outlining the procedure for 
vaccinating health-care workers.
Amended sections
The following amendments have been made:
•  Chapter 5, Hepatitis A, has been amended to reflect recently published 
information on the effectiveness of post-exposure prophylaxis with HAV 
vaccine compared to Human Normal Immunoglobulin (HNIG). 
•  Chapter 10, Mumps, has been amended to include more information 
on mumps illness and all the information on MMR vaccine as in Chapter 
8, Measles.
•  Chapter 11, Pertussis, has been amended in relation to changes to the 
guidance on contraindications and precautions for pertussis vaccine to 
reflect change in primary immunisation schedule.
•  Chapter 14, Rubella, has been amended to include more information 
on congenital rubella syndrome and all the information on MMR 
vaccine as in Chapter 8, Measles.
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•  Chapter 15, Tetanus, has been amended in relation to guidance for 
tetanus prophylaxis for clean and contaminated wounds.
•  Chapter 16, Tuberculosis, has been amended to provide clearer 
guidance on indications for BCG vaccine other than newborn babies.
Future Developments
As we publish the 2008 edition of the Immunisation Guidelines for 
Ireland we are aware of developments for new vaccines on the horizon.  
This reflects the rapidly expanding environment in the immunisation field. 
Updates and new recommendations will be published on the RCPI, NIO, 
HPSC and the Department of Health and Children websites along with 
the electronic version of these guidelines.
 
An example of this is the planned introduction of the human 
papillomavirus vaccine (HPV). Once the details of the HPV vaccination 
programme are finalised a chapter on HPV vaccine will be made 
available online.
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This chapter provides information on the following:
• Vaccine uptake and surveillance of vaccine-preventable disease
• Reporting of adverse reactions and quality defects
 n Terms used for frequency of adverse events
• Procurement and distribution of vaccine within the cold chain
• Definitions
• Abbreviations
• Useful websites
• Bibliography
Vaccine uptake and surveillance of vaccine-preventable 
disease
The Health Protection Surveillance Centre (HPSC), Middle Gardiner 
Street, Dublin 1 (www.hpsc.ie) is responsible for the surveillance of 
communicable diseases, examining the incidences of vaccine-preventable 
illness and examining trends in the uptake of vaccines (see figure 1.1).
The HPSC receives immunisation uptake data from each Health Service 
Executive (HSE) area and reports on uptake rates nationally, by HSE 
area and by Local Health Office area. These reports are published each 
quarter on its website www.ndsc.ie/hpsc/A-Z/VaccinePreventable/
Vaccination/.
Irish legislation specifies the infectious diseases that medical practitioners 
are required to notify to a Medical Officer of Health as soon as they 
become aware of or suspect that a patient is suffering from or is the 
carrier of a notifiable infectious disease. There is a similar requirement for 
a clinical director of a diagnostic laboratory to notify a Medical Officer 
of Health as soon as an infectious disease is identified in that laboratory. 
01
General Information
The HPSC collates and analyses these notifications weekly and also 
produces quarterly and annual reports.  
The HPSC particularly monitors the notifications of vaccine-preventable 
diseases and seeks to determine if vaccine failure has occurred. A good 
example of how this works was the detection of an increase in the number 
of Hib cases in fully vaccinated children in 2005. This led to concerns that 
a 3-dose infant schedule was no longer sufficient to maintain long-term 
protection. A similar situation had emerged in the UK a number of years 
previously. 
In response to this emerging trend in Ireland, and coupled with the 
scientific evidence that Hib vaccine efficacy is higher in those immunised 
at older than 12 months of age than in children vaccinated routinely 
as infants, the National Immunisation Advisory Committee (NIAC) 
recommended that a catch-up Hib dose be offered to children under 4 
years of age, in order to further protect this age-group from Hib disease.
Reporting of adverse reactions and quality defects
All suspected adverse reactions should be reported to the Irish Medicines 
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Figure 1.1 Quarterly immunisation uptake rates (%) in Ireland at 24 
months. Source: HPSC (1999-2007/Q2)
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Note: T3 and P3 uptake rates similar to D3; therefore only D3 plotted
Board (IMB), Kevin O’Malley House, Earlsfort Terrace, Dublin 2, using 
the Yellow Card System. This is a ‘Freepost’ system and cards are 
available from the Irish Medicines Board at the above address, or may 
be downloaded from their website, www.imb.ie. Reports should be as 
detailed as possible and include the batch number of the vaccine.  
Terms used for frequency of adverse events
Description   Detectable range
Very common >1/10
Common >1/100 and <1/10
Uncommon >1/1,000 and <1/100
Rare >1/10,000 and <1/1,000
Very rare <1/10,000
Quality defects are also monitored by the Irish Medicines Board (IMB), 
using a similar ‘Freepost’ Green Card System. Quality defects include 
missing labels/label texts, container defects, altered product appearance, 
particles in product etc. Full details of the defect and the batch number 
should be given on the Green Card. Cards are available from the Irish 
Medicines Board at the above address.
Procurement and distribution of vaccine within the cold 
chain
The National Immunisation Office (NIO) oversees the day-to-day 
implementation of the national immunisation programme by the Health 
Service Executive. The NIO is responsible for the procurement and 
distribution of vaccine within the cold chain. It also provides up-to-date 
information leaflets for parents and health-care professionals. It hosts a 
website www.immunisation.ie and is developing a national IT register for 
immunisations.
Cold chain management of vaccines
All vaccines are sensitive to heat, cold and light and must be kept at 
temperatures between 2-8ºC. Leaving vaccines outside this temperature 
range can result in the loss of vaccine potency.
The ‘Cold Chain’ is the system of correct  storage, transport and 
maintenance of vaccines to ensure that they are protected from 
inappropriate temperatures and light from the time of manufacture to 
administration.
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All routine vaccines are stored and delivered under temperature-
controlled conditions by the HSE National Cold Chain Delivery Service to 
General Practitioner (GP) surgeries, hospitals and Local Health Offices. 
Vaccine ordering and usage
• There should be a designated person in charge of the ordering, 
receipt and storage of vaccines. 
• The designated person should order sufficient vaccines from the 
National Cold Chain Delivery Service on a monthly basis. In an 
emergency additional supplies can be delivered.
• When vaccines are delivered they should be checked against the 
order for any damage or discrepancy. 
• Vaccines must placed in the refrigerator immediately and not left 
at room temperature.  
• Vaccines stored outside temperature-controlled conditions 
should not be used.
Vaccine storage
• Vaccine refrigerators are recommended for the storage of 
vaccines. Manufacturers’ recommendations on storage should be 
observed. 
• Vaccines should be stored in the pharmaceutical refrigerator 
which should not be overfilled, to allow air circulate around 
the packages. They should not be stored on the shelves or 
storage compartments of the door of non-pharmaceutical 
refrigerators.
• Vaccines must be stored in their original packaging, which should 
not touch the sides or back of the refrigerator.
• Door-opening should be kept to a minimum.
• Vaccines with the shortest expiry date should be used first. 
Vaccine stocks should be rotated so that vaccines with shorter 
expiry dates are at the front of the refrigerator.
• A maximum/minimum thermometer should be used in 
refrigerators where vaccines are stored, irrespective of whether 
the refrigerator incorporates a temperature indicator dial. 
The maximum and minimum temperatures reached should be 
monitored and recorded daily. Temperature record logs are best 
kept close to the refrigerator for ease of reference. 
• If temperatures outside the permitted range are recorded, 
or if there is a breakdown in supply or equipment, the Chief 
Pharmacist of the National Immunisation Office or the Senior 
Medical Officer should be contacted for further advice.
• The vaccine refrigerator should be defrosted regularly as 
ice builds up, and cleaned with a 1:10 solution of sodium 
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hypochlorite. Vaccines should be stored in another refrigerator or 
cool box while doing this.
• Records should be kept of refrigerator maintenance and 
servicing.
• Care should be taken to ensure that the electricity supply to the 
vaccine storage refrigerator cannot accidentally be interrupted. 
This can be achieved by using a switchless socket or by placing 
cautionary notices on plugs and sockets.
• Food and drink must not be stored in refrigerators used for 
vaccines. 
Disposal of vaccines
• Reconstituted vaccine must be used within the recommended 
period, varying from 1 to 4 hours, according to the 
manufacturer's instructions. 
• Single-dose containers are preferable; once opened, multidose 
vials must not be kept after the end of the session. 
• Unused vaccine, spent or partly spent vials should be disposed of 
safely by incineration. 
• Contaminated waste and spillage should be dealt with by heat 
sterilisation, incineration or chemical disinfection as appropriate.
• Expired vaccines must not be used and should be returned to 
the National Cold Chain Delivery Service company at the next 
delivery.
Needles and syringes
• Needles and syringes must be securely stored and delivery and 
distribution recorded. 
• Needles and syringes should be disposed of in sharps bins. 
• Sharps bins must not be left unattended in schools. 
• Sharps bins should be collected regularly and be disposed of 
safely.
Definitions
Adverse reaction is an event that is harmful and unintended and that 
occurs following administration of medicinal products (substances 
normally used in humans for the prophylaxis, diagnosis or treatment of 
disease or for the modification of physiological function). 
Antitoxin is a solution of antibodies derived from the serum of animals 
immunised with specific antigens (e.g. diphtheria antitoxin) used to 
achieve passive immunity or for treatment.
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Basic reproductive number (R0) is the average number of secondary 
infections resulting from each index case in a fully susceptible population. 
It is a measure of the transmissibility of an infection.
Immunisation denotes the process of artificially inducing or providing 
immunity. This may be either active or passive.
Active immunisation is the administration of a vaccine or toxoid in 
order to stimulate production of an immune response.
Passive immunisation is the administration of preformed antibodies 
(such as HNIG, specific antibody preparation and antitoxins) in order 
to provide temporary immunity. 
Immunoglobulin
Human immunoglobulin is that fraction of blood plasma that contains 
antibodies, notably those against infectious agents. Preparations of 
immunoglobulin belong to two main categories:
• Human Normal Immunoglobulin (HNIG).
• Human Specific Immunoglobulin/Hyperimmune Globulin.
Toxoid is a modified bacterial toxin that has been rendered non-toxic but 
has the ability to stimulate the formation of antitoxin.
Vaccine is a suspension of live attenuated or inactivated micro-organisms 
or fractions thereof, administered to induce immunity and thereby 
prevent infectious disease.
Inactivated vaccine is a vaccine that contains killed bacteria or 
viruses. The response may be weaker than for a live vaccine and so 
repeated doses are often needed.
Live attenuated vaccine is a vaccine that contains a weakened strain 
of live bacteria or viruses that replicate in the body and induce a 
longer-lasting immunity than inactivated vaccines.
Vaccination is the term used to refer to the administration of any vaccine 
or toxoid. 
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Abbreviations
AIDS:  Acquired Immunodeficiency Syndrome
ALS: Advanced Life Support
Anti-HBc: Antibody to Hepatitis B Core Antigen
Anti-HBs: Antibody to Hepatitis B Surface Antigen
Anti-HCV: Hepatitis C antibody
BCG: Bacille Calmette Guerin vaccine
CNS:  Central Nervous System
CPR: Cardiopulmonary Resuscitation
DTaP: Adsorbed Diphtheria, Tetanus and acellular Pertussis 
vaccine
HAV: Hepatitis A Virus
HBV: Hepatitis B Virus
HBIG: Specific Hepatitis B Immunoglobulin/Hyper-
immunoglobulin
HBeAg:   Hepatitis B e Antigen
HBsAg:  Hepatitis B Surface Antigen
HCW: Health-Care Worker
HDCV: Human Diploid Cell Rabies Vaccine
Hib: Haemophilus influenzae type b
HIV: Human Immunodeficiency Virus
HNIG: Human Normal Immunoglobulin
HRIG: Human Rabies Immunoglobulin
HPSC: Health Protection Surveillance Centre
HPV: Human Papilloma Virus
HSE: Health Service Executive
IBTS: Irish Blood Transfusion Service
IM: Intramuscular
IPD: Invasive Pneumococcal Disease
IPV: Inactivated Polio Virus vaccine
IU: International Units
MDR-TB: Multi-Drug Resistant Tuberculosis
MenC Meningococcal C 
MMR: Measles, Mumps and Rubella
NIAC: National Immunisation Advisory Committee
NIO: National Immunisation Office
NVRL: National Virus Reference Laboratory
OPV: Oral Polio Vaccine
PCV: Pneumococcal Conjugate Vaccine
PPD: Purified Protein Derivative      
PPV: Pneumococcal Polysaccharide Vaccine
RCPI: Royal College of Physicians of Ireland
ROI: Republic of Ireland
SC:  Subcutaneous
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SSPE: Subacute Sclerosing Panencephalitis
Td: Tetanus toxoid, low-dose diphtheria toxoid
Tdap: Tetanus, low-dose diphtheria and low-dose acellular 
pertussis vaccine
TIG: Tetanus Immunoglobulin
TST: Tuberculin Skin Test
Tu: Tuberculin
VZ: Varicella-Zoster
VZIG: Varicella-Zoster Immunoglobulin
VZV: Varicella Zoster Virus
WHO: World Health Organization
XDR-TB: Extensively Drug-Resistant Tuberculosis
This document is available on the RCPI, NIO, HPSC and Department of 
Health and Children websites in pdf format. The electronic version of the 
document will be regularly updated as changes are introduced to our 
immunisation schedule. 
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Useful websites
For further information and debate on immunisation, the following 
websites may be useful.
American Academy of Pediatrics
www.aap.org/new/immpublic.htm 
American Medical Association
www.ama-assn.org/medsci/immunize/vacautism.htm 
Australian Skeptics Dr Steve Basser: Anti-immunisation scare: The 
inconvenient facts  
skeptics.com.au/journal/anti-immune.htm 
Centers for Disease Control and Prevention (USA)
www.cdc.gov 
Department of Health and Children
www.dohc.ie/ 
Health Protection Surveillance Centre
www.hpsc.ie 
Immunisation Action Coalition
immunize.org 
National Alliance for Autism Research
www.naar.org/naar.asp 
National Immunisation Office
www.immunisation.ie 
National Institutes of Health
www.nih.gov 
National Network for Immunization Information
www.immunizationinfo.org 
Royal College of Physicians of Ireland
www.rcpi.ie 
United Kingdom, Medical Research Council
www.mrc.ac.uk/OurResearch/ResearchFocus/index.htm
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This chapter provides information on the following:
• Immunisation schedules
n Routine childhood immunisation schedule
n Interrupted immunisation courses
n Late primary immunisation
n Catch-up schedule for children aged 4 months to 10 years 
n Catch-up schedule for children aged 10 to 18 years
n Vaccination before minimum recommended interval
n Vaccination after the expiry date
n Immunisation of late entrants to Irish health-care system
• Conditions that are NOT contraindications to immunisation
• Contraindications and precautions to vaccines
• Immunisation of specific groups
n Adults
n Intramuscular vaccination in those with bleeding disorder 
or on anticoagulants
n Live vaccines and pregnancy
n Immunocompromised children
• Congenital (primary) immune deficiencies
• Severe immunodeficiency
• Moderate or non-specific immunodeficiency
• Asplenia and hyposplenism
•  Intensive chemotherapy and bone marrow transplant 
recipients
• Solid organ transplantation
• Standard cancer chemotherapy
• Corticosteroid therapy
• HIV Infection
n Vaccination of preterm infants
• Immunoglobulin
• Human Normal Immunoglobulin (HNIG)
02
General Immunisation 
Procedures
• Specific immunoglobulins
•  Live viral vaccines following immunoglobulin 
administration
• General guidelines for spacing the administration of killed and 
live antigens
• How to administer intramuscular (IM) injections
• How to administer subcutaneous (SC) injections
• How to administer intradermal injections
• How to hold a child during immunisation
• Bibliography
Adrenaline should be available at all times before 
giving vaccines.
 
Immunisation Schedules
Routine childhood immunisation schedule
Table 2.1 Routine childhood immunisation schedule
Age Immunisations Comment
Birth BCG 1 injection
2 months DTaP/Hib/IPV/Hep B + PCV 2 injections
4 months DTaP/Hib/IPV/Hep B + MenC 2 injections
6 months DTaP/Hib/IPV/Hep B + PCV + 
MenC
3 injections
12 months MMR + PCV 2 injections
13 months MenC + Hib 2 injections1
4 to 5 years DTaP/IPV + MMR 2 injections
11 to 14 years Tdap + BCG2 1 injection
1. If a combined MenC/Hib vaccine is available only one injection is required.
2   Only for those who are known to be tuberculin negative and have no previous BCG   
(see Chapter 16).
BCG  Bacille Calmette Guerin vaccine
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
Hib  Haemophilius influenzae b vaccine
IPV  Inactivated Polio Virus vaccine
Hep B  Hepatitis B vaccine
PCV  Pneumococcal Conjugate Vaccine
MenC  Meningococcal C vaccine
MMR  Measles, Mumps and Rubella vaccine
Tdap   Tetanus, low-dose diphtheria and low-dose acellular pertussis vaccine
Available evidence suggests that simultaneous administration of multiple 
Chapter 2  General Immunisation Procedures
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vaccines as in the Irish schedule is not only safe and effective, but can 
potentially increase uptake rates by up to 17%.
Interrupted immunisation courses
If an immunisation course is interrupted, it should be resumed as soon 
as possible. It is not necessary to repeat the course, regardless of the 
time interval from the previous incomplete course. With Hib and MenC 
vaccine, the course should be completed with the same brand of vaccine 
if possible. Some children for a variety of reasons may not have been 
immunised, or their immunisation history may be unknown or unreliable. 
Advice regarding vaccination of these children is provided in this chapter.
Late primary immunisation
Children who are not immunised or who are incompletely immunised 
and are older than the recommended age range should be immunised 
as soon as possible. Injections of vaccines that are not already combined 
by the manufacturer must be given in separate sites. It is currently 
recommended that PCV is not given at the same time as Hib/MenC 
booster. This is a precautionary measure until more data accumulates 
as to whether these two particular conjugate vaccines can be given at 
the same time without any interference between them. The number of 
Hib, PCV and MenC doses required depends on the child’s age. Hib 
and DTaP are not recommended over 10 years of age and MenC is not 
recommended over 22 years of age.
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Catch-up schedule for children aged 4 months to<10 years
Table 2.2 Catch-up schedule for children aged 4 months to<10 years
Minimum interval between doses
Vaccine Dose 1 to 
Dose 2
Dose 2 to 
Dose 3
Dose 3 to 
Dose 4
BCG 1 dose only
Diphtheria (D)
Tetanus (T)
Pertussis (aP) 
IPV 
Hib1
Hepatitis B
(as a 6 in 1 vaccine)
2 months 2 months 
(and 4 months after 
first dose)
DTaP/IPV as a 4 in 1 
vaccine at least 6 months 
and preferably 3 years 
after primary course 
Men C 1 month, or 
at the age 
recommended 
in the routine 
childhood 
immunisation 
schedule (Table 
2.1) if this is later.
No further dose 
if any dose 
given aged ≥12 
months.
2 months, or at the 
age recommended 
in the routine 
childhood 
immunisation 
schedule (Table 2.1) 
if this is later.
No further dose 
if any dose given 
aged ≥12 months
MMR 2
(not recommended 
if <12 months unless 
at risk; see Ch.8)
1 month, or 
at the age 
recommended 
in the routine 
childhood 
immunisation 
schedule (Table 
2.1) if this is later.
PCV
(not recommended 
if > 2 years unless at 
risk; see Ch. 12)3
1 month, or 
at the age 
recommended 
in the routine 
childhood 
immunisation 
schedule (Table 
2.1) if this is later.
No further dose 
if any dose 
given aged ≥12 
months
2 months, or at the 
age recommended 
in the routine 
childhood 
immunisation 
schedule (Table 2.1) 
if this is later.
No further dose 
if any dose given 
aged ≥12 months
1.  One dose of single Hib vaccine may be given to children up to 10 years of age if this is 
the only vaccine they require
2. The second dose of MMR is recommended routinely at 4-5 years but may be 
administered earlier.        
Chapter 2  General Immunisation Procedures
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Table 2.2 changed August 2010
Children vaccinated before their first birthday in the case of an outbreak should have a 
repeat MMR vaccination at 12 months of age, at least one month after the first vaccine 
with a further dose at 4-5 years of age. If a child aged <18 months receives a second 
MMR vaccine within 3 months  of the first MMR, a third MMR should be given at 4-5 
years of age.
3. PCV vaccine should be given to at risk children aged 24-59 months. For schedule for 
children at risk see detailed recommendation in Chapter 12.
Note A:  This schedule may be altered in certain circumstances, e.g. during a measles 
outbreak.
Note B:    For catch-up schedule the intervals between doses may be less than those 
 routinely recommended in order to complete the immunisation schedule rapidly.
Catch up schedule for children aged 10 years and older and adults
Table 2.3 Catch up schedule for children aged 10 years and older   
and adults
Minimum interval between doses
Vaccine Dose 1 to Dose 
2
Dose 2 to 
Dose 3
Dose 3 to 
Dose 4
Dose 4 to 
Dose 5 
BCG 1 dose only (up 
to 15 years of 
age  if in low 
risk group or 35 
years of age if 
in specified high 
risk group1) 
Tdap/IPV 1 month 1 month 5 years after 
primary course 
Tdap 10 years 
later
Men C 1 dose only (up 
to 23 years of 
age)
MMR 1 month 
1.  See Chapter 16 for specified high risk groups
Vaccination before minimum recommended interval
If a vaccine is given before the minimum interval recommended in Table 
2.3, it should not be considered as part of the primary series as there may 
be a sub-optimal immune response. If this happens, disregard the dose 
and give another dose at the recommended time, at least 1 month after 
the disregarded dose. However, inadvertently giving a dose less than 
4 days before the minimum recommended interval is unlikely to have a 
significantly adverse effect on the immune response to that dose. 
Chapter 2  General Immunisation Procedures
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Table 2.3 changed August 2010
Vaccination after the expiry date
If a vaccine is given after the last day of expiry month there may be 
a reduced immune response and that dose should be disregarded. 
A further dose should be given 1 month later. There is an increased 
likelihood of a local reaction following the repeat dose with diphtheria- 
and tetanus-containing vaccines, and parents/guardians should be 
informed of this.
Immunisation of late entrants to Irish health-care system
Immunisation records of children adopted from some low-income 
countries may not be accurate, and should be accepted with caution. 
Lack of protection against vaccine-preventable diseases may be due 
not only to erroneous records, but also to improper storage or handling 
of vaccines, or to immune defects such as those that can occur during 
severe malnutrition.
Decisions regarding whether to give or withhold vaccines are based on 
a number of factors, including the slight risk of over-vaccinating children. 
The following guidelines are based on the best available evidence:
1. BCG
BCG should be given to low risk children up to 15 years of age and 
specified high risk children and adults up to 35 years of age, who do not 
have documented evidence of BCG vaccination and who do not have 
a characteristic BCG scar and who are tuberculin (or interferon-gamma) 
negative (see Chapter 16 for indications re tuberculin test and specified 
risk groups).
2. Diphtheria, Tetanus, Pertussis 
More than 4 -5 doses of vaccines containing diphtheria, tetanus or 
pertussis antigens may very occasionally result in severe local (Arthus) 
reactions if given more frequently than recommended. If a major local 
or systemic reaction occurs, tetanus and diphtheria antibody levels may 
need to be checked. A high level indicates that subsequent doses are not 
necessary for at least 5 years. If a child at presentation is over 10 years of 
age acellular pertussis is given as appropriate.
3. Polio
Adverse reactions to IPV are extremely rare. It is recommended that 4 
doses of IPV containing vaccine be given, preferably before the age of 
4-6 years in keeping with the current Irish schedule.
Chapter 2  General Immunisation Procedures
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4. Hib, Men C, Pneumococcal 
Because adverse reactions are rare and because it is very unlikely that 
these vaccines would have been given to such children, age appropriate 
immunization should be given (see Table 2.2 and 2.3). 
5. Hep B
A 3 dose series (as part of a 6 in 1 vaccine) may be given to unvaccinated 
children up to the age of 10 years.  A 3-dose series of Hepatitis B vaccine 
may be given to children >10 years and adults who are unvaccinated, if 
required, as per the Irish recommendations (Chapter 6).
6. MMR 
Because adverse reactions to the MMR vaccine are rare , two doses 
should be given at 12 months and 4-5 years of age (or at least 1 month 
apart if aged over 4 years) unless there is a documented history of 2 
previous vaccinations. If in doubt, it is preferable to give an extra MMR 
vaccine. If a child aged <18 months receives a second MMR vaccine 
within 3 months  of the first MMR, a third MMR should be given at 4-5yrs 
of age.
Indications on BCG added. Changes to DTP, Polio, Hep B, MMR. Update August 2010. 
If there is uncertainty regarding previous vaccine history, it is 
preferable to give the vaccines, as the risk of lasting adverse 
events from administering extra doses is very small.
Conditions that are NOT contraindications to   
immunisation
1. Family history of any adverse reactions following immunisation.
2.  Minor infections without fever or systemic upset.
3. Family or personal history of convulsions. Antipyretic measures are 
advisable following immunisation of children under 5 years with a 
family history of febrile convulsions.
4. History of pertussis, measles, rubella or mumps infection in the 
absence of proof of immunity.
5. Prematurity or low birth weight (defer Hep B in those under 2kg 
unless there is a maternal history of HBV infection).
6. Stable neurological conditions e.g. cerebral palsy. 
7. Recent contact with an infectious disease.
Chapter 2  General Immunisation Procedures
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8. Asthma, eczema, hay fever, migraine or food allergy.
9. Therapy with antibiotics or low-dose oral or locally-acting steroids.
10. Child’s mother is pregnant.
11. Child being breastfed.
12. History of jaundice.
13. Child over the age recommended in immunisation schedule.
14. Recent or imminent surgery or general anaesthesia.
15. Corticosteroid replacement therapy.
Contraindications and precautions to vaccines
•  Minor illness with a temperature of less than 38°C is not a reason to 
defer immunisation.
•  Sometimes these recommendations differ from those in licensed 
information on the Summary of Product Characteristics (SPC).
•  The benefits and risks of giving specific vaccines should be carefully 
considered when the events listed as precautions exist.
•  When there are doubts as to whether or not to give a vaccine contact a 
Paediatrician or Public Health Specialist.
Table 2.4 Contraindications and precautions for specific vaccines
Vaccine Contraindications Precautions
General for all 
vaccines
Confirmed 
anaphylactic reaction 
to the vaccine or to a 
constituent
See introduction
Moderate or severe illness; defer 
until recovery, unless the benefits 
outweigh the risks
Latex allergy (see note 2 below)
DTP/DTaP/Tdap 
(see note 1 
below)
As above
(see note 1 below)
Evolving neurological conditions; 
defer until stable
IPV As above Pregnancy; give if benefits 
outweigh risks
MMR As above
Pregnancy
–  Recent administration of blood 
or blood product (defer for at 
least 3 months) 
–  Immune deficiency or 
suppression (see note 3 below)
–  Thrombocytopenia within 6 
weeks of a previous dose (see 
Chapter 8 )
Chapter 2  General Immunisation Procedures
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Notes 
1. Encephalopathy, temp >40.5°C, seizures, prolonged crying or hypotonic-
hyporesponsive episodes following a previous dose of a whole-cell pertussis-
containing vaccine have not been shown to result in permanent damage, are far less 
likely to occur following acellular pertussis vaccines, and are no longer regarded as 
either precautions or contraindications.
2. Vaccines supplied in vials or syringes containing rubber should not be used in those 
who had an anaphylactic reaction to latex.
3.  May need to seek medical guidance from treating physician, regarding severity of 
immunosuppression (see page 20).  
 
Immunisation of specific groups
Adults
Adults should receive the following vaccines: 
(a) Women sero-negative for rubella: MMR
(b) Women sero-negative for varicella: varicella vaccine (see Chapter 17)
(c) Previously non-immunised individuals: polio, tetanus, diphtheria and 
MenC (if under 23 years) (see relevant chapters)
(d) Individuals in specific high-risk groups: hepatitis B, hepatitis A, 
MMR, Hib, MenC, influenza, pneumococcal, varicella and BCG 
vaccines (see relevant chapters)
(e) Those travelling abroad (see Chapter 19).
(f) Those aged over 50 years: influenza (see Chapter 7).
(g) Those aged over 65 years: pneumococcal polysaccharide vaccine 
(PPV23) (see Chapter 12).
Intramuscular vaccination in those with bleeding disorders or on 
anticoagulants
There is little published information regarding the administration of 
intramuscular vaccines to persons with bleeding disorders or receiving 
anticoagulant treatment. 
If vaccines are given intramuscularly to such persons, it is prudent to 
use a 23-gauge needle, and to apply pressure to the vaccine site for 1-2 
minutes after the injections.
Chapter 2  General Immunisation Procedures
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Administration of vaccines by the subcutaneous route may be considered 
in those with severe bleeding disorders. However, immunogenicity of 
vaccines recommended for IM administration may not be as long-lasting 
if they are given subcutaneously. The patient or parent should be advised 
of this.
Live vaccines and pregnancy
Live vaccines should generally not be administered to pregnant women 
because of the theoretical possibility of harm to the foetus. However, 
where there is a significant risk of exposure, the need for immunisation 
should be balanced against the remote possibility of risk to the foetus.
Immunocompromised children
Over the last number of years there has been an increase in the number 
of immunocompromised children for a number of reasons such as better 
survival after cancer chemotherapy and in those with chronic disease such 
as cystic fibrosis. There is also an increase in the number of those with 
dysfunctional spleens (sickle cell disease, thalassaemia major) and with 
HIV.
For detailed guidance regarding vaccination of 
immunocompromised persons, consult the Royal College of 
Paediatrics and Child Health document ‘Immunisation of the 
Immunocompromised Child (2002)’, at www.rcpch.ac.uk/Health-
Services/Immunisation 
The decision whether or not to give a vaccine to such children must be 
made on an individual basis, and the risks and benefits carefully weighed. 
It is important to realise that the extent of immunocompromise can vary 
over time, as in those recovering from chemotherapy and those with HIV 
infection. The following, therefore, are to be regarded as guidelines.
Congenital (primary) immune deficiencies
Persons with B lymphocyte (humoral) defects or complement deficiencies 
are susceptible to infection with encapsulated bacteriae, especially Strep. 
pneumoniae, Haemophilus influenzae type b, N. meningitidis, and also to 
enteroviruses. Those with T-lymphocyte (cell-mediated immunity) defects 
are susceptible to most viruses and to a number of intracellular bacteria, 
fungi and parasites.
Severe immunodeficiency 
This group includes severe combined immunodeficiency (SCID), X-linked 
agammaglobulinaemia, and some children with Di-George syndrome (the 
degree of immune compromise in Di-George syndrome is very variable, 
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with many only having relatively minor impairment). They can be given 
non-live vaccines. Some can receive MMR, but they should not be given 
BCG.
Moderate or non-specific immunodeficiency This group includes 
IgA and IgG subclass deficiencies, chronic neutropaenia, chronic 
granulomatous disease, and complement deficiency diseases. These 
children should be given all routine vaccines, including MMR. They 
should also be given pneumococcal and influenza vaccines. Those with 
complement deficiencies should get meningococcal ACW135Y vaccine.
In addition to vaccination as recommended in this section, persons 
with these conditions who intend travelling abroad should be 
vaccinated as recommended in Chapter 19.
Asplenia and hyposplenism
This may be congenital, post-surgical or functional (sickle cell disease, 
thalassaemia major, storage disorders, coeliac disease etc.) Such 
persons are at risk of infection caused by encapsulated bacteria (Strep. 
pneumoniae, Hib, Meningococci, etc.)  
Children with these conditions can receive all routine childhood vaccines. 
In addition they should be given conjugated pneumococcal vaccine (PCV) 
up to the age of 5 years and polyvalent pneumococcal vaccine (PPV) over 
the age of 2 years (see Chapter 12). They should be re-immunised with 
this after a period of 5 years and should also be given long-term penicillin 
prophylaxis. They should also get annual influenza vaccine.
Adults with asplenia should receive PPV, Hib and MenC vaccines, and 
annual influenza vaccine. 
Intensive chemotherapy and bone marrow transplant recipients
It is likely that all those who receive an allogenic or autologous marrow 
transplant lose some or all of their natural and vaccine-derived immunity 
against vaccine-preventable diseases. Therefore such persons should be 
fully revaccinated with all age-appropriate vaccines.
Inactivated vaccines should be deferred for at least 12 months after 
bone marrow transplant, and at least 6 months after immunosuppressive 
treatment has been stopped; even then immune response may be sub-
optimal. 
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Those with graft versus host disease should not be vaccinated if they are 
receiving Intravenous Immunoglobulin (IVIG).
Live vaccines should be deferred for up to 2 years, and then given only 
if there is no graft versus host disease or ongoing immunosuppressive 
treatment.
Solid organ transplantation
Prior to surgery children should be up-to-date with routine primary and 
booster vaccination. Varicella vaccine should be given to non-immune 
persons. Those having haemodialysis prior to renal transplant should be 
given hepatitis B vaccine if they are unvaccinated.
After transplant, the routine schedule should continue. Pneumococcal 
(PPV or PCV depending on age – see Chapter 12) and annual influenza 
vaccines should be given.
Standard cancer chemotherapy
The degree of immune compromise varies depending on the disease and 
the treatment. It is often not possible to give a definite recommendation 
regarding when to give vaccines after such treatment has been 
completed.
During treatment, non-live vaccines should be given according to the 
schedule, as long as the child is free from infection and major organ 
toxicity, and is likely to remain so for 3 weeks.
Six months after treatment, a booster of DTaP/IPV/Hib, MenC, and MMR 
should be given. (Give Tdap if child is over 10 years of age.)
Live vaccines generally should be withheld for at least 6 months. 
However, the interval may vary depending on the type and intensity of 
immunosuppressant treatment, radiation treatment, underlying disease 
etc. An adequate immune response to inactivated vaccines should occur 
between 3 and 12 months post-treatment.
Corticosteroid therapy
The minimum amount and the duration of administration of systemic 
corticosteroids sufficient to cause immune suppression are not well 
defined. The following are empiric guidelines for administration of live 
virus vaccines to previously healthy persons receiving steroid therapy for 
non-immunocompromising conditions:
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1. Topical (skin or inhaled) or locally injected steroids do not 
usually cause immunosuppression, so live vaccines are not 
contraindicated.
2. Children receiving less than 2 mg/kg/day of prednisolone or its 
equivalent can be given live viral vaccines during treatment.
3. Children getting more than 2 mg/kg/day of prednisolone or 
its equivalent, or more than 20 mg per day for under 2 weeks, 
can be given live viral vaccines immediately after treatment is 
stopped.
4. Children getting over 2 mg/kg/day of prednisolone or its 
equivalent, or more than 20 mg/day, for more than 2 weeks, and 
those getting 1 mg/kg/day for over 1 month should not receive 
live viral vaccines for at least 3 months after treatment has been 
stopped.
For adults the equivalent dose of prednisolone is 40 mg or more 
per day for more than 2 weeks.
5. For those receiving combination immunosuppressant therapy, 
such as corticosteroids and methotrexate, live viral vaccines 
should be deferred for 6 months after stopping treatment.
6. Inactivated vaccines can be given when due, but immune 
response may be sub-optimal.
HIV infection
Active immunisation of HIV-positive persons
HIV-infected individuals, whether symptomatic or asymptomatic, should 
be immunised with all inactivated vaccines recommended in the primary 
vaccine schedule. Pneumococcal conjugate and polysaccharide vaccines 
should be given as recommended in Chapter 12. Yearly influenza vaccine 
beginning at 6 months of age is also recommended. 
MMR vaccine should be given at 12-14 months of age to HIV-infected 
children unless they are severely immunocompromised. The second dose 
should be given 1-2 months later, in order to ensure seroconversion as 
early as possible.
Varicella vaccine should be considered for asymptomatic or mildly 
symptomatic children with CD4 counts above 25%.
Since the immune response of HIV-infected children to all vaccines may 
be inadequate, these children may be susceptible to vaccine-preventable 
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diseases even if they have been vaccinated. Hence, chemoprophylaxis 
or immunoglobulin treatment should be considered in the event of 
exposure to these diseases.
Table 2.5 Vaccination of those who are HIV positive
Vaccine Asymptomatic HIV 
infection
Symptomatic HIV 
infection
Diphtheria, tetanus, pertussis, 
polio 
Yes Yes
MMR Yes Yes
Haemophilus Yes Yes
Meningococcal Yes Yes
PPV, PCV Yes Yes
Influenza Yes Yes
Hepatitis A and B Yes Yes
Varicella Yes Yes if CD4 >25%
BCG1, 2 No No
OPV1 No No
Yellow fever1 No No
1There is insufficient evidence at present to recommend the use of OPV, yellow fever or 
BCG in symptomatic HIV-infected individuals.
2See Chapter 16 re HIV and BCG.
Passive immunisation of individuals with HIV infection
Measles
Vaccine efficacy may be reduced in HIV-positive individuals. Human 
Normal Immunoglobulin (HNIG) may be used for susceptible 
symptomatic and asymptomatic HIV-positive individuals after exposure 
to measles if the response to vaccination has not been documented or is 
inadequate.
Tetanus
In the management of wounds classified as tetanus prone, HIV-positive 
individuals should receive Tetanus Immune Globulin (TIG) if the response 
to vaccination has not been documented or is inadequate.
Varicella
(a)  Asymptomatic HIV-positive individuals do not require Human 
Varicella-Zoster Immunoglobulin (VZIG) after contact with chickenpox 
since there is no evidence of increased risk of serious illness in these 
individuals.
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(b)  Symptomatic HIV-positive individuals should be given VZIG after 
contact with chickenpox unless they are known to have varicella-
zoster antibodies.
Vaccination of preterm infants
Preterm infants are more vulnerable when exposed to infections, 
particularly pertussis – 30% of pertussis deaths in the USA occur in 
preterm infants.   Therefore, routine vaccines should be started at 
8 weeks post-natal age in preterm infants of any gestational age. If 
the infant is still in hospital, the first vaccines should be given under 
cardiorespiratory monitoring for 48 hours, as there may be an increase in 
bradycardia and/or apnoeic episodes in these infants. Such episodes do 
not recur after subsequent vaccinations, nor have they been reported in 
preterm infants who have been discharged from hospital.
When compared with infants born at term, there is less of a rise 
and a more rapid decline in antibody levels following vaccination of 
preterm infants. However, there may be less interference from maternal 
antibodies in this group of infants, as most antibody transfer occurs in the 
third trimester.
Hepatitis B vaccine may not give an adequate immune response in infants 
weighing less than 2kgs, until they are aged one month. However, if a 
mother is HBsAg positive, her infant should be given the HepB vaccine at 
birth and further doses (as 6-in-1 vaccine) at 2, 4 and 6 months of age.
BCG vaccine should be given to preterm infants prior to discharge from 
hospital.
The presence of an intraventricular haemorrhage is not a contraindication 
to vaccination.
There is a lack of information regarding the effects of antenatal steroids 
on the immune response of preterm infants. Such infants should be 
vaccinated according to the current schedule.
Immunoglobulin
Human Normal Immunoglobulin (HNIG) is prepared from the pooled 
blood of donors who are negative to hepatitis B surface antigen 
(HBsAg), hepatitis C antibody (anti-HCV) and antibody to human 
immunodeficiency virus (HIV).  
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Human Normal Immunoglobulin (HNIG) for intramuscular use
It usually contains antibodies to varicella, hepatitis A and other viruses 
currently prevalent in the population. HNIG is available in 2, 5 and 10 ml 
vials. It is given by deep intramuscular injection. It should be stored at 
2-8°C and the expiry date on the package observed. Unused portions 
of an ampoule must be discarded. As recipients of intramuscular 
immunoglobulin can experience local pain and discomfort at the injection 
site, it should be administered deep into a large muscle mass, such as the 
gluteus maximus. Ordinarily, no more than 5 ml should be administered 
at any one site. 
Intramuscular HNIG should not be administered to any patient with 
severe thrombocytopenia or with a coagulation disorder. Caution should 
be exercised with any patient who has a history of adverse experience 
following HNIG administration.
Indications for use of HNIG include post-exposure prophylaxis or 
modification of hepatitis A infection and post-exposure modification of 
measles infections (see Chapters 5 and 8).
HNIG may interfere with the immune response to live viral vaccines; 
these should not therefore be given from 3 weeks before to at least 3 
months after an injection of HNIG. Yellow fever vaccine is an exception, 
as HNIG obtained from donors is unlikely to contain antibody to this 
virus; a similar situation applies to Oral Polio Virus vaccine when given as 
a booster dose.  
The vaccine and HNIG should be given in different limbs. If indicated, 
vaccination should be repeated approximately 3 months later.
Specific immunoglobulins
At present specific immunoglobulins are available for administration 
following exposure to tetanus, hepatitis B, rabies* and varicella-zoster 
virus. They are prepared from the pooled plasma of blood donors who 
have high antibody titres to specific infections. Recommendations for 
their use are found in the relevant sections.
When medicinal products prepared from human blood or plasma are 
administered, infectious diseases due to the transmission of infective 
agents cannot be totally excluded. This applies also to pathogens of 
hitherto unknown origin and pathogens as yet unidentified.
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* At present available from Cherry Orchard Hospital
To reduce the risk of transmission of infective agents, stringent controls 
are applied to the selection of blood donors and donations. In addition, 
virus removal and/or inactivation procedures are included in the 
production process.
The current procedures applied in the manufacture of medicinal products 
derived from human blood or plasma are effective against enveloped 
viruses such as HIV, hepatitis B and hepatitis C viruses, and non-
enveloped viruses.
Live viral vaccines following immunoglobulin administration
Live viral vaccines, with the exception of yellow fever and BCG vaccine 
(see below and Chapter 16), should not be given for at least 3 months 
following injection of immunoglobulin because the immune response 
may be inhibited.
BCG vaccine
Administration of blood or plasma transfusions, hepatitis B vaccine, 
hepatitis B immunoglobulin and normal immunoglobulin are thought not 
to reduce the effectiveness of BCG vaccine. A baby who has received 
blood or plasma transfusions can be subsequently immunised with BCG, 
after the observation period for transfusion reactions has ended (24 
hours).  
General guidelines for spacing the administration of killed 
and live antigens
The following table shows the recommended minimum intervals between 
vaccine doses.
Table 2.6 Recommended minimum interval between vaccine doses
Antigen combination Recommended minimal interval between 
doses 
≥2 killed antigens No minimum; may be administered 
simultaneously or at any interval between doses
Killed and live antigens No minimum; may be administered 
simultaneously or at any interval between doses
≥2 live antigens Four-week minimum interval if not administered 
simultaneously; however, oral polio vaccine 
(OPV) can be administered at any time before, 
with or after other live vaccines.
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Specific contraindications to individual vaccines are given in the 
relevant sections and must be observed.
How to administer intramuscular (IM) injections
This route is used for the majority of vaccines. For individual vaccines see 
relevant chapters.
Needle insertion
Giving an infant a carbohydrate-containing drink 1-2 minutes before 
injection reduces the pain of insertion.
• Insert needle at a 90º angle to the skin. The tissue around the 
injection site may be bunched up in young infants.
• Retain pressure on skin around injection site with thumb and index 
finger while needle is inserted.
• It is not necessary to aspirate before injecting, as there are no large 
blood vessels at the preferred injection sites.
• Multiple injections given in the same limb should be separated by 
at least 2.5 cm.
Table 2.7 Recommendations regarding preferred site and needle size for 
intramuscular injections 
Patient’s age Site (see illustrations below) Needle size
Birth to 12 months* Vastus lateralis muscle in 
anterolateral aspect of mid- or 
upper thigh
25 mm needle
23-25 gauge
12 to 36 months Vastus lateralis or deltoid muscle 25 mm needle
23-25 gauge
From 3 years upwards* Densest portion of deltoid 
muscle – between acromion and 
muscle insertion
25 mm needle
23-25 gauge
*Note:   Use a 16 mm length needle in infants under 2.5-3 kg. Use 38 mm length needle in 
women >90 kg, men >118 kg.
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IM site for infants and toddlers (birth to 36 months of age)
Insert needle at 90O angle into anterolateral aspect of middle or upper 
thigh.
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Vastus lateralis
 (shaded area)
IM injection site area
IM site for older toddlers, children and adults
Insert needle at 90O angle into densest portion of deltoid muscle 
– between acromion and insertion.
How to administer subcutaneous (SC) injections
Use this route for varicella and yellow fever vaccines.
Table 2.8 Recommendations regarding preferred site and needle size for 
subcutaneous injections 
Patient’s age Site (see illustrations below) Needle size
Infants (birth to 12 
months of age)
Fatty area of the 
Anterolateral thigh
16 mm needle
23-25 gauge
Toddlers (12 to 36 
months of age)
Fatty area of the anterolateral 
thigh or triceps region
16 mm needle
23-25 gauge
Children and adults Triceps region 16 mm needle
23-25 gauge
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Needle insertion
Insert needle at 45º angle to the skin 
• Pinch up on SC tissue to prevent injection into muscle.
• There is no need to aspirate prior to injection as there are no 
large blood vessels at the preferred injection sites.
• Multiple injections given in the same limb should be separated 
by at least 2.5cm.
SC site for infants and toddlers (birth to 36 months of age)
Insert needle at 45º angle into fatty area of anterolateral thigh. Pinch up 
skin to prevent injection into muscle.
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SC site for toddlers, children and adults
Insert needle at 45º angle into outer aspect of upper arm. Pinch up skin 
to prevent injection into muscle.
How to administer intradermal injections
Use for BCG and tuberculin PPD (Mantoux).
Site: 
The BCG is given into the skin at one site over the distal insertion of the 
deltoid muscle (approx. one third down the upper arm); tuberculin is 
generally injected into the ventral surface of the forearm
Technique: 
A 1 ml syringe with a 10-16 mm, 25-26G short-bevelled needle is used 
for BCG. A 1 ml tuberculin syringe can also be used for the Mantoux test. 
All air bubbles are removed. The skin is slightly stretched with thumb and 
index finger of one hand. The needle is inserted almost parallel to the 
surface, with the bevel upwards, to a length of approx. 5 mm and the 
dose is slowly injected.  
A bleb 7-10 mm in diameter should result (3 mm if the dosage is 0.05 ml 
as for neonatal BCG). If little resistance is felt when injecting and a diffuse 
swelling occurs rather than a tense bleb, the needle is too deep. If this 
occurs: 
• for BCG the needle should be withdrawn and the same needle 
reinserted intradermally at a site at least 5 cm away 
• for Mantoux the test should be repeated at least 5 cm away from 
the first injection.   
Injection site area
Elbow
Acromion
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No further immunisation should be given in the arm used for BCG 
immunisation for at least 3 months because of the risk of regional 
lymphadenitis. 
BCG intradermal injection
How to hold a child during immunisation
This method involves the parent/carer in embracing the child and 
controlling all four limbs. It avoids ‘holding down’ or overpowering the 
child, but it helps steady and control the limb of the injection site.
For infants and toddlers
Have parent hold the child on parent’s lap.
1.  One of the child’s arms embraces 
the parent’s back and is held under 
the parent’s arm.
2.  The other arm is controlled by the 
parent’s arm and hand. For infants, 
the parent can control both arms 
with one hand.
3.  Both legs are anchored with the 
child’s feet held firmly between the 
parent’s thighs, and controlled by 
the parent’s other arm.
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For older children
Hold the child on parent’s lap or have the child stand in front of the 
seated parent.
1.  Parent’s arms embrace the child 
during the process.
2.  Both legs are firmly between parent’s 
legs.
 
Analgesia, Antipyretics and Vaccines
Fever is a normal part of the inflammatory response, and is well-known 
to occur after vaccination. It is associated with improved antigen 
recognition, increased T-cell activity and immune responses. Fever which 
occurs after vaccination is generally benign and self-limiting; it rarely 
rises above 39.5.C.  When fever does occur after vaccination it can 
cause concern in parents and health-care professionals, who fear it is a 
pathological reaction, and that it may cause a febrile convulsion.  
Prophylactic use of antipyretics such as paracetamol and ibuprofen, 
at or shortly after vaccination, has become common.  A study has 
shown a substantial reduction in the primary antibody responses to 
all serotypes of PCV 10 and to Hib, diphtheria, tetanus and pertactin 
antigens of concurrently administered Hib and DTaP vaccines in those 
given prophylactic paracetamol at the time of vaccination.  It is likely that 
this reduction in the immune response is due to interference with the 
inflammatory response at the injection site.  It is known that ibuprofen 
can interfere with such a local response, although no studies similar to 
the referenced study have been carried out with Ibuprofen.Antipyretic 
drugs do not prevent febrile convulsions in at-risk children.
A study has demonstrated an analgesic effect with the use of sweet 
solutions (sucrose or glucose) immediately prior to vaccination in infants 
between 1 and 12 months of age.  
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In light of the above it is recommended that:
1.  Prophylactic antipyretics should not routinely be given at the time of 
vaccination. Either paracetamol or ibuprofen may be considered for 
treatment of fever >39.5C or for a significant reaction at the site of 
vaccination.
2.  Parents or vaccinators should consider administering glucose or 
sucrose solutions of 24-30% or greater concentration to infants 
immediately before vaccination. 
Information on Analgesia, Antipyretics and Vaccines added August 2010.
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Introduction
Diphtheria is an acute infectious disease affecting the upper respiratory 
tract and occasionally the skin. It is caused by Corynebacterium 
diphtheriae or C.ulcerans. Effective protection against the disease is 
provided by active immunisation. 
Since the introduction of vaccination against diphtheria, the disease and 
the organism have been virtually eliminated from Ireland. However, an 
immunisation rate of at least 85% must be maintained to protect the 
population against the possibility of a resurgence of the disease which 
could follow the introduction of cases or carriers of toxigenic strains from 
overseas.
Immunity decreases with age; approximately 65% of those over 30 years 
of age may be susceptible to diphtheria.
Approximately 5 secondary infections will result from each index case in a 
fully susceptible population.
Epidemiology
Humans are the only known reservoir of Corynebacterium diphtheriae. 
Transmission results primarily from close contact with a patient or carrier. 
Spread is by droplet infection, and on rare occasions through contact 
with articles soiled by contact with skin lesions of infected persons 
(fomites). The incubation period is usually 2-5 days, but occasionally can 
be longer. The disease is communicable for up to 4 weeks, but carriers 
may shed the organism for longer.
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There is little likelihood of acquiring natural immunity from sub-clinical 
infection. However, while no cases have been recently reported in 
Ireland, they have occurred in the UK, the former USSR states, India, 
China, and Bangladesh among other countries.
Effects of diphtheria
The disease is characterised by an inflammatory exudate which 
forms a greyish membrane in the upper respiratory tract resulting in 
nasopharyngitis and/or obstructive laryngotracheitis. There may also be 
moderate enlargement of cervical lymph nodes and oedema of the soft 
tissue of the neck. These local manifestations are associated with a low-
grade fever and the gradual onset of generalised manifestations over 1-2 
days. Cutaneous manifestations are less common. 
A toxin is produced by diphtheria bacilli which affects particularly 
myocardial, nervous and adrenal tissues and may result in life-threatening 
complications including myocarditis and neurological problems such as 
vocal cord paralysis and ascending paralysis similar to the Guillain-Barré 
syndrome.
Milder infection, particularly in vaccinated persons, may cause tonsillitis 
or pharyngitis with toxin production.
The case-fatality rate ranges from 3-29%, and is highest in the young and 
the elderly.
Diphtheria toxoid
Diphtheria immunisation protects by stimulating the production of 
antitoxin which provides immunity to the effects of the toxin. After a 
primary series of 3 properly spaced doses in adults and 4 doses in infants, 
efficacy is estimated at over 97%.
Toxoid should be stored at 2-8°C.
Indications
Immunisation of infants and children under 10 years
Primary immunisation
Diphtheria toxoid is recommended for infants from 2 months of age. The 
primary immunisation course consists of 3 doses given I.M. at 2, 4 and 6 
months of age. If a course is interrupted it may be resumed without the 
need to start again (see Chapter 2).
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Booster immunisation
A booster dose is recommended at 4-5 years of age. Booster doses 
should be given at least 3 years from the last dose of the primary course 
unless there is a documented history of 5 doses of tetanus toxoid having 
been given or the child is over 10 years of age. This is because all 
diphtheria vaccines are combined with tetanus toxoid. A further booster 
using low-dose diphtheria toxoid (Tdap) is recommended 10 years later.
If pertussis vaccine is refused by parents, the only available diphtheria 
and tetanus vaccines are Td and Td/IPV, which contain insufficient tetanus 
and diphtheria toxoid for primary immunisation. They are not intended 
for use as part of the primary vaccine schedule, may not give a sufficient 
immune response if so used, and are not licensed for such use.
Dose and route of administration
For primary immunisation of children under 10 years the dose is 0.5 
ml given by intramuscular injection into the deltoid region or the 
anterolateral thigh.
Immunisation of persons aged 10 years and over (unimmunised or 
partially immunised)
Primary immunisation
A special low-dose diphtheria toxoid such as Td must be used because 
of the possibility of a serious local reaction in an individual who is already 
immune. Three doses should be given, by intramuscular injection.  
Booster Immunisation
Low dose diphtheria toxoid must be used when the primary vaccination 
course has been delayed: the first booster should be given 5 years after 
the third dose and the second booster 10 years after that (see Chapter 2).  
Change: “Three doses should be given, by intramuscular injection” is replaced with “the 
first booster should be given 5 years after the 3rd dose and the 2nd booster should be 
given 10 years after that.” Update August 2010.
Contraindications 
Anaphylactic reaction to a preceding dose or any of the constituents.
Precautions 
Acute severe febrile illness, defer until recovery. 
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HIV positivity
HIV positive individuals may be immunised against diphtheria in the 
absence of any contraindications.
Adverse reactions
Local: Transient local reactions (pain, palpable lump, and erythema) may 
occur. They are more frequent with subsequent doses. Sequelae are very 
rare.
General: Malaise, transient fever and headache may occasionally occur. 
Dyspnoea, urticaria, angioedema, anaphylaxis and neurological reactions 
are very rare.  Anaphylaxis is extremely rare (0.6-3 per million doses). 
Contacts of a diphtheria case or carriers of a toxigenic 
strain
Table 3.1 Recommendations for vaccination of contacts of diphtheria 
cases and carriers 
Immune status Age-group Action
Immune (3 or more 
previous doses)
Under 10 years One injection of diphtheria 
toxoid as DT or DTaP/IPV
10 years and over One injection of low dose 
diphtheria toxoid such as Td 
or Tdap
Non-immune (<3 
previous doses)
Under 10 years Three injections of DTaP/IPV 
diphtheria toxoid, DT or 
DTaP at monthly intervals*
10 years and over Three injections of Td or 
Tdap at monthly intervals*
*  See Catch-up section, Chapter 2, for number of doses. These children may also need Hib 
and MenC vaccines.
Non-immunised contacts of a case of diphtheria should, in addition, be 
given a prophylactic course of Erythromycin, 20-30 mg/kg, 12 hourly for 
7 days, max 1g per dose.
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Introduction
Infections due to Haemophilus influenzae, a gram-negative coccobacillus, 
are an important cause of morbidity and mortality, especially in young 
children. Humans are the only known reservoir. The Hib vaccine was 
introduced into the primary schedule in Ireland in 1992 and subsequently 
there has been a dramatic fall in the incidence of invasive Hib disease. 
A booster dose at 12 months was introduced in 2006. The vaccine is 
specific for diseases caused by H. influenzae type b, and does not protect 
against infections caused by other haemophilus strains.
Epidemiology
The incidence of Hib disease fell significantly following introduction of 
the vaccine into the primary schedule in 1992. In 2002-2003 an increase 
of invasive Hib disease was noted in unvaccinated children aged under 
5 years. However, in late 2004 and 2005 an increase of disease in fully 
vaccinated children was observed. A catch-up booster vaccination of all 
children aged 12-47 months, and the addition of routine Hib booster 
vaccine to those aged 12 months was therefore recommended.
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Almost all invasive H. influenzae infections are caused by encapsulated 
strains, of which there are 6 serotypes (a-f). Type b (Hib) caused more 
than 80% of these infections in the pre-vaccine era. Non-encapsulated 
strains of haemophilus cause mucosal infection (e.g. otitis media) but 
rarely lead to serious invasive disease. Transmission is presumed to be by 
droplet spread.
The epidemiology has changed since the vaccine was introduced to 
the primary schedule. Prior to 1992, the highest incidence was in those 
under 1 year of age, with approximately 90% of all Hib disease occurring 
in those under 5 years of age. These infants are now protected if fully 
vaccinated. While there is evidence that carriage has been reduced, 
lessening the risk of exposure of unvaccinated persons, sporadic cases 
still occur in all age groups.
Effects of Hib disease
Invasive disease caused by H. influenza can affect many organs. The 
commonest effects are:
Meningitis The mortality rate is 2-5%, and neurological sequelae 
occur in 15-30% of survivors
Epiglottitis, with up to 10% mortality
Pneumonia, septic arthritis, cellulitis (usually involving the face or 
neck), otitis media, osteomyelitis, and pericarditis.
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Hib vaccines
Hib vaccines consist of Haemophilus influenzae b capsular poly- or 
oligosaccharide conjugated with tetanus or diphtheria toxoid. Vaccines 
currently licensed are listed in Appendix 1. An updated list can be found 
on the IMB website (www.imb.ie).
All Hib vaccines are inactivated. They should be stored at 2-8°C. When 
the product brand given in the first and second courses is not known or 
not available, the 3-dose series can be completed with any Hib vaccine.
Dose and route of administration
The dose is 0.5 ml given by intramuscular injection. If BCG has been 
given within the previous 3 months, a different limb should be used.
The primary course consists of three doses at 2, 4 and 6 months of age, 
as DTaP/IPV/Hib/Hep B. A booster dose of Hib vaccine is given at 13 
months of age. Children aged 12-47 months require only 1 dose. Booster 
immunisation is not normally required over 4 years of age. Unvaccinated 
children up to 10 years of age should be vaccinated. Such children may 
also need age-appropriate vaccination with DTaP, IPV, MenC, and MMR 
(see Chapter 2).
Indications 
1.  All infants at 2, 4 and 6 months of age, with a booster at 13 months 
of age.
2. Those less than 2 years of age who developed invasive Hib disease 
should be given Hib vaccine after one month. Immunocompetent 
children over 2 years of age who develop invasive Hib disease do 
not need to be immunised because the disease will most likely have 
induced a protective immune response
3. Persons at increased risk of invasive Hib disease, e.g. asplenia, 
hyposplenism, complement deficiency, etc irrespective of age, should 
be vaccinated. Those aged over 1 year should be given 2 doses of 
Hib vaccine (Hib/MenC if available) administered 2 months apart.  
4. Children and adults who have completed a primary series and are 
undergoing elective splenectomy may benefit from an additional 
dose of Hib vaccine, preferably at least 2 weeks prior to the 
operation. Those who have developed hyposplenism should also get 
2 doses.
5. Children aged 1-10 years who have never received Hib vaccine 
should be given 1 dose. 
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Contraindications
Anaphylactic reaction to a preceding dose or any of the constituents.
Precautions
Acute severe febrile illness, defer until recovery.
Hib vaccine may be given to immunocompromised patients, but 
adequate antibody levels may not be reached. 
Adverse reactions
Local: These include local redness, warmth or swelling at the injection 
site. Mild local reactions occur in about 20% of children.
General: Systemic reactions are uncommon, and include fever, irritability, 
headache, vomiting, diarrhoea, and rashes. Seizures have rarely been 
reported.
Immunisation and chemoprophylaxis of cases and 
contacts of invasive Hib disease
1. Household contacts (except pregnant women):
Household contacts are regarded as those who share living or 
sleeping accommodation with the case. 
(a)  Non-immunised contacts aged under 10 years should be 
given Hib vaccine.
(b)  Chemoprophylaxis is indicated for all household contacts 
irrespective of age or immunisation history in the following 
situations:
(i) if there are any children under 4 years of age who are 
unvaccinated or incompletely vaccinated
(ii) if there are any unvaccinated children under 10 years 
of age
(iii) if there are any persons at increased risk of 
invasive Hib disease (asplenia, hyposplenism, etc.) 
irrespective of their age or immunisation status.
2.  Play-group, creche or primary school contacts aged less than 10 
years:
Non-immunised room contacts under the age of 10 years  should 
be offered offered Hib vaccine. When two or more cases occur 
within 2 months, chemoprophylaxis should be offered to all 
room contacts, both adults and children.
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3. Index case:
The index case, if younger than 2 years of age, may have low 
levels of anticapsular antibodies and could get a second episode 
of disease. Therefore immunisation should be given according 
to the current recommended schedule irrespective of vaccine 
history, starting 1 month after onset of disease or as soon as 
possible thereafter.
The index case should also be given chemoprophylaxis prior to 
discharge if not treated with cefotaxime or ceftriaxone. These 
drugs eradicate Hib from the nasopharynx. Immunised children 
who develop invasive Hib disease have an increased incidence 
of IgG2 deficiency and should be considered for immunological 
evaluation.
Notes:
1. Rifampicin dose for prophylaxis:
(a) Infants under 1 year of age – 10 mg/kg once daily for 4 days
(b) Children and adults – 20 mg/kg once daily for 4 days, max. 
600 mg/day
2. Chemoprophylaxis is not recommended for pregnant women 
who are contacts of cases because rifampicin is not licensed for 
this indication.
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Introduction
Hepatitis A is an acute, usually mild and self-limiting disease of the 
liver caused by the hepatitis A virus (HAV). The disease varies in clinical 
severity from a mild illness lasting 1-2 weeks to a severely disabling 
disease lasting several months. Most patients make a complete recovery. 
HAV hepatitis does not progress to chronic liver disease and there is no 
chronic carrier state. On rare occasions the disease may be very severe, 
with fulminant hepatitis, liver coma and death. 
Severity of illness increases with age. Case fatality can reach 2% for adults 
over 50 years of age. Persons with pre-existing chronic liver disease have 
an elevated risk of death from fulminant hepatitis A. Infection confers life-
long immunity.
Epidemiology
Hepatitis A infection is common worldwide. The incidence of hepatitis 
A has been decreasing in developed countries over the past 50 years 
because of improved hygiene and sanitary conditions. In these countries, 
disease transmission is most frequent among household and sexual 
contacts of acute cases. It occurs sporadically in day-care centres with 
small children. It also occurs among travellers to endemic countries. 
Outbreaks have been reported frequently in injecting drug users and in 
men who have sex with men. In the developing world where standards of 
sanitation are poor, HAV infection is common and occurs in early life.
The incidence of hepatitis A in Ireland has fallen substantially since 
2002, with fewer than 60 cases notified per year (Figure 5.1). The age-
standardised incidence rate in 2005 was 1.4 per 100,000 population. 
It is likely that most people under the age of 50 in Ireland are now 
susceptible to HAV. 
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Transmission 
Person-to-person transmission
HAV infection is spread primarily by the faecal-oral route from person to 
person.
The risk of faecal-oral transmission is increased where there is close 
person-to-person contact, e.g. among infants, young children and those 
with learning disability, especially in day-care and residential homes. 
The risk is also increased where there is overcrowding and where poor 
hygiene standards prevail. Because most children have asymptomatic or 
unrecognised infections, they play an important role in HAV transmission and 
serve as a source of infection for others.
Sexual transmission: HAV may be transmitted by sexual oral-anal contact 
or by oropharyngeal secretions. There is an association with multiple 
anonymous sexual contacts.
HAV is transmitted by the faecal-oral route.
Infected persons are most likely to transmit HAV 1-2 weeks before 
the onset of illness.
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Figure 5.1 Number of hepatitis A notifications in Ireland, 1982-2006. 
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Less common modes of transmission
Food and water contamination
Contamination of water supplies with infected faeces occurs where 
sewage disposal is inadequate. Food washed in contaminated water 
or prepared by an infected person with poor standards of hygiene 
may cause viral transmission and infection. Shellfish harvested from 
contaminated sea water may also cause HAV outbreaks.
Percutaneous-intravenous transmission
A viraemia occurs briefly during HAV infection. Outbreaks of hepatitis A 
have rarely been linked to blood and blood product administration. The 
observed increased incidence of infection among intravenous drug users 
is probably due to poor standards of hygiene, although contamination of 
drugs, and needle-sharing, may contribute.
Effects of hepatitis A
The incubation period for HAV is approximately 28-30 days, with a range 
of 15-50 days. After 10-12 days the virus is present in the blood and is 
excreted into the faeces via the biliary tract. The virus is present in the 
blood but the viral load is much higher in the faeces. In children under 6 
years of age, most (70%) infections are asymptomatic. The frequency and 
severity of symptoms increase with age, with jaundice occurring in 70% 
of infected adults. 
The illness usually lasts up to 2 months, although 10-15% have prolonged 
or relapsing signs and symptoms for up to 6 months. There is no chronic 
carrier state and chronic liver damage is rare. Fulminant hepatitis can 
occur but is rare. 
Prevention
Good hygiene, particularly hand washing, is the cornerstone of 
prevention and should be promoted in settings and communities with 
higher rates or risk of infection. A selective vaccination policy is of benefit 
for certain groups with greater likelihood of infection.
Hepatitis A vaccine
HAV vaccines have been shown to be safe, immunogenic and efficacious. 
The vaccines are not licensed for use in children under 1 year of age and 
are not recommended by the manufacturers for use in pregnancy. The 
risk associated with vaccination should be weighed against the risk for 
hepatitis A in pregnant women who might be at high risk for exposure 
to HAV. HAV vaccines are available as either monovalent vaccines, or 
combined with either typhoid or hepatitis B vaccines.
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Monovalent vaccines
HAV vaccine is a formaldehyde inactivated vaccine prepared from hepatitis 
A virus grown in human diploid cells (MRC5) and adsorbed onto an 
aluminium hydroxide adjuvant. The vaccine should be stored at 2-8°C and 
should be protected from light.
The primary course of HAV vaccine is a single dose followed by a booster 
at 6-12 months. Approximately 95% of subjects acquire protective levels of 
HAV antibodies within 4 weeks of one dose, and over 99% after the second 
dose.  It is expected that immunity for at least 20 years is conferred by the 
full course.
Combined hepatitis A and hepatitis B (HBV) vaccine
A combined vaccine containing purified inactivated HAV virus and purified 
recombinant HBsAg may be used when protection against both HAV and 
HBV is required.
Combined HAV and typhoid vaccine
A combined vaccine containing purified inactivated HAV and purified Vi 
polysaccharide typhoid vaccine may be used where protection against HAV 
and typhoid fever is required.
Route of administration
Hepatitis A vaccine should be given intramuscularly in the deltoid 
region. For patients with severe bleeding tendencies (e.g. persons with 
haemophilia), subcutaneous injection may be considered. Hepatitis A 
vaccine should not be administered intravenously.
Indications 
Pre-exposure prophylaxis
Active immunisation with hepatitis A vaccine is recommended for:
• Travellers, including children 1 year and over, to areas with high or 
intermediate hepatitis A endemnicity (Africa, Asia, Central and South 
America, Eastern Europe, the Middle East). Vaccination should be 
carried out 2 or more weeks before departure. However, if the time 
before departure is short, the vaccine is still considered likely to prevent 
or at least modify the infection (see Chapter 19). HNIG could be used 
(if available) for travellers who are immunocompromised and should be 
given at a separate site
•	 Susceptible persons with chronic liver disease
•	 Non-immune patients with chronic hepatitis B or hepatitis C infection
•	 Solid organ transplant recipients who have not been immunised 
previously  – should be immunised prior to transplantation
•	 Persons with haemophilia and other recipients of plasma-derived 
clotting factors
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•	 Injecting drug users
•	 Men who have sex with men 
•	 Clients of learning disability services whose capacity to maintain 
good standards of hygiene is limited, and their carers
•	 Laboratory workers who may be exposed to HAV in the course of 
their work
•	 Sewage workers exposed to raw untreated sewage
•	 Susceptible staff who work with non-human primates that are 
susceptible to hepatitis A infection.
• Household members and other close personal contacts of adopted 
children newly arriving from countries with high or intermediate 
hepatitis A endemnicity (see first bullet).  Immunisation should 
preferably be offered before adoption. 
For those with recent close contact with infected individuals, see Post- 
exposure prophylaxis, below.
Where indicated, HAV vaccination can be combined with HBV 
vaccination.
 
For those aged over 50 years or with a history of jaundice, haemophilia 
or residence in a high-risk area, prevaccination testing for immunity to 
hepatitis A may be considered in order to reduce costs. Post-vaccination 
testing for anti-HAV is not indicated.
Contraindications
Anaphylactic reaction to a preceding dose or any of the constituents. 
Individuals who have had a confirmed anaphylactic hypersensitivity to 
egg products should not be given the hepatitis A vaccine Epaxal, as a 
component of that vaccine is prepared on hens’ eggs.
Precautions
Acute severe febrile illness, defer until recovery. Safety data in pregnant 
women are not available, but the risk is considered to be low or non-
existent because the vaccines contain inactivated purified viral proteins. 
Adverse reactions
Side effects are infrequent and mild.  
Post-exposure prophylaxis
Hepatitis A vaccine is usually recommended for the management 
of contacts of cases and for outbreak control.  Human normal 
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immunoglobulin (HNIG) may be indicated in addition to, or instead of, 
vaccine in limited circumstances as described below.  Immunoprophylaxis 
should be given to household and close contacts of cases that have no 
previous history of hepatitis A vaccine or of laboratory confirmed hepatitis 
A infection as soon as possible after exposure to HAV.
Following the publication of recent data comparing the efficacy of 
hepatitis A vaccine and HNIG after exposure to HAV, HAV vaccine is now 
recommended for persons aged 1 to 50 years, who are within two weeks 
of exposure and who have no previous history of hepatitis A vaccine or of 
laboratory confirmed hepatitis A infection.  
For persons aged 51 years and over and those with underlying medical 
conditions, who are within two weeks of exposure and who have no 
previous history of hepatitis A vaccine, or of laboratory confirmed hepatitis 
A infection, HNIG (if available) is recommended in addition to vaccine, 
because of the absence of information regarding vaccine performance, and 
the more severe manifestations of hepatitis A in these groups.
For children under 12 months of age, no intervention for the child is 
recommended.  However, vaccine should be offered to non-immune carers 
(to prevent tertiary infection) and consideration given – in conjunction with 
the local office of public health – to exclusion of the child from childcare.
In general the use of HNIG more than 2 weeks after the last exposure is 
not indicated. However, if HNIG is given after 2 weeks from last exposure 
it may modify disease severity and may be offered to those 51 years of age 
and over and those at risk of severe complications (those with chronic liver 
disease, including chronic hepatitis B or C infection).
Monovalent hepatitis A vaccine is the preferred vaccine for post exposure 
prophylaxis as no data exists regarding the performance of the combination 
vaccine for prophylaxis after exposure to HAV.  If a contact is at ongoing 
risk of HAV infection because of their lifestyle or for any other reason, they 
should be offered vaccine irrespective of whether they are offered HNIG.
Serological testing of the contacts may be performed, but is usually not 
recommended as it may result in unnecessary delay in the administration of 
prophylaxis.
Subgam® is available in Ireland for Hepatitis A prophylaxis.  It is unlicensed 
for this indication, as Hepatitis A antibody levels in Subgam® are below the 
recommended WHO standard of 100IU/ml.  As a result, the dose required 
to prevent or modify hepatitis A infection is higher than for previous 
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products.  The recommended dosage of Subgam® to provide levels of 
antibody equivalent to that achieved with products meeting the WHO 
standard is:
<10 years 500 mg* by intramuscular injection
≥10 years 750 mg* by intramuscular injection
*Subgam® is presented as three vial sizes of 250mg, 750mg, and 1500mg 
of protein
Vaccine and HNIG may be given at the same time, but in different sites, 
when both rapid and prolonged protection is required.
•	  Child-care centre staff, children, and their household contacts. 
If one or more hepatitis A cases are associated with a centre, 
immunoprophylaxis (as above) should be offered to the children and 
the adult carer(s) in contact with the index case. If the centre admits 
children in nappies, immunoprophylaxis should be offered to all 
children and staff in the centre. Where HAV infection is confirmed 
in 2 or more households of children attending such a centre, 
immunoprophylaxis should similarly be offered to all children and staff. 
In centres that do not provide care to children in nappies, hepatitis A 
vaccine or HNIG need be administered only to classroom contacts of 
the index patient.  When an outbreak occurs (i.e. hepatitis cases in 3 
or more families) immunoprophylaxis should also be considered for 
members of households that have children in nappies.  No specific 
intervention is recommended for children under 12 months of age.
•	  Schools, hospitals, prisons and work settings. 
 Immunoprophylaxis is not normally indicated when a single case 
occurs in a school, office or other work-setting. Instead, the 
importance of careful hygiene practices should be emphasised.  In 
a school setting, parents of children in the same class should be 
informed of the risk of possible exposure.  Immunoprophylaxis as 
above should be offered to persons who have close contact with 
index patients if an epidemiological investigation indicates HAV 
transmission has occurred in this setting.  
•	  Food or waterborne outbreaks. If a food handler is diagnosed with 
hepatitis A, immunoprophylaxis should be offered to other food 
handlers at the same location, if the risk of transmission is high. 
Administration of immunoprophylaxis to patrons should only be 
considered if: (1) during the time the food handler was likely to be 
infectious, the food handler had both directly handled uncooked 
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foods or foods after cooking and had diarrhoea or bad hygiene 
practices and (2) patrons can be identified and treated within two 
weeks of exposure.
•	  Close personal contact. Immunoprophylaxis should be offered to 
previously unvaccinated household or sexual contacts of persons 
with serologically confirmed recent HAV infection.  
In addition, people who have shared illicit drugs with a person who has 
serologically confirmed hepatitis A should receive hepatitis A vaccine, or 
HNIG and hepatitis A vaccine simultaneously.  People at continued risk of 
infection should be advised to receive a second dose of vaccine at 6-12 
months after the first dose.  
HNIG can interfere with the response to live virus vaccines (see Chapter 2 
for more information on HNIG).
Bibliography
CDC (2006). Prevention  of  hepatitis A through active or passive immunization. 
Recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR; 55 
(No. RR-7);1-23.
Crowcroft NS, Walsh B, Davison KL, Gungabissoon U on behalf of PHLS Advisory 
Committee on Vaccination and Immunisation (2001).  Guidelines for the control of hepatitis 
A virus infection. Commun Dis Public Health; 4:213-27.
Hawker J, Begg N, Blair I, Reintjes R, Weinberg J (2005). Communicable Disease Control 
Handbook. 2nd ed. Massachusetts: Blackwell Publishing.
Health Protection Surveillance Centre (2006). Annual report 2005. Available from: www.
ndsc.ie/hpsc/AboutHPSC/AnnualReports/ 
Heymann D, editor (2004). Control of Communicable Diseases Manual. 18th ed. 
Washington: APHA.
Kumar P, Clark M, editors (2005). Clinical Medicine. 6th ed. Edinburgh: Elsevier Saunders.
Salisbury D, Ramsay M, Noakes K, editors (2006). Immunisation against infectious disease. 
London: Department of Health.
Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov 
MO, Margolis HS and Bell BP (2007). Hepatitis A Vaccine versus Immune Globulin for 
Postexposure Prophylaxis. NEJM; 357(17): 1685-94.
Chapter 5  Hepatitis A
56
Introduction
Hepatitis B virus (HBV) is an important cause of serious liver disease 
including acute and chronic hepatitis, cirrhosis and primary hepatocellular 
carcinoma. People with chronic HBV infection can transmit the infection 
for many years. A safe and effective vaccine is available for the 
prevention of HBV infection.
Epidemiology
The World Health Organization (WHO) estimates that over 350 million 
people worldwide are chronically infected with HBV (Figure 6.1). The 
WHO has categorised countries based upon the prevalence of hepatitis B 
surface antigen (HBsAg) into:
• High endemicity (≥8%): sub-saharan Africa, most of Asia and the 
Pacific Islands
• Intermediate endemicity (2-7%): Southern parts of Eastern and 
Central Europe, Middle East and Indian sub-continent, Central 
and South America
• Low endemicity (<2%): Most of Western Europe and North 
America, Australia.
In Ireland the prevalence of serological markers of hepatitis B infection 
is low. A national study in the general population in 1999 estimated the 
prevalence of past exposure to hepatitis B (anti-core antibody, anti-HBc) 
to be 0.51%. Between 2003 and 2006, a prevalence of HBsAg of 0.01% 
was detected in new blood donors tested by the Irish Blood Transfusion 
Service donor screening programme. One in 2,000 to 1 in 6,000 pregnant 
Irish-born women are HBsAg positive, depending on the population 
surveyed. 
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A higher HBV prevalence is seen in some population groups in Ireland. 
The prevalence of anti-HBc in Irish prisoners in 1998 was 8.7% overall and 
in injecting drug-using prisoners was 18.5%. Homeless people also have 
evidence of increased exposure to hepatitis B, with a prevalence of anti-
HBc of 9% in a study performed in Dublin in 1999-2000. 
Figure 6.2 shows the number of statutory notifications of  hepatitis B 
infection in Ireland, 1982-2006. The increase in notifications since 1998 
may be largely attributed to changes in immigration patterns and the 
introduction of active screening in high-risk populations. Most of these 
notifications are cases of chronic infection. For HBV notifications received 
by the Health Protection Surveillance Centre in 2006, 90% of the chronic 
HBV cases, where country of birth was known, were born in a country of 
either high or intermediate prevalence.
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Changes to the Infectious Diseases Regulations in January 2004, with the 
introduction of case definitions, the differentiation between acute and 
chronic cases, and mandatory laboratory notification, have had a positive 
impact on the quality of information available on HBV in Ireland and may 
also have resulted in increased numbers of notifications (see Figure 6.3).
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Figure 6.2 Number of notifications of  hepatitis B, 1982-2006.
Source: HPSC
*Case definitions introduced and laboratories required to notify cases of notifiable infectious diseases from January 2004.
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Transmission 
The virus is transmitted by infected blood or body fluids. Transmission 
mainly occurs by:
• Sexual intercourse, including vaginal and anal
• Blood–to-blood contact (e.g. sharing of personal care items 
such as toothbrushes, razors or by other equipment used by 
injecting drug users (IDUs), needlestick injuries, ear-piercing, 
tattooing)
• Perinatal transmission from infected mother to child
• Transmission has rarely followed bites from infected 
individuals
Transmission by transfusion of contaminated blood or blood products 
is now rare because of routine screening of blood donors and viral 
inactivation of certain blood products.
HBV has been found in virtually all body secretions and excretions. 
However, only blood (and serum-derived fluids), saliva, semen and 
vaginal fluids have been shown to be infectious. People with chronic HBV 
infection are the primary reservoirs of infection.
Patterns of transmission vary according to the prevalence in a particular 
country. In areas of high prevalence, infection is predominantly acquired 
by perinatal transmission in infants, or by horizontal transmission among  
children younger than 5 years. In low-endemicity countries, most 
infections are acquired in adulthood where sexual transmission or sharing 
blood-contaminated needles by IDUs account for most new infections. In 
areas of intermediate endemicity, the pattern of perinatal, childhood and 
adult infection is mixed and nosocomial infection may be important.
In household settings, non-sexual transmission may occur. However, the 
precise mechanisms of transmission are unknown but may possibly be 
due to contact of non-intact skin or mucous membranes with blood-
containing secretions or saliva.  Transmission from sharing towels, razors 
or toothbrushes also may occur. HBV can survive in the environment for 1 
week or longer. 
The risk of an infant acquiring HBV perinatally from an infected mother 
is 70-90% where the mother is HBsAg and hepatitis B e antigen (HBeAg) 
positive; the risk is 5-20% where the mother is HBsAg positive but 
HBeAg negative.
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Effects of Hepatitis B infection 
The incubation period ranges from 40 to 160 days, with an average of 
60-90 days. HBV infection has different clinical manifestations depending 
on the patient’s age at infection. In general, the frequency of clinical 
disease increases with age, whereas the percentage of chronic infections 
decreases.
Many acute infections with HBV are sub-clinical or may present with 
a ’flu-like illness. In patients with clinical illness, the onset is usually 
insidious, with tiredness, anorexia, vague abdominal discomfort, nausea 
and vomiting, and sometimes arthralgias and rash. Jaundice occurs in 
approximately 10% of young children and in 30-50% of adults. Acute 
HBV may occasionally lead to fulminating fatal hepatic necrosis.
Chronic infection, defined as the presence of HBsAg in the serum for at 
least 6 months, occurs in more than 90% of those infected perinatally, 
but this decreases to 20-50% in children infected between 1 and 5 
years of age. Between 2 and 10% of infected immunocompetent adults 
become chronically infected and the risk is probably greater for those 
whose immunity is impaired. Those in whom HBeAg is detectable 
(indicating active viral replication) are most infectious. However, recent 
evidence indicates that those infected with mutant HBV may have high 
levels of HBV DNA in the absence of HBeAg and are therefore also 
highly infectious.  Approximately 20-25% of individuals with chronic HBV 
infection develop progressive liver disease leading to cirrhosis and are 
at increased risk of developing hepatocellular carcinoma. Globally, HBV 
causes 60-80% of the world’s primary liver cancers.
Hepatitis B vaccine
HBV vaccine contains recombinant HBsAg, derived from yeast cells, 
adsorbed onto aluminium hydroxide adjuvant. The vaccine is effective 
at preventing infection in individuals who produce specific antibodies to 
HBsAg (anti-HBs). However, around 10-15% of adults fail to respond or 
have a poor response to 3 doses of vaccine. Poor response is associated 
with age over 40 years, male gender, obesity and smoking. Lower 
seroconversion rates have also been reported in alcoholics, particularly 
those with advanced liver disease. Patients who are immunosuppressed 
or have chronic renal failure may respond less well and may require larger 
or more frequent doses of vaccine (see below). 
HBV vaccine is used for pre-exposure and post-exposure protection and 
provides long-term protection. Pre-exposure immunisation with HBV 
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vaccine is the most effective means of preventing HBV transmission. 
Non-responders at risk of HBV exposure need to report promptly any 
inoculation injury, as passive prophylaxis with specific immunoglobulin 
may be required in these cases. Post-exposure, HBV vaccine is 
highly effective at preventing infection, provided that the vaccine is 
administered preferably within 48 hours but up to 7 days post-exposure. 
Vaccine efficacy studies have shown that 90-100% of vaccinated persons 
who develop anti-HBs concentrations greater than or equal to 10 mIU/ml 
after a primary series are protected from HBV infection.
Indications 
In 1992 the WHO recommended that HBV vaccine be incorporated into 
all national programmes by 1997.  
In 2007 the National Immunisation Advisory Committee (NIAC) 
recommended that universal infant HBV vaccination should be introduced 
in Ireland. This is to run in parallel with the pre-existing targeted 
immunisation programme for those individuals who are at increased risk 
of HBV because of their occupation, lifestyle or other factors (e.g. close 
contact with a case or carrier). 
Ideally, immunisation should be carried out before the risk of exposure 
to HBV (pre-exposure prophylaxis) but it may also follow exposure (post-
exposure prophylaxis).
Pre-exposure prophylaxis
Universal immunisation
All infants should be offered HBV vaccine as part of the routine childhood 
immunisation schedule at 2, 4 and 6 months (see schedule Chapter 2).
Targeted immunisation programme
The following groups are at increased risk of HBV infection and should 
receive HBV vaccine if non-immune:
1. Persons with occupational risk of exposure to blood or blood-
contaminated environments
• Doctors, nurses, dentists, midwives, laboratory staff, mortuary 
technicians, ambulance personnel, cleaning staff, porters, 
medical, nursing and dental students, other health-care 
professionals
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• Staff and carers in centres for those with learning disability 
(including day-care facilities, special schools and other centres)
• Security and emergency services personnel
• Prison staff in regular contact with prisoners
2. Family and household contacts
• The spouses, sexual partners, family and household contacts of 
acute cases and individuals with chronic infection. Where testing 
for markers of current or past infection is clinically indicated, this 
should be done at the same time as the administration of the 
first dose. Vaccination should not be delayed while waiting for 
results of the tests. Further doses may not be required in those 
with clear evidence of past exposure
• Families adopting children from countries with a high or 
intermediate prevalence of hepatitis B. These children should 
be tested for evidence of current or past hepatitis B infection 
and the household contacts offered immunisation if required, 
preferably before the adoption. If the status of the child is 
unknown these families should be recommended vaccination
• All short-term foster carers who receive emergency placements, 
and their families, should be offered HBV vaccination. Permanent 
foster carers, and their families, who accept a child known to be 
at high risk of HBV should also be offered immunisation
• Babies born to mothers with acute or chronic HBV infection (see 
also Post-exposure prophylaxis below) 
3. Injecting drug users and their contacts
• All IDUs
• Sexual partners of IDUs (whether they inject or not)
• Children of IDUs
• Non-injecting drug-users living with current injectors
• Those who are at risk of progressing to injecting drug use (e.g. 
on other illicit substances) 
4. Individuals at high risk due to medical conditions
• People with haemophilia and those receiving regular transfusions 
of blood or blood products, and carers responsible for the 
administration of such products
• Clients in centres for those with learning disability (including day-
care facilities, special schools and other centres)
• Patients with chronic renal failure. Early immunisation of patients 
with evolving chronic renal failure is advised, before they require 
dialysis or transplantation. The immune response to HBV may 
be reduced in patients with chronic renal failure compared to 
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immunocompetent individuals and a more rapid decline in anti-
HBs has been observed
• Patients with chronic liver disease including those with persistent 
hepatitis C infection. Such patients should be vaccinated against 
HBV as concurrent HBV infection may increase the risk of liver 
disease
5. Members of other high-risk groups
• Individuals who change sexual partner frequently, men who have 
sex with men (MSM), male and female commercial sex workers, 
attendees at clinics for sexually transmitted infections (STIs) and 
those diagnosed with an STI
• Inmates of custodial institutions 
• Tattoo and body piercing artists/practitioners
• Immigrants from areas with a high or intermediate prevalence of 
HBV
• Travellers to areas with a high or intermediate prevalence of HBV
• Homeless people
• Children born to parents from high or intermediate endemicity 
countries
Post-vaccination serological testing
Routine post-vaccination testing for anti-HBs is recommended 2 months 
after completing the course of vaccination for persons who are at 
continuing risk of HBV exposure, e.g. health-care workers, patients on 
renal dialysis, sexual partners of HBsAg positive persons. This does not 
apply to children receiving routine childhood immunisation with hepatitis 
B vaccine.
Following primary vaccination, it is preferable to achieve anti-HBs levels 
above 100 mIU/ml although levels above 10 mIU/ml are generally 
accepted as protecting against infection. Anti-HBs titre often declines 
post-vaccination but a rapid anamnestic response develops after 
exposure to the virus.
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Table 6.1 Actions required following post-vaccination testing (except for 
patients with renal failure)
Anti-HBs level Action required
0 or <10 mIU/ml Non responder. 
It is advisable to test for anti-HBc*. If anti-HBc 
negative, repeat full course of hepatitis B vaccine (a 
different brand of vaccine is advised). 
Recheck anti-HBs at 2 months post completion. If 
anti-HBs remains <10 mIU/ml, person is susceptible 
to HBV.
10-99 mIU/ml Low response.  
If low level anti-HBs confirmed by 2 different assays, 
administer booster dose of vaccine but there is no 
need to retest for anti-HBs.
100 mIU/ml or greater Good response.
No need for further vaccination or anti-HBs 
investigations. 
 *For those who are performing exposure-prone procedures, HBsAg testing should also be carried out.
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Table 6.2: Actions required following post-vaccination testing for 
patients with renal failure* (If there is no evidence of HBV infection)
Anti-HBs level Action required
0 or <10 mIU/ml Non responder. 
Repeat full course of hepatitis B vaccine (a different 
brand of vaccine is advised). Recheck anti-HBs 
2-months post completion.
If anti-HBs remains <10 mIU/ml, person is 
susceptible to HBV.
– Test for HBsAg every month
10-99 mIU/ml Low response.  
Give booster dose of vaccine. Check anti-HBs 2 
months later using 2 different assays. Adequate 
response if both  ≥10 mIU/ml.
Re-check anti-HBs annually and if anti-HBs 
decreases to <10 mIU/ml give booster dose but no 
need to check the anti-HBs level until next annual 
check is due.
– Test for HBsAg every 3 months 
100 mIU/ml or greater Good response.
Re-check anti-HBs annually and if anti-HBs 
decreases to <10 mIU/ml give booster dose but no 
need to check the anti-HBs level until next annual 
check is due.
* REF: The Prevention of Transmission of Blood-Borne Diseases in the Health Care Setting 2005
Booster doses
To date there are no conclusive data to support the need for booster 
doses of HBV vaccine in immunocompetent individuals who have 
responded to a primary course. Studies have shown that those who show 
a protective response after vaccination are protected for at least 15 years 
and it is likely that protection is life-long. 
For haemodialysis patients and other immunocompromised people 
at continued risk of infection, the need for booster doses should be 
assessed by annual anti-HBs testing, and a booster dose should be given 
if the anti-HBs level is <10 mIU/ml.
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Dose 
Currently licensed vaccines contain different concentrations of 
antigen per ml. The appropriate manufacturer’s dosage should be 
adhered to. Higher doses of vaccine (40 mcg) should be used for 
adult patients with chronic renal failure, and considered for other 
immunosuppressed adults.
Schedules
(a) Infant HBV vaccination
HBV vaccine should be administered at 2, 4 and 6 months of age as part 
of the routine childhood immunisation schedule. 
(b) Vaccination of those other than infants
The basic schedule consists of three doses of vaccine at 0, 1 month and 6 
months. 
Alternative accelerated schedules (e.g. 0, 1 and 2 months; 0, 7 and 21 
days) exist (see manufacturer’s guidelines) if more rapid protection is 
required for those at immediate risk or for those where compliance with 
the duration of the basic schedule is difficult to achieve. These should be 
followed by a dose of vaccine at 12 months to complete the course.
Route of administration
The vaccine is given intramuscularly in the deltoid region. In the case of 
infants, the vaccine may be given in the anterolateral thigh. The gluteal 
region should not be used as the vaccine efficacy may be reduced. 
Exceptionally, the vaccine may be administered by deep subcutaneous 
injection in patients at risk of haemorrhage.
Hepatitis B vaccine should not be given in the gluteal region.
Vaccine interchangeability
Different HBV vaccine products can be used to complete a primary 
immunisation course or, where indicated, as a booster dose in individuals 
who have previously received another HBV vaccine. One of the licensed 
higher dose vaccine products (used for adult patients with chronic renal 
failure, and considered for other immunosuppressed adults) is NOT 
interchangeable.  
Contraindications
Anaphylactic reaction to a preceding dose of a HBV-containing vaccine or 
any of the constituents.
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Precautions
Acute severe febrile illness, defer until recovery. The response may be 
impaired in those who are immunocompromised, and a further dose of 
vaccine may be necessary.
Pregnancy and breastfeeding
No adverse effect on the developing foetus has been observed 
when pregnant women have been immunised against HBV. Because 
HBV infection may result in severe disease in the mother and chronic 
infection in the newborn infant, pregnancy is not a contraindication to 
immunisation. If an antenatal patient is HBsAg negative but at risk of HBV 
infection, she should be immunised during pregnancy. Breastfeeding is 
not a contraindication to immunisation.
Adverse reactions
Local: Hepatitis B vaccine is generally well tolerated. The commonest 
reactions are soreness and redness at the injection site.  
General: Fever, rash, malaise and influenza-like symptoms are less 
commonly reported after vaccination. 
Post-exposure prophylaxis
Specific hepatitis B immunoglobulin (HBIG) is available for passive 
protection and is normally used in combination with HBV vaccine to 
confer passive/active immunity after exposure. At present only one HBIG 
preparation is authorised in Ireland and this is an intravenous preparation. 
HBIG provides short-term protection (3-6 months).
Post-exposure prophylaxis is recommended for the following groups
1. Babies born to mothers who are HBV infected (HBsAg positive)
Perinatal transmission of HBV infection can be prevented in 
approximately 95% of infants born to HBsAg positive mothers by early 
active and passive immunoprophylaxis of the infant. Routine screening 
of all antenatal patients for HBsAg is essential for identifying women 
whose infants will require post-exposure immunoprophylaxis beginning 
at birth. All babies born to these mothers should receive a complete 
course of vaccine at 0, 2, 4 and 6 months and also HBIG within 24 hours 
of birth. The doses at 2, 4 and 6 months may be given as the routine 6 
in 1. Following the administration of HBIG and the first dose of vaccine, 
arrangements should be made to follow up the child for serological 
assessment and subsequent doses of vaccine. 
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Pre-term babies: It is important that premature infants receive the full 
paediatric dose of HBV vaccine, and HBIG. 
Hepatitis B vaccine should be administered concurrently with HBIG in the 
anterolateral thigh (in a different site from the HBIG).  
Infants born to mothers who are HBV infected should be tested 2 months 
after completing HBV immunisation to determine HBV status and post-
vaccination response.
2.  Household exposures
HBIG and hepatitis B vaccine are recommended for unimmunised 
infants under 12 months of age if the mother or primary care giver has 
acute HBV infection. Prophylaxis with HBIG is not indicated for other 
unimmunised household members of persons with acute HBV infection 
unless they have identifiable blood exposure to the index patient, such as 
by sharing of toothbrushes or razors. Such exposures should be managed 
as in sexual exposures. All household contacts of acute and chronic 
cases should be screened and offered hepatitis B vaccine if susceptible.  
Vaccination should not be delayed while waiting for results of the 
tests. 
3.  Sexual exposure
Exposure to acute cases: Sexual partners of individuals suffering from 
acute hepatitis B and who are seen within one week of last contact 
should be offered both HBIG and vaccine.
Exposure to chronic cases: Sexual contacts of newly identified chronic 
cases should be offered vaccine. HBIG may be added if unprotected 
sexual contact occurred in the past week (a risk assessment may be 
needed depending on whether the contact is a long-term sexual partner 
or recent partner).
4.  HCW or others accidentally exposed to blood or body fluids
Individuals who sustain such injuries should wash the affected area 
well with soap and warm water and seek medical advice. The response 
required in terms of vaccination and/or HBIG will depend on a detailed 
risk analysis of the source, the vaccination/anti-HBs status of the person 
exposed, and the type of exposure. The appropriate prophylaxis should 
be commenced immediately according to Table 6.3. 
A significant exposure is one from which HBV transmission may result:
• Percutaneous exposure to blood or body fluids, e.g. needlestick 
or other contaminated sharp object injury, a bite that causes 
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bleeding or other visible skin puncture
• Mucocutaneous exposure to blood or body fluids, e.g. contam-
ination of non-intact skin, conjunctiva or mucous membrane
• Sexual exposure (unprotected sexual intercourse, oral sex)
• Community needlestick injury (discarded needles and syringes in 
public places)
Dose and route of administration of HBIG
HBIG should be administered according to the manufacturer’s guidelines 
and should ideally be given within 48 hours of exposure but not later 
than a week after exposure. 
Injuries from discarded needles in the community
Injuries from discarded needles and syringes in public places create 
considerable anxiety regarding the possible transmission of blood-borne 
pathogens. While these injuries pose less of a risk than that resulting 
from a needlestick injury in health-care settings, the perception of risk 
often results in the necessity for evaluation, testing and counselling of the 
injured person. 
Management of such injuries includes acute wound care and 
consideration of the need for prophylactic management. Hepatitis B 
virus is the most stable of the major blood-borne viral pathogens and 
can survive in the environment for 1 week or longer. It is advisable to 
administer a full course of HBV vaccine to those susceptible to HBV 
infection. HBIG is not usually required unless the needle comes from 
a known hepatitis B positive source and a risk assessment identifies a 
significant risk of HBV transmission. The likelihood of transmission of 
other blood-borne viruses such as hepatitis C or HIV is very remote.
Recommendation: archive a baseline serum specimen from the injured 
person, initiate hepatitis B vaccination and test samples collected at 3 
and 6 months for HBsAg and anti-HBc, and at 2 months post-completion 
of course of vaccination, for anti-HBs.
Interpretation of Hepatitis B results is set out in Table 6.4, provided for 
reference.
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Introduction
Influenza is an acute illness of the upper and/or lower respiratory tracts. 
It is usually self-limited, with recovery in 2-7 days, but it can be severe. It 
affects all age groups and is characterised by the abrupt onset of fever 
headache, myalgia, cough, sore throat and malaise. 
Epidemiology
Influenza is highly infectious, spreading rapidly especially in 
institutions. It is a segmented, single-stranded RNA virus of the familiy 
orthomyxoviridae. There are three types of influenza virus: A, B and C. 
The first two types are responsible for most clinical illnesses. Influenza 
A viruses can infect a wide range of animal and avian species. Two 
surface antigens make these viruses antigenically labile. These are  
haemagglutinin antigen (H: 15 different types) and neuraminidase (N: 
9 different types), although only H1, H2, H3, N1 and N2 have been 
implicated in widespread human infection. 
Influenza A undergoes two kinds of antigenic mutation due to changes 
in these surface antigens. Minor changes, due to point mutations in the 
haemagglutinin antigen, termed ‘antigenic drift’ are seen progressively 
from season to season, and this is the reason why the vaccine 
composition changes each year. Major changes, termed ‘antigenic shift’, 
occur periodically and can result in the introduction of virtually novel 
viruses, with a different haemagglutinin, into a population, facilitating 
pandemic spread with the potential for severe morbidity and high 
mortality. Mutations only rarely occur in influenza B.
Antigenic variation results in the circulation of viruses to which a given 
population may have little immunity, accounting for the high attack rates 
commonly seen in influenza outbreaks. 
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Influenza outbreaks occur virtually every year (Fig 7.1), although the 
extent and severity of the outbreaks vary widely. Localised outbreaks 
occur at variable intervals, usually once every 1-3 years. In some 
outbreaks, influenza B viruses circulate simultaneously with influenza A 
viruses. Although pandemics provide the most dramatic evidence of the 
impact of influenza overall, outbreaks that occur between pandemics 
account for greater mortality and morbidity, although over a longer 
period of time. Since 1977 influenza A (H1N1), influenza A (H3N2) and 
influenza B viruses have been in circulation.
There is increasing concern regarding the emergence and distribution of 
the highly pathogenic avian influenza (H5N1) and the potential for the 
emergence of a new pandemic strain. Human infections have occurred 
but predominantly only in those in close contact with infected poultry. 
Efficient person-to-person transmission, a pre-requisite for a pandemic 
strain, has not yet been documented.
Influenza A epidemics begin abruptly, reach a peak over a 2-3 week 
period, generally last for 2-3 months and often subside as rapidly as they 
began. Epidemics begin almost exclusively during the winter months. 
A major determinant of the extent and severity of an outbreak is the 
level of immunity in the population, although all the factors that result in 
epidemics are not fully understood. 
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Figure 7.1  Influenza-like illness (ILI) rate per 100,000 population and the 
number of positive influenza specimens detected by the NVRL during the 
2003/2004, 2004/2005, 2005/2006 & 2006/2007 seasons. Source: HPSC
IL
I r
at
e 
pe
r 1
00
,0
00
 p
op
ul
at
io
n
0
5
01
51
02
52
03
53
04
54
05
55
06
56
07
nosaeS azneulfnI
N
um
be
r o
f p
os
iti
ve
 s
pe
ci
m
en
s
0
02
04
06
08
001
A azneulfnI B azneulfnI setar ILI
2003/2004 2004/2005 2005/2006 2006/2007
Infl
uenza
Effects of Influenza
Influenza outbreaks result in significant morbidity in the general 
population. In those with chronic underlying disease, especially the 
elderly, complications are common and hospitalisation rates high. Eighty 
to 90% of reported deaths from influenza occur in the elderly, mainly from 
bacterial pneumonia, but also from the underlying disease. 
Primary influenza A pneumonia is uncommon and is characterised by the 
abrupt onset of a rapidly progressive diffuse pneumonia with pulmonary 
haemorrhage which is often fatal. The frequency of overt pulmonary 
involvement in influenza A infection is age dependent: 4% in those 10-39 
years, 36% in those aged 60-69 years and to 73% in those 70 years of age 
or older.
Severe influenza can be complicated also by encephalitis or 
meningoencephalitis.
Transmission
Influenza is spread from person to person by direct contact, by 
droplet infection or by contact with materials recently contaminated 
by nasopharyngeal secretions. Airborne spread can also occur. It is 
highly contagious, especially in close contact environments such as 
homes for the elderly. Virus can be detected in respiratory secretions 
from just before the onset of clinical illness to 4-5 days after symptom 
onset. Shedding can be more prolonged in young children and in the 
immunocompromised.
Influenza vaccine
A vaccine, recommended by WHO, is prepared each year, using 
virus strains similar to those considered most likely to circulate in the 
forthcoming season. Current vaccines are trivalent, containing antigens 
from two type A and one type B virus strains.  
The virus is egg-grown, inactivated with formalin, and ‘split-virus’ or 
subvirion; preparations are made using solvents or detergents. ‘Surface 
antigen’ vaccines containing highly purified preparations of viral 
neuraminidase and haemagglutinin antigens are also available. Whole-
virus, split-virus (subvirion), and surface-antigen vaccines are of equivalent 
efficacy but the latter two are less likely to induce febrile reactions in 
children. All are supplied in a prefilled syringe.  
Currently available inactivated influenza vaccines provide 70-90% 
protection against influenza in persons under 65 years of age. Protective 
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efficacy against infection is lower in the elderly. However, morbidity and 
mortality in the elderly are significantly reduced. Protection lasts about 1 
year. Annual vaccination with the most recent strains is recommended.
The vaccines should be stored at 2-8ºC and protected from light. They 
should be allowed to reach room temperature and shaken well before 
they are given.
The World Health Organization monitors the strains of influenza 
circulating every year.
The Department of Health and Children and the HSE advise on 
the appropriate vaccine for annual use each year, based on WHO 
recommendations.
Remember annual immunisation is necessary. Ideally, give in 
September/October each year but can be given throughout the 
year. (Antibodies may take up to 10-14 days to reach protective 
levels so give early.)
Children under 9 years of age require two doses of vaccine, 
separated by 4-6 weeks, if receiving the vaccine for the first time.
Indications
Vaccination is recommended for:
1. Those older than 6 months of age who are at increased risk of 
influenza-related complications including the following groups:
a) Persons aged 50 years or older 
b) Those with chronic illness requiring regular medical 
follow-up (e.g. chronic respiratory disease, including 
cystic fibrosis, moderate or severe asthma, chronic heart 
disease, bronchopulmonary dysplasia, diabetes mellitus, 
haemoglobinopathies, chronic renal failure, chronic liver 
disease, chronic neurological disease including multiple 
sclerosis, hereditary and degenerative disorders of the 
central nervous system)
c) Immunosuppression due to disease or treatment, including 
asplenia or splenic dysfunction 
d) Children on long-term aspirin therapy (because of the risk of 
Reyes Syndrome)
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e) Children with any condition (e.g. cognitive dysfunction, spinal 
cord injury, seizure disorder, or other neuromuscular disorder) 
that can compromise respiratory function especially those 
attending special schools/ day centres
f)  Those with morbid obesity i.e. Body mass index equal to or 
over 40
g) Residents of nursing homes, old people’s homes, and other 
long-stay facilities where rapid spread is likely to follow 
introduction of infection
2. Those likely to transmit influenza to a person at high risk for influenza 
complications (including household contacts and out-of-home care 
givers)
3. Health-care workers, both for their own protection – as these are a 
group likely to come in contact with influenza during outbreaks – and 
for the protection of their patients (see Chapter 18)
4.  People who have close, regular contact with pigs, poultry or water 
fowl
5.  All pregnant women at any stage of pregnancy. Studies indicate 
that pregnancy may increase the risk of complications from influenza 
(especially H1N1 disease) because of the alterations in heart rate, 
lung capacity, and immunological function.  It is estimated that 
immunisation could prevent 1-2 hospitalisations per 1,000 pregnant 
women. Because influenza virus vaccine is not a live vaccine it is 
considered very safe in pregnancy.
Addition to indication 1 (b) and 1 (e). Addition of indication 1 (f). Change to indication 
4.Updated February 2011 Change to indication 5 . Updated September 2011
Dose and route of administration 
As dose recommendations for children can vary between products 
please consult the individual data sheets.
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Table 7.2 Dose and route of administration of influenza vaccine
Age group Dose
Children 6 months to <9 years A single injection of 0.5 ml IM. If 
receiving influenza vaccine for the first 
time, 2 doses are required; the second 
dose should be given 4 weeks after the 
first dose. 
Adults and children ≥9 years A single injection of 0.5 ml IM 
Immunosuppressed people ≥ 
6 months 
A single injection of 0.5 ml IM If 
receiving influenza vaccine for the first 
time, 2 doses are required; the second 
dose should be given 4 weeks after the 
first dose. 
Table 7.2 changed.  Update September 2011
• The deltoid muscle is the recommended site for adults and older 
children.
• The anterolateral thigh may be used for infants and young 
children.
• Antibody levels take from 10-14 days to rise. 
• The ideal time for immunisation is before the influenza season, 
i.e. from September to October. Note: if travelling to the 
southern hemisphere check Chapter 19.
Influenza vaccine may be given at the same time, but at a different site, 
as pneumococcal vaccine. 
Anyone may choose to have the ‘flu vaccine.
Changed September 2011
Contraindications
Anaphylaxis following a previous dose of influenza vaccine or any of its 
constituents (other than ovalbumin – see precautions)
Changed September 2011
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Precautions
1. Acute severe febrile illness, defer until recovery
2.  Egg allergy: Those with confirmed egg anaphylaxis and non-
anaphylactic egg allergy can be given an influenza vaccine with an 
ovalbumin content <0.06μg per dose-see Table 7.3. Vaccines with 
ovalbumin content equal to or more than 0.06 μg per dose or where 
content is not stated should not be used in egg-allergic individuals
Table 7.3 Influenza vaccination for those with egg allergy
History Recommendation
Non-anaphylactic egg allergy 
without severe  asthma (BTS/
SIGN <4)
Seasonal influenza vaccine with 
ovalbumin content <0.06μg per dose, 
in primary care, with observation for 60 
minutes
Egg anaphlyaxis or egg 
allergy and severe asthma 
(BTS/SIGN >4)
Refer to hospital specialist for 
vaccination with seasonal influenza 
vaccine with ovalbumin content 
<0.06μg per dose.
Skin testing is not necessary and 
vaccine should be given as a single 
dose with observation for 60 minutes 
NB: As for all vaccinations, facilities should be available and staff trained 
to recognise and treat anaphylaxis
3.  Co administration with PCV 13: Vaccine safety data from the United 
States earlier in 2011 reported a small but increased risk of febrile 
convulsions among children aged 12-23 months who received PCV13 
at the same time as inactivated influenza vaccine used in the 2010-
2011 season (risk approximately 1 in 1,640 vaccinees). 
Therefore, for the 2011-2012 influenza season for children aged 12-23 
months of age who are recommended influenza vaccine, consideration 
may be given to separating PCV13 and seasonal influenza vaccines by 
an interval of at least one week to decrease the risk of febrile seizures 
occurring.
Changed September 2011
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Adverse reactions
Local: Soreness and redness around the vaccination site occurs in up to 
one-third of people.
General: Injectable influenza vaccines contain inactivated virus and 
cannot cause influenza.
• Fever, malaise and myalgia commencing 6-12 hours after 
immunisation and lasting for about 48 hours, occur rarely.
• Immediate reactions such as urticaria, angio-oedema, 
bronchospasm, and anaphylaxis occur very rarely. Such reactions 
are most likely due to hypersensitivity to the egg protein.
• Guillian Barré syndrome has on rare occasions been temporally 
associated with influenza vaccination.
Antiviral agents  
If considering using antivirals check the HPSC website to discover 
whether influenza is circulating and only use antivirals if this is confirmed. 
Antivirals such as neuraminadase inhibitors can be used for treatment 
and prophylactic purposes during influenza epidemics. People who may 
be considered for prophylaxis include:
• Unimmunised patients in the ‘at risk’ groups, including health-
care workers, for 2 weeks while the vaccine takes effect
• At-risk patients, who had an anaphylactic reaction to egg, for the 
duration of an outbreak
• Control of influenza outbreaks in a closed setting such as 
institutions with high-risk individuals
• Protection of immunocompromised children who may not 
respond to vaccine.
Antiviral agents are not a substitute for immunisation for the 
control and prevention of influenza.
Influenza surveillance
The Health Protection Surveillance Centre in partnership with the Irish 
College of General Practitioners (ICGP) and the National Virus Reference 
Laboratory (NVRL) have established a network of 52 computerised 
sentinel practices who report on a weekly basis the number of patients 
seen with influenza-like illness. Virological confirmation by the NVRL is 
required to identify that influenza is the causative virus, with classification 
of type and sub-type. 
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A weekly influenza report, including clinical and virological data, is 
compiled throughout the influenza season, from October to May.  
Since the 2005/2006 season there has been reporting during the inter-
season period, of clinical data on a weekly basis, virological data on a 
fortnightly basis, and monthly surveillance reports are produced. Reports 
of worldwide influenza activity are also provided as part of the overall 
monitoring of influenza activity.   
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Introduction
Measles is an acute viral illness caused by a morbillivirus of the 
paramyxovirus family. There is only one antigenic type, with a number 
of genotypes. Humans are the only known host. Both infection and 
appropriate immunisation confer long-lasting immunity. 
One case of measles can infect 15-20 unvaccinated people. A vaccine 
uptake rate of at least 90-95% with 2 doses is required to halt endemic 
transmission of the virus and thus eliminate measles.
Measles remains a leading cause of vaccine-preventable death 
worldwide. In 2004 an estimated 450,000 people died from measles, 
mostly in low-income countries. Eighty percent of those dying were aged 
under 5 years. In Europe in 2004, 29,000 cases were reported. The WHO 
has set a target date of 2010 for the elimination of measles and rubella in 
Europe.
Epidemiology 
The incidence of measles in Ireland declined dramatically after the 
introduction of monocomponent measles vaccine in 1985, from 10,000 
cases in that year to 201 cases in 1987. In 1988 a combined measles, 
mumps and rubella vaccine (MMR) was introduced for children aged 
12-15 months. In 1992 a second dose of MMR was recommended to be 
given at 10-14 years of age. In 1995 a measles and rubella (MR) catch-up 
campaign was carried out. In 1999 the age for the second dose of MMR 
was reduced to 4-5 years.
An outbreak of measles in 1993 affected more than 4,000 people, and 
in 2000 over 1,600 cases of measles were reported, with 3 associated 
deaths (Figure 8.1).
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From 2001-2006 there were 1,562 cases of measles notified in Ireland.  
Incomplete vaccine coverage together with a pool of susceptible 
unvaccinated older children resulted in rapid spread of the infection 
during these outbreaks (Figure 8.2). 
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Figure 8.1 Number of measles notifications in Ireland, 1980-2006. 
Source: HPSC
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Figure 8.2 Number of measles notifications in Ireland, 2001-2006. 
Source: HPSC
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Transmission of measles is by droplet infection. The virus can remain 
viable on infected surfaces for up to 2 hours.
The incubation period is 10 days (range 7-18 days) with a further 2-4 days 
before the rash appears. Patients are infectious from 4-5 days before to 4 
days after the onset of rash.  
Effects of measles
The prodromal phase is characterised by fever, malaise, rhinitis, 
conjunctivitis and cough. The erythematous and maculopapular rash first 
appears behind the ears and spreads to the face, trunk and limbs over 3-
4 days. The rash may become confluent in places. It begins to fade after 
3-4 days, leaving a temporary brownish discolouration. Koplik’s spots, 
which are small red spots with blueish-white centres, may appear on the 
mucous membranes of the mouth from 2 days before to 2 days after the 
rash appears.
Approximately 30% of measles cases have one or more complications, 
which are more common in children under 5 years of age and in adults 
over 20 years of age. The complications include pneumonia (1-6%), otitis 
media (7-9%), diarrhoea (8%), convulsions (0.5%) and encephalitis (0.1%). 
Transient immunedeficiency can occur, with decreased numbers of T cells 
and leucopoenia, which can last for weeks. 
There are three types of measles encephalitis:
1. Acute demyelinating encephalomyelitis occurs about one 
week after the onset of the rash in approx 1/1,000 cases, has 
a mortality of about 15% and results in residual neurological 
sequelae in 20-40% of survivors.
2. Measles inclusion body encephalitis, a delayed type of 
encephalitis, occurs in immunocompromised patients. It 
can occur without a preceding measles-like illness, and is 
characterised by acute neurological compromise, loss of 
conciousness, seizures and progressive neurological damage.
3. Sub-acute sclerosing panencephalitis (SSPE), a degenerative 
CNS disease progessing to death. If measles infection occurs 
in children under 2 years of age the rate of SSPE is 1 in 8,000 
infections. If infection occurs in children under 1 year of age, the 
risk of SSPE is 16 times greater than with infection occuring over 
5 years of age.
Death occurred in 1 in 500 notified cases in Ireland in the outbreak 
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of 2000. The case fatality rate is highest in children under 1 year of 
age, lowest in those aged 1-9 and rises again in teenagers and adults. 
Pneumonia accounts for 56-86% of measles-associated deaths.
Complications and mortality rates are high in the immunocompromised, 
the malnourished and in those with vitamin A deficiency. Severe 
complications may occur in up to 80% of these patients, with case-fatality 
rates of 70% in patients with cancer. Measles is the most important cause 
of blindness in children with borderline vitamin A levels, by precipitating 
xerophthalmia.
Modified measles occurs primarily in those who receive immunoglobulin 
as post-exposure prophylaxis or in infants with residual maternal 
antibodies. It is characterised by a prolonged incubation period, mild 
prodrome and a sparse, discrete rash of short duration. A similar illness 
has been reported in previously vaccinated persons.
Measles vaccine
Measles vaccine is only available as MMR (Measles, Mumps and Rubella 
vaccine). The vaccine contains attenuated measles, mumps and rubella 
viruses which are cultured separately and mixed before lyophilisation. 
The lyophilised powder is reconstituted using the diluent supplied 
and shaken well to completely dissolve the pellet. The reconstituted 
vaccine is yellow in colour and should only be used if clear and free from 
particulate matter.
An up-to-date list of licensed vaccines is contained in Appendix 1, or can 
be accessed on the IMB website, www.imb.ie.
MMR does not contain thiomersal or any other preservatives. It must 
be kept refrigerated at 2-8ºC, and protected from light. It should 
be used within 1 hour of reconstitution. Failure to adhere to these 
recommendations can result in loss of vaccine potency and diminished 
effectiveness. 
Over 90% of individuals develop immunity to measles and rubella after 
1 dose of vaccine. Two doses give protection in over 98% of people 
(see point 1, Indications). Between 61% and 91% are protected against 
mumps after 1 dose; and 98% are protected after 2 doses. Serological 
and epidemiological evidence indicates that vaccine-induced immunity is 
possibly lifelong.
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Low rates of seroconversion occur in those under 12 months of age, 
because of maternal antibodies.
Deferral of MMR following blood or immunoglobulin transfusion 
(except anti-RhD immunoglobulin, see p. 90/112/145)
Deferral of MMR following blood or immunoglobulin transfusion
Blood and blood products may contain significant levels of virus-specific
antibody, which could prevent vaccine virus replication. Where possible,
MMR should be deferred for at least 3 months after receipt of low-dose
immunoglobulin, 6 months after red-cell transfusion, and 11 months after
high-dose immunoglobulin (as for Kawasaki Disease). Anti-RhD 
immunoglobulin can be administered simultaneously or at any time in 
relation to MMR (varicella on page 142).  If the MMR vaccine
is administered within these timeframes, a further dose should be given
outside these times.
Laboratory investigation to determine vaccine response is not routinely 
recommended. 
Persons who are tuberculin-positive may have a negative tuberculin test 
for 3 months after measles infection or MMR vaccine. 
Scientific evidence shows no association between the MMR vaccine 
and autism or inflammatory bowel disease.
Dose and route of administration
The dose is 0.5 ml by deep intramuscular injection. The deltoid is the 
recommended site of administration. The anterolateral thigh may also be 
used.
Alcohol swabs are best avoided as alcohol can inactivate the MMR 
vaccine.  If alcohol is used to clean the skin it must be allowed to 
evaporate completely before the injection is given.
When other injectable vaccines are being given concurrently with MMR, 
different sites should be used.
MMR may be given at the same time as DTaP, IPV, MenC, Hib and 
Hep B in situations where the latter are overdue.
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Indications
1. All children at 12-15 months of age, with a second dose at 4-5 
years of age. For older children who have not received 2 doses, 
MMR vaccine should be given as soon as possible, and a second 
dose one month later. Allowing 3 months between doses is 
likely to maximise the response rate in children aged under 18 
months. Where protection against measles is urgently required 
the second dose can be given 1 month after the first. If children 
aged under 18 months are given the second dose less than 3 
months after the first dose, they need a third dose to ensure full 
protection. This can be given at 4-5 years.
MMR vaccine can be given to those who have a history of 
measles, mumps or rubella infection.
2. Measles outbreaks
Outbreaks of measles should be controlled by immunising all 
susceptible individuals within 72 hours of contact, as vaccine-
induced immunity develops more rapidly than natural antibody.  
• If these persons have had no previous measles vaccine, a 
second dose is given one month later.  
• During an outbreak, particularly if there are high attack 
rates in younger infants, MMR vaccine may be given to 
children as young as 6 months of age. However, maternal 
antibodies may compromise the response to the vaccine. 
Therefore children vaccinated before their first birthday 
should have a repeat vaccination at 12-15 months of age, 
at least 1 month after the first vaccine, with a further dose 
at 4-5 years of age.  
• Some persons may require HNIG (see below).
3. Children with chronic conditions such as cystic fibrosis, congenital 
heart or kidney disease, failure to thrive or Down syndrome are at 
particular risk of measles infection and should be immunised with 
MMR vaccine.  
4. Children coming from low-income countries have probably 
received measles vaccine but not rubella or mumps vaccine. 
Therefore, unless there is a reliable history of vaccine 
administration, these children should be regarded as 
unimmunised, and given 2 doses of MMR one month apart.
5. Individuals born before 1978 are likely to have had measles 
infection.  MMR vaccine should be offered to such individuals on 
request if they are considered at high risk of exposure.
6. Health-Care Workers (HCWs) in the following situations (see 
Chapter 18). Protection is important both for themselves and 
in the context of their ability to transmit measles to vunerable 
groups.
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• Those who do not have evidence either of measles 
infection or of having received 2 doses of MMR vaccine 
should be given 2 doses of MMR, separated by at least 1 
month.
• If an outbreak occurs in an institution or an area served by 
an institution, HCWs should be given 1 dose of MMR. 
When measles outbreaks occur, susceptible persons should be 
given MMR within 72 hours of contact with a case.
Antibody response to the mumps and rubella components of the 
MMR vaccine does not develop quickly enough to provide effective 
prophylaxis after exposure to suspected mumps or rubella. Human 
normal immunoglobulin is not recommended for the post-exposure 
protection of pregnant women exposed to rubella. Human normal 
immunoglobulin is not routinely used as post-exposure protection from 
mumps.
Contraindications
1. Anaphylaxis following a previous dose of MMR or one of its 
constituents (e.g. Neomycin, Gelatin)
2. Significantly immunocompromised persons, such as those with 
untreated malignant disease and immunodeficiency states other 
than HIV infection, and those receiving immunosuppressive 
therapy, high-dose x-ray therapy and current high-dose systemic 
corticosteroids (see Chapter 2)
3. Pregnancy. Furthermore, pregnancy should be avoided for 1 
month after MMR
There is no evidence to recommend or support the use of single 
vaccines against measles, mumps or rubella in place of the 
combination MMR vaccine.
The following are NOT contraindications to MMR vaccine
1. Allergy to egg, even anaphylaxis following egg. If there is a 
genuine concern regarding serious allergy, a paediatrician may 
be consulted and the vaccine given in hospital although this is 
not medically necessary. Currently-used measles and mumps 
vaccines do not contain significant amounts of egg cross-reacting 
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proteins and recent data suggest that anaphylactic reactions to 
MMR are not associated with hypersensitivity to egg antigens but 
to other vaccine components (Gelatin or Neomycin)
2. Breast-feeding
3. HIV-positive patients who are not severely immunocompromised
4. Personal or family history of convulsions. Advice regarding the 
possibility and treatment of pyrexia should be given
5. Immunodeficiency in a family member or household contact
6. Uncertainty as to whether a person has had 2 previous MMR 
vaccines
7. Administration of anti-RhD immunoglobulin. As anti-RhD 
immunoglobulin does not interfere significantly with the 
antibody response to MMR (varicella on p. 145) vaccine, the two 
injections may be given simultaneously (in different syringes, at 
different sites), or at any time in relation to each other.
Precautions
1. Acute severe febrile illness, defer until recovery
2. Injection with another live vaccine within the previous 4 weeks
3. Recent administration of blood or blood products (see above)
4. Patients who developed thrombocytopenia within 6 weeks of 
their first dose of MMR should undergo serological testing to 
decide whether a second dose is necessary. The second dose 
is recommended if the patient is not fully immune to the 3 
component viruses.
Adverse reactions
Soreness and erythema may occur at the injection site (3-8%). Fever (6%), 
rash (7%), headache, vomiting and salivary gland swelling may occur. A 
febrile convulsion occurs in 1 in 1,000 children.
‘Mini-measles’ may occur 6-10 days after immunisation and consists of 
mild pyrexia and an erythematous rash. ‘Mini-mumps’ with salivary gland 
swelling may rarely occur during the third week after immunisation. Very 
rarely, anaphylaxis, erythema multiforme, thrombocytopoenia, and nerve 
deafness have been reported.
The rubella component may occasionally produce a rash, mild arthralgia, 
and lymph-node swelling 2-4 weeks post-vaccination, particularly in post-
pubertal females (up to 25% of recipients). The incidence is lower than 
after natural disease. 
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There is no evidence of congenital rubella syndrome or increase in other 
teratogenic effects in women inadvertently given rubella vaccine before 
or during early pregnancy, but pregnancy remains a contraindication.
Adverse reactions are considerably less common (under 1%) after a 
second dose of MMR.
Protection of contacts with immunoglobulin
The following children and adults who come into contact with measles 
should be considered for treatment with human normal immunoglobulin 
(HNIG) as soon as possible after exposure (at least within 5 days):
1. Those with compromised immunity (see Chapter 2)
2. Infants age 5-12 months (those aged under 5 months will usually 
have maternal antibodies)
3. Infants of mothers who develop measles, as such infants will not 
have maternally derived antibodies
4. Non-immune pregnant women. As most such women are 
immune to measles, measles IgG should be checked. HNIG can 
be offered to non-immune subjects. They should also be offered 
MMR vaccine after delivery, at least 3 months after receiving 
HNIG.
Although administration should not wait for laboratory confirmation 
of measles in the index case, a complete risk assessment should be 
undertaken prior to administration of the HNIG.
If HNIG is not available, in certain high-risk situations IVIG can be given, 
as it usually contains similar measles antibody levels to HNIG.
Those contacts on maintenance IVIG do not need either HNIG or IVIG if 
they have been given IVIG within 3 weeks prior to exposure.
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Introduction
Meningococcal infection is the spectrum of disease caused by Neisseria 
meningitidis and includes meningitis, septicaemia and, less commonly, 
other invasive infections such as septic arthritis or endopthalmitis. The 
meningococci are Gram-negative diplococci and are divided into at least 
13 antigenically distinct serogroups; most disease-associated strains 
belong to serogroups A, B, C, Y or W135. In Ireland serogroup B and C 
strains accounted for over 99% of all invasive meningococcal disease 
prior to the introduction of the serogroup C conjugate vaccine in 2000. 
The significance of the meningococcus as a pathogen lies in the 
potential severity of the illness, the absence of effective vaccines 
against all individual meningococcal serogroups, the unique ability of 
the organism to cause outbreaks or epidemics, and the intense public 
anxiety that follows a case or outbreak. In Ireland the majority of cases of 
meningococcal infection are sporadic.
Epidemiology
N. meningitidis is a human-only pathogen and is carried in the 
nasopharynx. Overall approximately 10% of the population is 
asymptomatic carriers. Carriage is uncommon in infancy and early 
childhood with peak carriage rates (up to 25%) occurring in the 15-
19 year age group. Transmission occurs from person-to-person via 
respiratory droplets or direct mucosal contact with respiratory secretions 
of a person carrying the organism. Naturally acquired serum bactericidal 
antibodies to N. meningitidis result from carriage, the duration of 
immunity induced is unknown.
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A small minority of individuals who pick up N. meningitidis develop 
invasive infection after an incubation period which is typically 1-10 
days, usually less than four days. The reasons why invasive infection 
develops in some individuals but not in others are unclear. Factors that 
have been identified as increasing the risk of invasive infection include 
active or passive smoking, a preceding severe respiratory tract infection 
particularly influenza A, and living in closed or semi-closed communities 
such as military barracks or halls of residence, often in the setting of 
dormitory accommodation. 
Individuals with late complement or properdin deficiencies, or those with 
functional or anatomic asplenia, have an increased risk of invasive and/
or recurrent meningococcal disease. There is a strong association with 
susceptibility to meningococcal disease and deficiencies in the early 
complement components (C1, C4, C2 but especially C3) and the late lytic 
components (C5 – C9) of the complement pathway. C2 deficiency is the 
most common familial complement deficiency detected in Ireland.
•  Individuals with C3 defects are at risk of severe infection with 
encapsulated bacteria including N. meningitidis.
•  Meningococcal disease in individuals with deficiencies of late 
complement components (C5-C8) is almost always caused by 
serogroup W135, Y or 29E (serogroups B and C are less common).
•  Recurrent meningococcal disease is typical in persons with C5-C8 
deficiencies.
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Figure 9.1 Notifications of serogroup B and serogroup C meningococcal 
infection in Ireland, by month and year 1999-2010. Source: HPSC
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Individuals who have had recurrent meningococcal infection should 
be tested for complement deficiency; investigations should ideally be 
performed some weeks following infection. 
Properdin deficiency is a very rare X-linked defect. Screening for 
properdin deficiency should be considered when there is a family history 
of meningococcal disease occurring in accordance with an X-linked 
pattern (many males affected).
Invasive meningococcal disease occurs in all countries worldwide. The 
infection is endemic in Northern Europe, with a background incidence 
of 2-3 culture confirmed cases per 100,000 per annum. In Ireland the 
infection shows a seasonal variation, the majority of cases occurring in 
winter and early spring. Periodic upsurges in meningococcal activity 
resulting in hyperendemic disease occur, associated with increased 
circulation of distinct subtypes and/or a hypervirulent strain or strains.
There have been many large epidemics of meningococcal disease 
following introduction and spread of hypervirulent strains. Epidemic 
disease is characterised by an increased case-attack rate and altered 
age distribution, with increased numbers of cases seen in adolescents 
and adults. Examples include serogroup A epidemics in England 
and Wales that coincided with each of the two world wars, and large 
epidemics involving serogroup A or serogroup W135 strains have occurred 
in association with the annual pilgrimage (Hajj) to Mecca, Kingdom 
of Saudia Arabia, with importation into other countries by returning 
pilgrims.
However, in the last 100 years, the highest burden of disease has been 
in the so-called ‘meningitis belt’ of sub-Saharan Africa, due mainly to 
serogroup A or less commonly, serogroup W135 with attack rates of up to 
1/1,000 and reported mortality rates of up to 40%. Epidemic disease with 
distinct serogroup B strains has also occurred, including a large epidemic 
in Norway in the 1970s and in New Zealand in the last 15 years.
Invasive meningococcal disease may occur at any age but in endemic 
countries, sporadic infection is most common in infancy and early 
childhood, with a second smaller peak of incidence in adolescents and 
young adults. Outbreaks or epidemics are typically associated with a 
shift in the age groups affected with increased numbers of cases in older 
individuals. 
In Ireland, the overall case-fatality rate is less than 5%. Serogroup C 
infection is typically associated with higher morbidity and mortality rates 
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in adolescents and young adults than in other age groups. Overall, the 
mortality rates are higher in individuals with septicaemia than in those 
with meningitis alone. Survivors may have permanent morbidity including 
skin scarring, digit and/or limb amputation, seizures, hearing loss, brain 
damage or chronic renal failure.
Impact of N. meningitidis serogroup C conjugate vaccine in Ireland 
Since the introduction of the N. meningitidis serogroup C conjugate 
(MenC) vaccine into the Irish schedule in 2000, the incidence of 
serogroup C disease has shown a 97% reduction, from 132 culture and/
or PCR confirmed cases in 1999 to 4 culture and/or PCR confirmed cases 
in 2010 (Figure 9.1 and Figure 9.2). In the same period the number of 
culture and/or PCR confirmed cases of serogroup B disease fell from 285 
in 1999 to 93 in 2010.
Effects of meningococcal disease
The onset of disease may be fulminant, with abrupt onset of fever, 
prostration, shock, a rapidly progressing purpuric rash and death; or it 
may be insidious, with a mild upper respiratory prodrome of 2 or 3 days. 
In an infant or young child the common early symptoms (reluctance to 
feed, trivial fever and irritability) are non-specific. Clinical recognition of 
meningococcal disease in the initial phase of the illness is problematic. 
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Figure 9.2 Crude incidence rate (per 100,000) of invasive meningococcal 
disease in Ireland, by year,1997-2010.Source: HPSC
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The patient’s skin may appear blotchy or pale. A typical non-blanching 
petechial or purpuric rash may be present with meningococcal 
septicaemia; however, the rash may be very scanty and may initially be 
erythematous.
One review of the course of illness in children prior to admission to 
hospital found that most had only non-specific symptoms in the first 
4-6 hours, with the classic features of haemorrhagic rash, meningism 
and impaired consciousness developing later (median onset 13-22 
hours). In contrast, early symptoms of sepsis (leg pains, cold hands 
and feet, abnormal skin colour) were present in 72% at a median time 
of 8 hours. The signs and symptoms of meningococcal meningitis are 
indistinguishable from the signs and symptoms of bacterial meningitis 
caused by other pathogens, with the exception of the rash, which may be 
present in some 40% of patients.
Meningococcal vaccines 
There are currently three meningococcal vaccines available in Ireland:
A) Conjugate Meningococcal C Vaccine
B) Conjugate Quadrivalent (ACW135Y) Vaccine
C) Polysaccharide Quadrivalent (ACW135Y) Vaccine
Indications
Individuals for whom meningococcal vaccines are recommended 
Routine programme
Conjugated meningococcal C (Men C) vaccine is recommended as part 
of the routine childhood immunisation programme and for individuals 12 
months to 23 years who have not had a dose after 12 months of age.
Contacts of cases- detailed below
Children and adults with asplenia or splenic dysfunction or complement 
or properidin deficiency
Children and adults with asplenia or splenic dysfunction are considered 
to be at increased risk of invasive meningococcal disease (detailed 
above). However, these individuals may have a sub-optimal response 
to meningococcal vaccines. Administration of quadrivalent conjugate 
ACW135Y vaccine is now recommended for these individuals. See below 
for details.
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Meningococcal vaccines information
A. Meningococcal serogroup C conjugate vaccine (MenC)
The serogroup C polysaccharide antigen is attached to a carrier protein. 
The conjugated vaccines induce a T-cell dependent memory response 
from 2 months of age. For optimal and long-lasting priming of the 
immune system, a booster is recommended in the second year of life. 
Dose and route of administration
The dose at all ages is 0.5 ml, given by intramuscular injection in the 
anterolateral thigh or the deltoid region.
In patients with thrombocytopenia or bleeding disorders, MenC vaccine 
may be given subcutaneously (see Chapter 2).
Indications
Primary schedule
Infants under 12 months require 2 doses, at 4 and 6 months, with a 
booster at 13 months. Those over 12 months who have not received 
MenC vaccine when under 1 year of age need only 1 dose. 
Contacts of cases of serogroup C disease
Close contacts of cases of meningococcal infection have an increased risk 
of developing the disease in subsequent weeks. MenC vaccine should 
be given to all previously unimmunised close contacts (of all ages), in 
addition to chemoprophylaxis. Close contacts who are only partially 
immunised should complete the course of vaccine. Those who completed 
a course more than one year before should be offered a booster.
Index Cases of serogroup C disease
Index cases should be offered conjugate quadrivalent (ACW135Y) vaccine 
to provide protection against all four groups, even though recurrent 
meningococcal infection is rare.
Local outbreaks of serogroup C disease
Immunisation has been shown to be effective in controlling outbreaks 
in institutions (e.g. schools) and communities, reducing the incidence of 
infection.
For confirmed serogroup C infection, MenC conjugate vaccination 
should be offered to all close contacts who had not previously been 
immunised with MenC conjugate vaccine. Close contacts who are 
partially vaccinated should complete the course of MenC vaccination. 
Close contacts of any age who were only immunised in infancy and those 
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who completed the recommended immunisation course (including the 
13 month booster) more than one year before should be offered an extra 
dose of MenC conjugate vaccine. 
Children and adults with asplenia or splenic dysfunction or complement 
or properidin deficiency
Children and adults with asplenia or splenic dysfunction are at 
increased risk of invasive disease with capsulated organisms including 
meningococcal disease. However, these individuals may have a sub-
optimal response to meningococcal vaccines. Quadrivalent conjugate 
ACW135Y vaccine instead of MenC vaccine is now (2011) recommended 
for these individuals. See section B on quadrivalent conjugate ACW135Y 
vaccine. 
Those children who may have commenced the routine immunisation 
schedule with MenC but are identified to have asplenia or splenic 
dysfunction or complement or properidin deficiency prior to completion 
of the primary schedule of MenC vaccination are recommended the 
conjugate ACW135Y vaccine instead of MenC vaccine to complete the 
course. See section B on conjugate ACW135Y vaccine 
Contraindications
Anaphylactic reaction to a preceding dose or any of the constituents, 
including meningococcal serogroup C polysaccharide, or the carrier 
protein (diphtheria toxoid or CRM197).
Precautions
Acute severe febrile illness, defer until recovery.
Pregnancy: There is no evidence of risk from immunising pregnant 
women or those who are breast-feeding, with inactivated viral or 
bacterial vaccines or with toxoids. Hence, MenC vaccine may be given 
when there is a high risk of the individual developing the disease.
Adverse reactions
Local: Injection site reactions may occur, are generally mild and last for 
approximately 24-48 hours.
General: Generalised reactions are rare. 
B.  Conjugate quadrivalent (ACW135Y) vaccine (newly licensed in 
Ireland in 2011)
Conjugate quadrivalent (ACW135Y) vaccine is made from capsular 
polysaccharide extracted from cultures of serogroup A, C, W135 and Y 
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Neisseria meningitidis. The polysaccharides are conjugated to CRM197. 
Conjugation improves the immunogenicity, especially in young children and 
older people
The vaccine is licensed in Ireland for those aged 11 years and older. It is not 
currently licensed for infants or children < 11 years of age. However, data show 
a better antibody response to all serogroups after two doses of conjugate 
vaccine than seen with the polysaccharide vaccine; the response to serogroup 
C is comparable with that seen with the monovalent MenC conjugate vaccine. 
Based on this and experience with other conjugate vaccines, immunity is 
expected to be higher, longer-lasting and confer less risk of immunological 
tolerance than the polysaccharide vaccine. 
For this reason, conjugate vaccine is recommended in preference to 
polysaccharide vaccine in children under five years of age and is the preferred 
vaccine for individuals five years of age or older at risk of exposure to Neisseria 
meningitidis groups A, C, W135 and Y, to prevent invasive disease (see table 
19.1)
Dose and route of administration
The dose at all ages is 0.5 ml, given by intramuscular injection in the 
anterolateral thigh or the deltoid region.
Schedules 
Infants 2 months and over
Two doses of 0.5 ml given with at least one month interval. Children at 
continued increased risk (see below “Indications”) should additionally 
receive a third dose after 12 months of age (these doses replace the MenC 
vaccine)
Children > 12 months and adults
Single dose of 0.5 ml given by intramuscular injection. 
Booster
The conjugate quadrivalent (ACW135Y) vaccine is likely to provide longer 
lasting protection than the polysaccharide vaccine. However, the need for 
and the timing of booster dose has not been determined.
For children who have previously received any  dose of conjugate 
quadrivalent (ACW135Y) vaccine as infants should be given an additional dose 
if they are at continued risk or travelling to an area that puts them at risk of 
meningococcal disease. A routine booster is not currently recommended for 
children who received one dose after the age of 12 months. 
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Indications
Children and adults at increased risk of meningococcal disease (due 
to congenital or acquired aspenia, hyposplenism, or complement or 
properidin deficiency) 
•  These under 13 months of age should be immunised in accordance with 
the routine schedule, but replacing the MenC vaccine with conjugate 
quadrivalent (ACW135Y) vaccine. The vaccine can be administered at 
1 month intervals. A further booster dose of conjugated quadrivalent 
(ACW135Y) vaccine should be given after 12 months of age.
•  Children over 1 year of age, and adults, should be immunised with 2 
doses of conjugate quadrivalent (ACW135Y) vaccine at least 1 month 
apart.
•  Children who have been fully immunised with MenC should be given a 
dose of conjugate quadrivalent (ACW135Y) vaccine at least  one month 
after the MenC vaccine 
Travel related (further detail in Meningococcal vaccination 
recommendations for Travel below)
•  All children < 5years who are travelling to an area with an increased risk 
of A, W135 or Y 
•  For children aged 5 years to 10 years, conjugate quadrivalent (ACW135Y) 
vaccine is preferred to polysaccharide due to better immune response
•  For individuals aged 11 years and older who are travelling to an area 
with an increased risk of A, W135 or Y conjugate quadrivalent (ACW135Y) 
vaccine is preferred to polysaccharide due to better immune response
Cases of confirmed serogroup A, W135 or Y infections
Index cases who have not been immunised with the conjugate 
quadrivalent (ACW135Y) vaccine should complete an immunisation course 
with conjugate quadrivalent (ACW135Y) vaccine .Those who received  
the conjugate quadrivalent (ACW135Y) vaccine  more than 12 months 
previously should be given a second dose.
Contacts of confirmed serogroup A, W135 or Y infections 
Vaccination with conjugate quadrivalent (ACW135Y) vaccine should be 
offered to all close contacts of any age (two doses, one month apart if 
aged between 2 – 12 months; one dose in older individuals). 
Contraindications 
Anaphylactic reaction to a preceding dose or any of the constituents 
of the vaccine, including the meningococcal polysaccharide, diphtheria 
toxoid or the CRM197 carrier protein or tetanus toxoid.
Chapter 9  Meningococcal Infection
103
M
en
in
g
o
co
cc
al
In
fe
ct
io
n
Se
p
te
m
b
er
 2
0
1
1
Precautions
Acute severe febrile illness, defer until recovery. The presence of a minor 
infection is not a contraindication.
Adverse reactions
Local: Injection site reactions and malaise occur in approximately 10% of 
recipients.
Pregnancy and breast-feeding 
Meningococcal vaccines may be given to pregnant women when clinically 
indicated. 
Although insufficient clinical data on the use of conjugate quadrivalent 
(ACW135Y) vaccine  during breast-feeding are available, it is unlikely 
that secreted antibodies in milk would be harmful when ingested by a 
breastfed infant. Therefore, conjugate quadrivalent (ACW135Y) vaccine 
vaccine may be used during breast feeding.
Individuals with latex allergies
The tip cap of the syringe contains 10% Dry Natural Rubber. 
Although the risk for developing allergic latex reactions is very small, 
healthcare professionals should consider the benefit- risk balance 
prior to administering this vaccine to patients with known history of 
hypersensitivity to latex. 
C.  Polysaccharide Quadrivalent (ACW135Y) Vaccine -Plain 
polysaccharide (PS) 
Polysaccharide quadrivalent (ACW135Y) vaccine is effective against 
serogroup A, C, W135 and Y meningococci. Immunity develops in 
more than 90% of recipients within 5-7 days of a single injection. 
However, young children respond less well than adults, with limited 
or short-lived response before five years of age. For these reasons, 
and following the availability of the conjugate quadrivalent (ACW135Y) 
vaccine, the polysaccharide quadrivalent (ACW135Y) vaccine is no longer 
recommended for children less than five years. The polysaccharide 
quadrivalent (ACW135Y) vaccine is an alternative to the conjugate vaccine 
in individuals older than 5 years of age.  
Dose and route of administration (see table 9.1)
For individuals aged older than 5 years
A single dose of 0.5 ml is given by intramuscular injection.
Chapter 9  Meningococcal Infection
104
M
ening
o
co
ccal
Infectio
n
Sep
tem
b
er 2
0
1
1
Booster dose of vaccine
For those at continued risk, a reinforcing dose should be given every five 
years. 
Children who were immunised with polysaccharide quadrivalent vaccine, 
prior to the availability of the conjugate quadrivalent (ACW135Y) vaccine 
(in 2011) should receive a dose of the conjugate vaccine if further doses 
are required (travel or at risk). (See travel section below).
Contraindications 
Anaphylactic reaction to a preceding dose or any of the constituents.
Precautions
Acute severe febrile illness, defer until recovery.
Adverse reactions
Local: Injection site reactions occur in approximately 10% of recipients 
and last for approximately 24-48 hours.
General: Generalised reactions are rare although pyrexia occurs more 
frequently in young children than in adults.
Pregnancy and breastfeeding. Meningococcal vaccines may be given to 
pregnant women when clinically indicated. 
Meningococcal vaccination recommendations for Travel 
Quadrivalent ACW135Y vaccines are indicated for immunisation of 
individuals travelling to high risk areas where epidemics or hyperendemic 
disease with serogroup A, C or W135 infection occur, particularly those 
visitors who live or travel rough such as hitchhikers or trekkers. 
Conjugate quadrivalent (ACW135Y) vaccine is recommended in preference 
to plain polysaccharide vaccine for individuals travelling to high risk areas 
because of the better immune response, particularly in children and older 
people. . It is the recommended vaccine for children under five years of 
age, and is the preferred vaccine for individuals five years of age or older 
(see table 19.1). 
High-risk travelers are those who live or work with local people, and 
those who live or travel ‘rough’. At present this recommendation includes 
travel to sub-Saharan Africa and the Kingdom of Saudi Arabia (for the 
latter, ACW135Y vaccination is now a visa entry requirement).
Infection
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From time to time, meningococcal disease outbreaks occur in various 
parts of the world. Where such outbreaks are due to vaccine-preventable 
strains, vaccination may be recommended for some groups of travelers 
to the affected areas. The advice of an appropriate Specialist should be 
sought.
Note: Visa entry requirements should be checked in good time prior to 
travel to individual countries.
Table 9.1. Summary of recommendations regarding use of quadrivalent 
ACW135Y vaccines for travel, by age group 
Age Quadrivalent vaccine
Conjugate quadrivalent 
(ACW135Y)
Polysaccharide quadrivalent 
(ACW135Y)
Infants aged 2-12 
months *
(Off label)
Two 0.5 ml doses, 1 month 
apart
Not recommended
Children aged one 
year to four years 
(Off label) 
One dose of 0.5 ml
 Not recommended
Children aged five 
years to ten years 
Off-label (but preferred)
One dose of 0.5 ml
 Single dose of 0.5 ml
Individuals aged 11 
years and older
(Preferred)
One dose of 0.5 ml
 One dose of 0.5ml
* Note: Replace the MenC vaccine with conjugate quadrivalent (ACW135Y) vaccine if the 
infant requires the conjugate quadrivalent (ACW135Y) vaccine at the same time as the 
routine MenC vaccinations. If the infant has already had two MenC vaccines then two 
conjugate quadrivalent (ACW135Y) vaccines should also be given 
Serogroup B vaccines
The serogroup B capsule is weakly immunogenic and also contains 
antigens that may cross-react with human neurological tissue. No vaccine 
for international use has yet been licensed but vaccine trials of a new 
MenB vaccine are currently underway. 
Management of suspected cases, contacts, carriers and 
outbreaks
A Initial management of suspected cases
Primary care
In view of the often rapid progression and high mortality rate of 
meningococcal disease, early treatment of suspected cases with penicillin 
may be life-saving. It is recommended that GPs carry supplies of this drug 
in an emergency bag.
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Recommended dosage of Benzylpenicillin
Adults and children >10 years 1,200 mg
Children 1-9 years 600 mg
Children <1 year 300 mg
This should be given intravenously when possible. It can be given by the 
intramuscular route in shocked patients but is not as effective.
Penicillin should not be given if there is a history of penicillin anaphylaxis 
(which is extremely rare) and patients should go to hospital as quickly as 
possible.
Hospital care
Each acute hospital should have readily available guidelines in place for 
the management of suspected invasive meningococcal disease.
Advice should be sought form the local Department of Public Health 
for management of suspected outbreaks. The most up-to-date 
information on management of contacts is available from Departments
of Public Health. 
Chemoprophylaxis
Close contacts of all individuals with invasive meningococcal disease are 
at increased risk of developing infection. This risk is highest in the first 
7 days following onset of symptoms in the index case, and falls during 
the following weeks. If prophylaxis is not given, the absolute risk to an 
individual in the same household one to 30 days after an index case 
is about one in 300.  Chemoprophylaxis should be given as soon as 
possible after identification of the index case, but can be given up to 1 
month later if a contact is not immediately identified or traced. The aims 
of chemoprophylaxis are to eliminate carriage from recently colonised 
susceptible individuals in the period before invasive disease may 
develop, and to reduce spread of the organism.
The following persons should be given prophylaxis:
1.  The index case should be given chemoprophylaxis when able to take 
oral medication and before discharge from hospital, unless the disease 
had already been treated with ceftriaxone. When the disease has been 
treated with cefotaxime it may be prudent to give chemoprophylaxis 
until studies are available on its effectiveness in eradicating carriage.
2.  Those who in 7 days prior to the onset of illness of the index case
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•  shared living or sleeping accommodation with the patient; including 
child-minders and baby-sitters
•  had mouth kissing contact with the patient
•  were in the same nursery/crèche as the patient, where the nature of 
nursery/crèche contact is similar to that for household contacts. This 
includes adult carers.
3.  HCWs (including those present at autopsy) who did not wear a 
(surgical) mask and whose mouth or nose was directly exposed to 
infectious airborne droplets or secretions within one metre of a 
probable or confirmed case of meningococcal disease, who has not 
received at least 24 hours appropriate antibiotic treatment.
HCWs should wear surgical masks when in close contact with an 
infectious case for the first 24 hours after the initiation of effective 
antimicrobial treatment.
 
4.  Chemoprophylaxis is not necessary for classmates of an index case 
unless a number of cases occur during the same term:
•  If two or more cases of infection with the same strain occur in one 
class all class members and staff should receive prophylaxis
•  If the cases occur in different classes, management is more difficult 
but should be guided by such considerations as 
o the interval between the cases
o the size of the contact group
o the carriage rate in the school
o whether the cases are due to a vaccine-preventable strain
o the degree of public concern, particularly if a death has 
occurred 
o the incidence of the disease in the wider community.
In such situations management should be discussed with a 
relevant Specialist.
5.  Special consideration is needed when an index case has attended a 
house party in the preceding 7 days, especially if pre-school children 
were present. If chemoprophylaxis is appropriate it should be given to 
all attendees, both adults and children. 
6.  Special consideration should be given to situations in which there is 
greater than usual interaction between members of the extended 
family and an index case, particularly where overcrowding or adverse 
environmental living conditions exist. 
7.  Ideally chemoprophylaxis should be given to all contacts as soon as 
possible after notification of the index case. However, it can be given 
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up to a month after identification of an index case, as carriage may 
persist for a long period.
It is not recommended that prophylaxis be given routinely to passengers 
on public transport, e.g. bus, train, where an index case has been 
identified.
Meningococcal
Prophylactic antibiotics
Rifampicin
This is the drug of choice in most circumstances, and should be given 
promptly and preferably within 24 hours of diagnosis of the index case.
All close contacts should be advised that infection can occur even if 
prophylaxis is given. This is because the antibiotic may not be effective 
if the contact is incubating disease, or because the contact may become 
recolonised and then develop the disease. Contacts should be advised to 
seek medical advice should symptoms develop.
Dose of Rifampicin
Children 0-12 months    5 mg/kg 12 hourly for 2 days
Children 1-12 years    10 mg/kg 12 hourly for 2 days
Children over 12 years & adults  600 mg 12 hourly for 2 days
Side-effects
Rifampicin recipients should be informed about the following possible 
side-effects:
• interference with contraceptive pill
• interference with anticoagulants
• red coloration of urine, sweat and tears
• permanent discolouration of soft contact lenses
Precautions and contraindications to Rifampicin
Anaphylaxis to a previous dose, severe liver disease or pregnancy.
Alternative prophylaxis
•  Ceftriaxone as a single intramuscular dose (250 mg in adults, 125 mg in 
children under 12 years).
•  Although not licensed for this purpose a single dose of ciprofloxacin 
(500 mg orally for adults) has been shown to be effective. 
Ciprofloxacin is the preferred chemoprophylaxis agent for women 
on the contraceptive pill as rifampicin can affect the efficacy of oral 
contraceptive therapy.
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Pregnancy
While no drug can be regarded as absolutely safe in pregnancy, harmful 
effects on the foetus have not been documented in relation to use of 
ceftriaxone.
Meningococcal vaccines
Contacts of a case of infection with a vaccine-preventable strain should 
be immunised with the appropriate vaccine (see above). The aim of 
immunisation is to prevent late secondary cases.
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Introduction
Mumps is an acute viral illness caused by a paramyxovirus. Humans are 
the only known host. It is characterised by swelling of one or more of 
the salivary glands, usually the parotid. The virus can be isolated from 
2-7 days before to 9 days after onset of symptoms. Approximately 10 
secondary infections will result from each index case in a fully susceptible 
population. 
Epidemiology
Transmission is by airborne or droplet spread. The incubation period 
is approximately 17 days (range 14-25 days). Cases are infectious from 
about 6 days before to 10 days after onset of symptoms, although 
maximum infectivity is from 2 days before to 5 days after onset of 
symptoms. High-risk groups are those in a close-contact environment 
such as pre-school, school and third-level colleges, health-care workers, 
and international travellers. Recently in Ireland the highest incidence has 
been in 18-24 year olds.
A national mumps outbreak commenced in November 2004 (Figure 
10.1). The outbreak predominantly affected those born before 1988, 
particularly those born between 1983 and 1986. MMR was first 
introduced in 1988.
10
Mumps
Introduced in 1988 as part of MMR
NOTIFIABLE
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Effects of mumps
Up to 40% of mumps infections may be asymptomatic and up to 50% will 
have non-specific or primarily respiratory symptoms.
Prodromal symptoms are non-specific and include mylagia, low-grade 
fever, anorexia, and headache. Salivary gland inflammation, particularly 
of the parotid gland (unilateral or bilateral), is the most common 
manifestation and occurs in 50-70% of affected individuals.
Mumps virus affects the CNS in up to 50% of cases, but less than 10% are 
symptomatic. Typically, symptoms are mild, with meningism (headache, 
photophobia and neck stiffness) being the commonest. Other CNS 
manifestations include encephalitis, ataxia, transverse myelitis, and 
sensorineural deafness. Meningoencephalitis occurs more frequently 
in adults than children and in boys more than girls. It resolves without 
sequalae in 3-10 days. Parotitis may be absent in up to 50% of these 
cases.
       
Other complications include pancreatitis (4%), orchitis (approximately 
25% of post-pubertal men, rarely causing sterility), oophritis and mastitis 
in post-pubertal females, and nephritis. Rarer complications include 
arthralgia, arthritis and cardiac abnormalities. Death is rare. 
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Figure 10.1 Annual number of mumps notifications in Ireland, 1988-2006. 
Source: HPSC
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Mumps vaccine
Mumps vaccine is only available as MMR (Measles, Mumps and Rubella 
vaccine). The vaccine contains attenuated measles, mumps and rubella 
which are cultured separately and mixed before lyophilisation. 
The lyophilised powder is reconstituted using the diluent supplied 
and shaken well to completely dissolve the pellet. The reconstituted 
vaccine is yellow in colour and should only be used if clear and free from 
particulate matter.
An up-to-date list of licensed vaccines is contained in Appendix 1, or can 
be accessed on the IMB website, www.imb.ie.
MMR does not contain thiomersal or any other preservatives. It must 
be kept refrigerated at 2-8ºC, and protected from light. It should 
be used within 1 hour of reconstitution. Failure to adhere to these 
recommendations can result in loss of vaccine potency and diminished 
effectiveness. 
Over 90% of individuals develop immunity to measles and rubella after 
1 dose of vaccine. Two doses give protection in over 98% of people 
(see point 1, Indications). Between 61% and 91% are protected against 
mumps after 1 dose; and 98% are protected after 2 doses. Serological 
and epidemiological evidence indicates that vaccine-induced immunity is 
possibly lifelong.
Low rates of seroconversion occur in those under 12 months of age, 
because of maternal antibodies.
Deferral of MMR following blood or immunoglobulin transfusion 
(except anti-RhD immunoglobulin, see p. 90/112/145)
Deferral of MMR following blood or immunoglobulin transfusion
Blood and blood products may contain significant levels of virus-specific
antibody, which could prevent vaccine virus replication. Where possible,
MMR should be deferred for at least 3 months after receipt of low-dose
immunoglobulin, 6 months after red-cell transfusion, and 11 months after
high-dose immunoglobulin (as for Kawasaki Disease). Anti-RhD 
immunoglobulin can be administered simultaneously or at any time in 
relation to MMR (varicella on page 142).  If the MMR vaccine
is administered within these timeframes, a further dose should be given
outside these times.
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Laboratory investigation to determine vaccine response is not routinely 
recommended. 
Persons who are tuberculin-positive may have a negative tuberculin test 
for 3 months after measles infection or MMR vaccine.  
Scientific evidence shows no association between the MMR vaccine 
and autism or inflammatory bowel disease.
Dose and route of administration
The dose is 0.5 ml by deep intramuscular injection. The deltoid is the 
recommended site of administration. The anterolateral thigh may also be 
used.
Alcohol swabs are best avoided as alcohol can inactivate the MMR 
vaccine.  If alcohol is used to clean the skin it must be allowed to 
evaporate completely before the injection is given.
When other injectable vaccines are being given concurrently with MMR, 
different sites should be used.
MMR may be given at the same time as DTaP, IPV, MenC, Hib and 
Hep B in situations where the latter are overdue.
Indications
1.  All children at 12-15 months of age, with a second dose at 4-5 years of 
age. For older children who have not received 2 doses, MMR vaccine 
should be given as soon as possible, and a second dose one month 
later. Allowing 3 months between doses is likely to maximise the 
response rate in children aged under 18 months. Where protection 
against mumps is urgently required the second dose can be given 1 
month after the first. If children aged under 18 months are given the 
second dose less than 3 months after the first dose, they need a third 
dose to ensure full protection. This can be given at 4-5 years. MMR 
vaccine can be given to those who have a history of measles, mumps 
or rubella infection.
2  Children coming from low-income countries have probably received 
measles vaccine but may not have received  rubella or mumps vaccine. 
Therefore, unless there is a reliable history of vaccine administration, 
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these children should be regarded as unimmunised, and given 2 doses 
of MMR one month apart.
3.  Individuals born before 1978 are likely to have had mumps  infection. 
MMR vaccine is not routinely recommended but may be offered 
to such individuals on request if they are considered at high risk of 
exposure.
4. Health-Care Workers (HCWs) in the following situations (see Chapter 
18). Protection is important both for themselves and in the context of 
their ability to transmit mumps to vulnerable groups.
•  Those who do not have evidence either of mumps infection or of 
having received 2 doses of MMR vaccine should be given 2 doses of 
MMR, separated by at least 1 month.
•  If an outbreak occurs in an institution or an area served by an 
institution, HCWs without a history of mumps infection or of having 
received two doses of MMR should be given 2 doses of MMR.
Antibody response to the mumps component of the MMR vaccine
does not develop quickly enough to provide effective prophylaxis
after exposure to suspected mumps. However, the vaccine can provide
protection against future infection. Therefore, contact with
suspected mumps provides a good opportunity to offer MMR to
previously unvaccinated individuals. If the individual is already incubating
mumps, MMR vaccination will not exacerbate the symptoms. Human
normal immunoglobulin is not routinely used as post-exposure protection
from mumps.
Contraindications
1. Anaphylaxis following a previous dose of MMR or one of its 
constituents (e.g. Neomycin, Gelatin)
2. Significantly immunocompromised persons, such as those with 
untreated malignant disease and immunodeficiency states other 
than HIV infection, and those receiving immunosuppressive 
therapy, high-dose x-ray therapy and current high-dose systemic 
corticosteroids (see Chapter 2)
3. Pregnancy. Furthermore, pregnancy should be avoided for 1 
month after MMR
There is no evidence to recommend or support the use of single 
vaccines against measles, mumps or rubella in place of the 
combination MMR vaccine.
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The following are NOT contraindications to MMR vaccine
1. Allergy to egg, even anaphylaxis following egg. If there is a 
genuine concern regarding serious allergy, a paediatrician may 
be consulted and the vaccine given in hospital although this is 
not medically necessary. Currently-used measles and mumps 
vaccines do not contain significant amounts of egg cross-reacting 
proteins and recent data suggest that anaphylactic reactions to 
MMR are not associated with hypersensitivity to egg antigens but 
to other vaccine components (Gelatin or Neomycin)
2. Breast-feeding
3. HIV-positive patients who are not severely immunocompromised
4. Personal or family history of convulsions. Advice regarding the 
possibility and treatment of pyrexia should be given
5. Immunodeficiency in a family member or household contact
6. Uncertainty as to whether a person has had 2 previous MMR 
vaccines
7. Administration of anti-RhD immunoglobulin. As anti-RhD 
immunoglobulin does not interfere significantly with the 
antibody response to MMR (varicella on p. 145) vaccine, the two 
injections may be given simultaneously (in different syringes, at 
different sites), or at any time in relation to each other.
Precautions
1. Acute severe febrile illness, defer until recovery
2. Injection with another live vaccine within the previous 4 weeks
3. Recent administration of blood or blood products (see above)
4. Patients who developed thrombocytopenia within 6 weeks of 
their first dose of MMR should undergo serological testing to 
decide whether a second dose is necessary. The second dose 
is recommended if the patient is not fully immune to the 3 
component viruses.
Adverse reactions
Soreness and erythema may occur at the injection site (3-8%). Fever (6%), 
rash (7%), headache, vomiting and salivary gland swelling may occur. A 
febrile convulsion occurs in 1 in 1,000 children.
‘Mini-measles’ may occur 6-10 days after immunisation and consists of 
mild pyrexia and an erythematous rash. ‘Mini-mumps’ with salivary gland 
swelling may rarely occur during the third week after immunisation. Very 
rarely, anaphylaxis, erythema multiforme, thrombocytopoenia, and nerve 
deafness have been reported.
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The rubella component may occasionally produce a rash, mild arthralgia, 
and lymph-node swelling 2-4 weeks post-vaccination, particularly in post-
pubertal females (up to 25% of recipients). The incidence is lower than 
after natural disease. 
There is no evidence of congenital rubella syndrome or increase in other 
teratogenic effects in women inadvertently given rubella vaccine before 
or during early pregnancy, but pregnancy remains a contraindication.
Adverse reactions are considerably less common (under 1%) after a 
second dose of MMR.
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Introduction
Pertussis (whooping cough) is a highly infectious bacterial disease 
caused by Bordetella pertussis, a fastidious gram-negative coccobacillus. 
Following infection or immunisation immunity wanes over 1-2 decades. 
Subsequent infection tends to be milder, may not be diagnosed, but is 
infectious. Approximately 16 secondary infections will result from each 
index case in a fully susceptible population.
Epidemiology
Pertussis occurs endemically with periodic outbreaks. Worldwide, 
over 45 million cases occur annually, with more than 250,000 deaths. 
Epidemiological data on pertussis in the Republic of Ireland have been 
gathered annually since 1941. There has been a steady decline in 
mortality which commenced before the introduction of the vaccine, but 
the rate of decline accelerated following its introduction.
Prior to the introduction of vaccination most cases occurred in young 
children. Now the highest incidence, morbidity and mortality are in 
infants. More cases have recently been occurring in adolescents and 
adults. This change in the epidemiology of pertussis is due to the 
waning immunity that occurs after both disease and vaccination, and to 
a reduction in natural boosting. Thirty per cent of adults with a cough 
lasting longer than 2 weeks may have pertussis. Most infants and young 
children who contract pertussis are infected by a family member.
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The large increase in notifications of pertussis that occurred in the 1980s 
followed a scare in the late 1970s regarding a possible association of the 
vaccine and encephalopathy, which led to low-vaccine uptake (see Figure 
11.1).
Humans are the only known hosts of B. pertussis. Transmission occurs 
by close contact via droplet infection from the respiratory tract of 
symptomatic individuals. The incubation period is 7-10 days (range 4-
21). As many as 90% of non-immune household contacts acquire the 
infection. Communicability is greatest in the catarrhal stage before the 
onset of paroxysms of coughing, but may last for up to 3 weeks. Macrolide 
antibiotics decrease infectivity and may limit secondary spread if given 
early in the course of the infection in those aged over 6 months. They have 
no effect on the course of the illness if given after the cough is established.
Effects of pertussis
Pertussis is primarily a toxin-mediated disease. Bacteria attach to the 
respiratory cilia and produce toxins which paralyse the cilia. This, and 
inflammation, interfere with the clearing of secretions. Many factors 
determine disease severity, including age of the patient and time since 
vaccination or previous infection.
The initial catarrhal stage has an insidious onset and is the most infectious 
period. Cough is limited, the main symptom being rhinorrhoea. An 
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Figure 11.1 Number of pertussis notifications in Ireland, 1988-2006. 
Source: HPSC
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irritating cough gradually becomes paroxysmal, with a characteristic 
inspiratory whoop and/or vomiting in about 50% of cases. This 
paroxysmal stage usually occurs within 1-2 weeks, and often lasts for 2-
3 months. In young infants, the typical ‘whoop’ may never develop and 
coughing spasms may be followed by periods of apnoea and cyanosis. 
Pertussis may be complicated by bronchopneumonia (in 22% of 
infants) and by cerebral hypoxia with resulting risk of seizures (3% of 
infants, more in those less than 6 months), and encephalopathy. These 
complications and deaths occur most commonly in infants under 6 
months of age. The highest mortality rate is in preterm infants. The case-
fatality rate ranges from 0.04-4%.
Among adolescents and adults the only symptom may be a prolonged 
cough. This lasts for at least 3 weeks in over 80%, and for up to 90 days 
in over 25% of cases.
Diagnosis on clinical grounds can be difficult. The organism can be 
grown on selective media, with incubation for 10-14 days. This requires 
rapid and careful transport of a nasopharyngeal aspirate or swab in an 
appropriate medium. Cultures cannot be considered negative until after 
10 days. Cultures are less likely to be positive if the person has been 
immunised, if antibiotics have been taken, or if cough has been present 
for more than 2 weeks.
PCR, ELISA within 1 week of symptom onset and 4-6 weeks later, and 
direct fluorescent antibody testing can aid diagnosis.
Treatment
If treatment is begun within 3 weeks of onset of symptoms it can limit 
transmission, and may reduce the duration of the disease if started in the 
catarrhal stage. Prophylaxis is recommended for vulnerable household 
contacts. These may be defined as those who live in the same house or 
stayed overnight in the same room as the index case, and are under 5 
years of age and unimmunised or partially immunised, or have congenital 
heart disease or severe asthma, or are immunocompromised
Suggested antibiotic prophylactic regimes:
1. Erythromycin, 20-25 mg/kg BD (max 2g per dose) for 7days 
is effective in preventing culture positive pertussis in 67% of 
household contacts, but may have limited clinical impact
2. Clarithromycin, 10 mg/kg BD (max 500 mg/dose) for 7 days
3. Azithromycin, 10 mg/kg once daily (max 500 mg per dose) for 5 
days.
Chapter 11  Pertussis
121
P
er
tu
ss
is
 
Erythromycin has been associated with pyloric stenosis in those aged 
under 1 month, but the risks of pertussis are far greater than the risks 
from erythromycin in this age group. There are no large-scale trials of 
either Clarithromycin or Azithromycin in this situation.
Pertussis vaccine
This is no longer available as a single vaccine. Pertussis vaccines contain 
purified acellular pertussis antigens, which cause significantly less 
local and systemic reactions than whole-cell vaccines. Antigens differ 
between vaccines but usually include inactive pertussis toxin, filamentous 
haemagglutinin and pertactin.
The vaccine should be stored between 2-8°C. If the vaccine has been 
frozen, it should not be used.
A full course of vaccine confers protection in over 80% of recipients. 
Immunity wanes with age, and is low or absent 10-12 years after primary 
immunisation. High vaccine uptake rates, including booster doses, are 
therefore very important in order to reduce the incidence of pertussis. In 
those not fully protected the disease is usually less severe.
Dose and route of administration
The dose is 0.5 ml, given by intramuscular injection into the anterolateral 
thigh or deltoid.
Indications
The primary course consists of 3 doses given at 2, 4 and 6 months, with 
a booster at 4-5 years. A further booster, using Tdap which contains low-
dose acellular pertussis vaccine, is recommended at 11-14 years. If the 
primary course is interrupted it should be resumed but not repeated, 
allowing appropriate intervals between the remaining doses.
If pertussis vaccine is refused by parents, the only available diphtheria 
and tetanus vaccines are Td and Td/IPV. They are not intended for use as 
part of the primary schedule, may not give a sufficient immune response 
if so used, and are not licensed for such use. 
Pertussis vaccination should be considered for children aged less than 
10 years who are exposed to pertussis, if they have received less than 4 
doses of the vaccine. Children may be given dose four at as early as 12 
months of age, preferably 6 months after dose three (for catch-up doses, 
see Chapter 2).
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Contraindications
Anaphylaxis to a previous pertussis-containing vaccine or to one of its 
constituents.
Precautions 
Acute severe febrile illness; defer until recovery.
Note; The following are no longer regarded either as 
contraindications or precautions. They have not been shown to cause 
permanent harm and are significantly less common after acellular than 
after whole-cell vaccines
1 Temperature of more than 40.5°C within 48 hours of a previous 
dose of a pertussis-containing vaccine
2 Hypotonic-hyporesponsive episode within 48 hours of a previous 
dose of a pertussis-containing vaccine
3 Seizures within 72 hours of a previous dose of a pertussis-
containing vaccine
4 Persistent, inconsolable crying lasting more than 3 hrs within 48 
hours of a previous dose of a pertussis-containing vaccine
Adverse reactions
Local: Minor side-effects (e.g. local redness, swelling) occur in about 15-
20% of recipients. Very rarely a major local reaction involving swelling 
and erythema of most of the diameter of a limb can occur. This resolves 
without sequelae, and is not a contraindication to further vaccination.
General: Fever and irritability can occur. However, temperature over 
40°C is rare. Serious side-effects such as prolonged, inconsolable crying 
or hypotonic-hyporesponsive episodes are very rare and have not been 
shown to cause long-term problems. Administration of paracetamol or 
ibuprofen at the time of immunisation may reduce the incidence of local 
and febrile reactions.  
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Introduction
Streptococcus pneumoniae (pneumococcus) is an important cause 
of serious infection, especially in young children, older adults and 
immunocompromised people. Invasive pneumococcal disease (IPD) is 
defined as the isolation of S. pneumoniae from a normally sterile site 
(e.g. blood, cerebrospinal fluid (CSF), joint, pleural, or pericardial fluid). 
Non-invasive manifestations of the disease include otitis media, sinusitis 
and bronchitis. IPD is a disease mainly occurring in children under 5 years 
and those aged ≥65 years. Individuals with severe chronic disease or 
immunodeficiency are also at increased risk of this disease.
Although more than 90 polysaccharide capsular serotypes of 
pneumococci are known, most infections are caused by a limited number 
of serotypes. In higher-income countries the serotypes most commonly 
implicated are 1, 4, 6B, 7F, 9V, 14, 18C, 19F and 23F. The fact that 
relatively few serotypes cause most invasive disease has allowed for the 
development of effective vaccines.
Epidemiology
Pneumococcal infection is a leading cause of death worldwide. Mortality 
is highest in patients who develop sepsis or meningitis. Pneumococcal 
meningitis case fatality rates of 11-16% were reported in Ireland in the 
years 2004-2009. Transmission is from person to person by droplet 
infection. The incubation period varies by site of infection, and can be as 
short as 1-3 days. Infection can occur at any time throughout the year but 
rates peak during the winter months (Figure 12.1). 
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Figure 12.1 Invasive pneumococcal disease (IPD) notifications in Ireland 
by month, 2004-2009. Source: HPSC
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From 2004 to 2009 a total of 1741 cases of IPD were reported, 56% male 
and 44% female. Most cases occurred in older people (≥65 years of age, 
39%) and in the 0-4 year age group (19%) (Figure12.2).
Figure 12.2 Age distribution of invasive pneumococcal disease (IPD) 
notifications, 2004-2009. Source: HPSC
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Effects of pneumococcal infection
Pneumococcal infection is the most common cause of bacteraemia, 
septicaemia, bacterial meningitis, pneumonia, sinusitis, and acute otitis 
media in children. It can also cause periorbital cellulitis, endocarditis, 
pericarditis, peritonitis, and soft tissue, bone and joint infection. 
Individuals who are more susceptible to pneumococcal infection include 
those with hyposplenia or asplenia (including those with sickle cell and 
coeliac disease), those immunocompromised by disease or its treatment 
(e.g. leukaemia), and those with other chronic illnesses.
Pneumococcal vaccines
There are two different types of pneumococcal vaccine: 
1.  Pneumococcal Polysaccharide Vaccine (PPV23). This incorporates 23 
of the most common capsular types*, which account for up to 90% 
of all serious pneumococcal infections. The vaccine should be kept 
refrigerated at 2-80C. It is only suitable for use in those ≥2 years of 
age; an adequate antibody response does not develop in those under 
2 years of age.
2.  Pneumococcal Conjugate Vaccines (PCV 7, 10 and 13) contain 
polysaccharide antigens from 7, 10 or 13 serotypes* conjugated to 
a protein. These vaccines should be kept refrigerated at 2-80C. They 
have enhanced immunogenicity compared with the polysaccharide 
vaccine, and are immunogenic from 6 weeks of age. Conjugate 
vaccines are  active against 75-90%  of serotypes causing invasive 
disease, including a significant number of penicillin-resistant strains. 
The number of doses required for optimum immunogenicity depends 
on the age at which immunisation is initiated.  There is a lower 
response to conjugate vaccines in preterm infants, but the response is 
adequate to confer significant protection. 
In Ireland PCV7 was recommended for at risk children in 2002 and was 
introduced into the routine primary immunisation schedule in September 
2008, along with a catch up programme for all children under 2 years of 
age. 
The incidence of confirmed cases of IPD in Ireland declined by 12% 
in 2009 compared with the previous year (Figure 12.3), with a 37% 
reduction in the rates in children younger than 2 years. The introduction 
of PCV7 into the childhood immunisation schedule in the US in early 2000 
resulted in a 69% reduction in the rates of IPD in children under 2 years.
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In December 2010 PCV13 vaccine replaced PCV7 in the Irish childhood 
immunisation programme. PCV13 includes antigens from the seven 
serotypes contained in PCV7 plus six additional serotypes which cause 
IPD. The introduction of PCV13 is expected to provide increased 
protection with coverage of approximately 90% of serotypes responsible 
for IPD in children under 2 years of age.
Pneumococcal conjugate vaccines reduce the rates of nasopharyngeal 
colonisation by vaccine serotypes, thus decreasing the potential for 
transmission from children to other children and to adults. In the US 
there has been a significant reduction in the incidence of IPD in the adult 
population since 2001. In Ireland a similar decline is not yet evident (Oct. 
2010). In 2008, 160 cases in those aged 65 years and older were notified 
compared to 157 in 2009; the age specific incidence rates are shown in 
Figure 12.3.
Figure 12.3 Age specific incidence rates (ASIR) of invasive pneumococcal 
disease notifications, 2004-2009. Source: HPSC
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Indications for pneumococcal vaccination.
1.  All infants from 2 months of age as part of the routine childhood 
immunisation schedule (see Chapter 2).
2.  All those aged 65 years and older. 
3.  Individuals at higher risk of IPD, ie those with: 
a.   Asplenia or splenic dysfunction (including splenectomy, sickle cell 
disease and coeliac disease).
b.   Chronic renal disease, nephrotic syndrome or renal transplant.
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c.   Chronic heart, lung, or liver disease, including cirrhosis.
d.  Diabetes mellitus.
e.   Complement deficiency (particularly early component deficiencies 
C1, C2, C3, C4).
f.   Immunosuppressive conditions (e.g. some B- and T-cell disorders, 
HIV infection, leukaemia, lymphoma, Hodgkin’s disease) and those 
receiving immunosuppressive therapies.
  Note: Individuals with primary immunodeficiency may have a suboptimal response 
to all vaccines. Pneumococcal vaccines are unlikely to be immunogenic in children 
with certain primary immune deficiencies involving significant B cell compromise 
who are receiving regular IVIG replacement therapy. However vaccination should be 
given as it may have some effect.
g.   CSF leaks either congenital or complicating skull fracture or 
neurosurgery.
h.  Intracranial shunt.
i.   Candidates for, or recipients of, a cochlear implant.
j.   Children under 5 years of age following invasive pneumococcal 
disease, irrespective of vaccine history (See section below Children 
under 5 years who have had IPD). 
k.  Smokers and alcoholics (see section below for rationale). 
For vaccine types and schedule for individuals at risk of IPD see Table 
12.2 below.
Pneumococcal vaccination should  ideally be completed at least 2 
weeks prior to elective splenectomy or cochlear implant.
Dose and route of administration
1.  Pneumococcal Conjugate Vaccines (PCV 7, 10 and 13). A dose of 0.5 
ml should be given by intramuscuscular injection in the deltoid area or 
the antero-lateral aspect of the thigh.
2.  Pneumococcal Polysaccharide Vaccine (PPV23). A dose of 0.5 ml 
should be given by intramuscuscular injection in the deltoid area. 
Pneumococcal vaccination schedule:
1.   Healthy children under 2 years of age    
Up to 3 doses of PCV are recommended; the number of doses 
required depends on the age of child as shown in Table 12.1 (see also 
primary immunisation schedule, Chapter 2).
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Table 12.1 Routine childhood immunisation with Pneumococcal 
Conjugate Vaccine (PCV13)
Age at first vaccination Number of doses  
and intervals between doses
<12 months 
(3 doses in total)
Doses 1 and 2 at 2 month intervals
Dose 3 given at ≥12 months of age, at least 2 
months after dose 2
No further dose if any dose given aged ≥12 
months
Note: 
(a) Infants who have received 2 doses of PCV7 before PCV13 was introduced can be given 
PCV13 as the 3rd dose. 
(b) Those who have received 1 dose of PCV7 can be given PCV7 as their 2nd dose if it is 
available; if not PCV13 can be used. 
(c) Children aged 12 -< 24 months who have already received one dose of PVC7 at ≥ 12 
months do not require a dose of PCV13.
  
2.  Children under 18 years at higher risk of pneumococcal infection  
 (see a-j above)
Immunisation with PCV13 followed by immunisation with 
polysaccharide vaccine (PPV23) is recommended to afford broader 
protection for children up to 5 years of age, as shown in Table 12.2. 
Children 5-18 years should be given one dose of PPV23.
PCV13 may be used in those aged 5 -18 years who are at significantly 
increased risk of IPD***see Table 12.2.
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Table 12.2 Pneumococcal immunisation for children at increased risk of 
IPD
Age at first 
vaccination
Pneumococcal vaccine type, number of doses and 
intervals 
Pneumococcal conjugate 
vaccine (PCV13)
Pneumococcal 
polysaccharide vaccine 
(PPV23)
6 weeks -<12 months
(3 PCV13 +1 PPV23)
Doses 1 & 2 at 2 month 
intervals
Dose 3 given at ≥12 months 
of age, at least 2 months 
after dose 2
No further dose if 1 or 
2* doses given aged ≥12 
months.
One dose given ≥24 
months of age at least 2 
months after 3rd dose of 
PCV13
12-<24 months
(1 or 2 PCV13 + 
1 PPV23)
1 or 2* doses at 2 month 
intervals
One dose given ≥24 
months of age, at least 2 
months after final dose 
of PCV13
24 months to 5 
years**
(1 or 2* PCV13 + 
1 PPV23)
1 or 2* doses at 2 month 
intervals
One dose (at least 2 
months after dose of 
PCV13)
>5- <18 years***
(0 or 1*** PCV13 + 
1 PPV23)
0 or 1*** dose One dose (at least 2 
months after dose of 
PCV13 if this was given)
* 2 doses of PCV13 are required when it is anticipated that response may be blunted, e.g. 
children with asplenia/hyposplenia, IgA-, IgG subclass-, and specific antibody deficiencies. 
For children with complement deficiency or chronic granulomatous disease one dose of 
PCV13 followed by one dose of PPV23 is adequate.
**A single dose of PCV13 may be given opportunistically to children under 5 years of age 
who are in an at risk group and who have completed a course of PCV 7 
*** For children from 5-<18 years with functional or anatomic asplenia, including sickle cell 
disease, HIV infection or other immunocompromising condition, cochlear implant or CSF 
leak, consider giving one dose of PCV13 regardless of previous history of PCV7 or PPV23
3. Adults aged 65 years and older
 One dose of Pneumococcal Polysaccharide Vaccine (PPV23).
4. Individuals 18-64 years of age at higher risk of IPD
 One dose of Pneumococcal Polysaccharide Vaccine (PPV23).
5. Smokers and Alcoholics (added to high-risk group in 2010)
 One dose of Pneumococcal Polysaccharide Vaccine (PPV23).
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  Cigarette smokers are at increased risk of invasive pneumoccocal 
disease. In a US multi-centre population-based, case-control study, 
the risk for IPD among immunocompetent cigarette smokers aged 18-
-64 years was four times the risk for controls who had never smoked 
(AOR = 4.1; CI = 2.4--7.3). Significant dose-response relationships with 
risk for IPD also were observed for number of cigarettes smoked and 
pack-years of smoking.
  Subsequent studies confirmed that smoking also increases the risk for 
IPD among other groups, including immunocompromised persons. 
  Individuals with a history of alcohol abuse are 1.6- 7.1 times more 
likely to develop IPD than non-alcoholics. Proposed reasons for the 
higher risk include increased bacterial colonization, reduced ciliary 
motility and immune system compromise.
Booster doses of PPV23
Booster doses are not routinely recommended for immunocompetent 
people as there is a lack of evidence of improved immunity and an 
increased incidence of local side-effects after repeated doses. 
•  For individuals whose antibody levels are likely to decline more 
rapidly, (e.g. those with no spleen, with splenic dysfunction, 
immunosuppression including that associated with HIV infection, 
nephrotic syndrome or chronic renal disease), a once only booster 
PPV23 vaccine should be given 5 years after the first dose. 
•  Adults 65 years or older should receive a second dose of PPV23 if they 
received vaccine more than 5 years before and were less than 65 years 
of age at the time of the first dose. 
•  The need for and benefit of repeated booster doses among other high-
risk individuals is unclear, and they are not routinely indicated. 
Contraindications
Anaphylactic reaction to a preceding dose of the vaccine or to any of the 
constituents.
Precautions
1. Revaccination within 5 years of a previous dose of Polysaccharide 
Pneumococcal Vaccine. However, if the vaccine has been given during 
chemotherapy or radiotherapy, revaccination 3 months after treatment 
is recommended.
2. Acute severe febrile illness; defer until recovery.
3. Pregnancy. As a general principle, vaccination in pregnancy should be 
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avoided. Pneumococcal vaccination can however be given in pregnancy 
if there is an urgent need for protection. 
Adverse reactions
Local: Localised tenderness and erythema at the injection site may 
occur. Subcutaneous administration may cause a severe local reaction. 
No increase in localised reactions with repeated doses of PCV has 
been reported.  Reimmunisation with PPV23 has produced severe local 
reactions especially if less than 5 years has elapsed since the first injection.
General: Occasional low-grade fever lasting less than 24 hours.
Management of cases and contacts, and during outbreaks
Cases of invasive pneumococcal disease (IPD)
Any case of invasive pneumococcal infection or lobar pneumonia believed 
to be due to S. pneumoniae should prompt a review of the patient’s 
history to establish whether they are in a recognised risk group and have 
been vaccinated. Patients with risk factors who have not previously been 
vaccinated should be given vaccination on discharge from hospital; they 
should continue vaccination as for other at-risk people (see section on 
recommendations for the use of pneumococcal vaccination).
Children under 5 years of age who had IPD
All children under 5 years of age who have had IPD, should receive a 
dose of pneumococcal conjugate vaccine (PCV13) irrespective of vaccine 
history.
Children under 12 months who are unvaccinated or partially vaccinated 
should complete the immunisation schedule.
All children under 5 years of age who have had IPD should be evaluated 
for risk factors predisposing them to pneumococcal infection. If they are 
found to fall into one of the risk groups, they should continue PCV and 
PPV23 vaccination as for other at-risk children (see section above on 
Indications for pneumococcal vaccination).
All new cases of IPD in children eligible for routine PCV will require follow-
up as part of the surveillance of this vaccination programme. 
Contacts
Antibiotic prophylaxis is not indicated for close contacts of a case 
of invasive pneumococcal disease as such contacts are not normally 
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at increased risk of pneumococcal infection.  Clusters of invasive 
pneumococcal disease should be discussed with local health-protection 
or infection-control teams.
Outbreaks
Outbreaks of pneumococcal infection in hospitals and residential 
care homes need prompt investigation. Control measures including 
vaccination may be appropriate; these measures should be agreed in 
discussion with local health-protection or infection-control teams.
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Introduction 
Poliomyelitis is an acute illness which may result from invasion of the 
gastro-intestinal tract by one of three types of polio virus (1, 2 and 3). 
The virus has a high affinity for nervous tissue. Inactivated poliomyelitis 
vaccine (Salk) was introduced to Ireland in 1957 and replaced by 
attenuated live oral polio vaccine (Sabin) in the early 1960s. Inactivated 
polio vaccine was reintroduced into the primary immunisation schedule in 
2001. Individuals born before 1958 may not have been immunised.
One case of polio can potentially infect up to 5 non-immune contacts.
Epidemiology
Poliomyelitis is endemic in some low-income countries where epidemics 
of poliomyelitis occur. In countries where the disease incidence is low, 
but where transmission still exists, polio cases are seen sporadically or 
as outbreaks among unimmunised individuals. Outbreaks have recently 
occurred in Afghanistan, Angola, India, Namibia, Nigeria and Pakistan. 
This shows the ongoing threat of wild polio virus, and the need to 
maintain high immunisation levels and to report cases of acute flaccid 
paralysis (AFP). 
The most recent case of wild poliomyelitis notified in Ireland was in 1984. 
If current trends continue, and polio is eradicated in the near future, 
there will be no need for polio vaccines.
Transmission is through contact with the faeces or pharyngeal secretions 
of an infected person. The incubation period ranges from 3-21 days, but 
may be longer. Cases are most infectious from about 10 days before 
to 7 days after the onset of symptoms. However, carriers and some 
immunocompromised persons may shed virus in the faeces for longer 
than 6 weeks.
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Effects of poliomyelitis
Most infections are clinically inapparent. Clinical disease may range in 
severity from a non-paralytic fever to aseptic meningitis or paralysis. 
Symptoms include headache, gastro-intestinal disturbance, malaise and 
stiffness of the neck and back, with or without paralysis. The proportion 
of inapparent to paralytic infections may be as high as 1,000:1 in children 
and 75:1 in adults. A case-fatality rate of more than 50% can occur in 
young adults.
At present an active surveillance system for acute flaccid paralysis is in 
operation in Ireland. This commenced in September 1998. In any case 
of acute flaccid paralysis, it is essential to obtain two faecal samples 24-
48 hours apart for viral culture, as soon as possible after the onset of 
paralysis.
Poliomyelitis vaccine
Poliomyelitis vaccine is available in two forms: Inactivated Polio Vaccine 
(IPV) and live Oral Polio Vaccine (OPV).
1  Inactivated Polio Vaccine (IPV)
IPV contains polioviruses of all three types which have been inactivated 
by formaldehyde. The primary course consists of 3 injections at least 
1 month apart. An up-to-date list of licensed vaccines is contained in 
Appendix 1, or can be accessed on the IMB website, www.imb.ie 
Indications
Recommendations for IPV vaccination
Children
• All children should receive four doses of IPV at 2, 4 and 6 months, 
and 4-5 years of age.
• The preferred interval between the first 3 doses is 2 months. If 
accelerated protection is needed, the minimum interval between 
doses is 4 weeks.
• No additional doses are necessary if more time than recommended 
elapses between doses.
• Those who started the vaccine series with one or more doses of OPV 
should receive IPV to complete the series. A minimal interval of 4 
weeks should elapse between OPV and IPV but a gap of at least 2 
months is preferable.
• IPV can be administered simultaneously with all other routinely 
recommended childhood vaccines. 
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These recommendations may differ from recommendations contained in 
the manufacturer’s literature.
Unimmunised persons aged 10 years and over 
Three doses of an IPV containing vaccine 1 month apart, with a booster 5 
years later, are recommended, as per Chapter 2.
Incompletely immunised persons aged 10 years and over and fully 
immunised persons at increased risk of exposure
The course should be completed with an IPV containing vaccine. Fully 
vaccinated persons aged 10 years and over at increased risk of exposure 
to wild poliovirus should be given a single dose of Td/IPV (or Tdap/IPV if 
indicated). An interval of at least 6 months should be left between doses 
3 and 4. At-risk persons include:
 • Those traveling where poliomyelitis is epidemic or endemic
 •  Those in contact with patients who may be excreting wild 
poliovirus
 • Those in contact with specimens that may contain wild poliovirus
Contraindications
A previous anaphylactic reaction to IPV, Neomycin or Streptomycin
Precaution
Acute severe febrile illness, defer until recovery.
Even though there is no convincing evidence of an increased rate of 
adverse events, IPV should not be administered to a pregnant female 
unless the benefits of vaccination outweigh theoretical risks.
2  Live Oral Polio Vaccine (OPV)
The risks of Vaccine Associated Paralytic Polio (VAPP) following OPV of 
approximately 1 case per 2.5 million doses are greater than the risks of 
wild poliovirus poliomyelitis except in those travelling to areas where 
polio virus is endemic.
OPV is no longer licensed or available in Ireland.
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Introduction
Rubella is a mild disease caused by a toga virus whose only host is 
humans. Up to 50% of infections are asymptomatic. Its most serious 
effects are on the foetus, and prevention of the congenital rubella 
syndrome is the main aim of rubella vaccination. 
Epidemiology
The incubation period is 14-21 days, with most individuals developing a 
rash 14-17 days after exposure. Respiratory transmission occurs by direct 
or droplet spread. It may be transmitted by asymptomatic cases. Most 
infections occur in winter or early spring. Individuals with rubella are most 
infectious from 1 week before to 1 week after onset of the rash. Infants 
with congenital rubella may shed high titres of virus from their naso-
pharynx or in the urine for over 1 year.
Since the introduction of Rubella vaccine in 1971, notifications of 
rubella have decreased (Figure 14.1). There is a longer interval between 
outbreaks and the numbers infected are smaller. In order to prevent 
outbreaks 95% uptake of 2 doses of MMR vaccine is required.
Effects of rubella
Acquired rubella
When symptoms occur they are generally mild. In children, rash is usually 
the first manifestation and a prodrome is rare. In older children and 
adults there is often a prodromal illness with low-grade fever, malaise, 
coryza and mild conjunctivitis. Lymphadenopathy involving post-
auricular and sub-occipital glands may precede the rash. The rash is an 
erythematous maculo-papular rash which initially occurs on the face and 
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neck. The rash is short-lived and is not specific to rubella and therefore 
laboratory confirmation is recommended.
Arthralgia and arthritis, which may last for up to 1 month, occur 
frequently in adult females (up to 70%) but are rare in adult males and 
children. Fingers, wrists and knees are usually affected.
Post-infectious encephalitis occurs in 1 in 6,000 cases, more often in 
adult females. Haemorrhagic manifestations occur in approx. 1 in 3,000 
cases, more commonly in children and are due to thrombocytopoenia or 
vascular damage. Cerebral, GIT or renal haemorrhage may result. Effects 
may last from days to months, but most patients recover.
Congenital rubella syndrome (notifiable)
Maternal rubella infection in pregnancy may result in foetal loss or 
major defects affecting almost all organ systems. Manifestations may 
be delayed for up to 4 years. The congenital rubella syndrome (CRS) 
comprises eye, ear, heart and CNS defects. Deafness is the most 
common and sometimes the only manifestation, especially when infection 
occurs after 16 weeks gestation. 
Cardiac defects include patent ductus arteriosus, pulmonary stenosis, 
septal defects and coarctation of the aorta. Eye defects include cataracts, 
microphthalmia, pigmentary retinopathy, and glaucoma. Neurological 
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problems include encephalitis, microcephaly, mental handicap, 
and behavioural problems.  Other abnormalities include hepatitis, 
splenomegaly, thrombocytopoenia, and growth retardation. Diabetes 
mellitus occurs frequently in later childhood in those with the CRS. 
Reinfection with rubella may occur, as impaired cell-mediated immunity 
has been demonstrated in some children with CRS.
The overall risk of defects depends on the stage of pregnancy. If followed 
up after birth, up to 85% of infants infected in the first 8-10 weeks 
will be affected. The risk of foetal damage declines to about 10-20%, 
with infection occuring between 11-16 weeks and with only deafness 
occurring up to 20 weeks of pregnancy. Defects are rare after 20 weeks. 
Preconceptional testing for rubella immunity is recommended.
Assessment of immunity
Satisfactory evidence of protection against rubella would include 
documentation of having received either 2 doses of rubella-containing 
vaccine or a positive antibody test for rubella. It has been reported that 
viraemic infection can occur in vaccinated persons who have low levels 
of detectable antibody. On rare occasions, clinical reinfection and foetal 
infection have been reported and CRS has occurred in infants born to 
women with serological evidence of rubella immunity prior to infection. 
Rubella vaccine
Rubella vaccine is only available as MMR (Measles, Mumps and Rubella 
vaccine). The vaccine contains attenuated measles, mumps and rubella 
which are cultured separately and mixed before lyophilisation. 
The lyophilised powder is reconstituted using the diluent supplied 
and shaken well to completely dissolve the pellet. The reconstituted 
vaccine is yellow in colour and should only be used if clear and free from 
particulate matter.
An up-to-date list of licensed vaccines is contained in Appendix 1, or can 
be accessed on the IMB website, www.imb.ie.
MMR does not contain thiomersal or any other preservatives. It must 
be kept refrigerated at 2-8ºC, and protected from light. It should 
be used within 1 hour of reconstitution. Failure to adhere to these 
recommendations can result in loss of vaccine potency and diminished 
effectiveness. 
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Over 90% of individuals develop immunity to measles and rubella after 
1 dose of vaccine. Two doses give protection in over 98% of people 
(see point 1, Indications). Between 61% and 91% are protected against 
mumps after 1 dose; and 98% are protected after 2 doses. Serological 
and epidemiological evidence indicates that vaccine-induced immunity is 
possibly lifelong.
Low rates of seroconversion occur in those under 12 months of age, 
because of maternal antibodies.
Deferral of MMR following blood or immunoglobulin transfusion 
(except anti-RhD immunoglobulin, see p. 90/112/145)
Deferral of MMR following blood or immunoglobulin transfusion
Blood and blood products may contain significant levels of virus-specific
antibody, which could prevent vaccine virus replication. Where possible,
MMR should be deferred for at least 3 months after receipt of low-dose
immunoglobulin, 6 months after red-cell transfusion, and 11 months after
high-dose immunoglobulin (as for Kawasaki Disease). Anti-RhD 
immunoglobulin can be administered simultaneously or at any time in 
relation to MMR (varicella on page 142).  If the MMR vaccine
is administered within these timeframes, a further dose should be given
outside these times.
Laboratory investigation to determine vaccine response is not routinely 
recommended. 
Persons who are tuberculin-positive may have a negative tuberculin test 
for 3 months after measles infection or MMR vaccine.    
Scientific evidence shows no association between the MMR vaccine 
and autism or inflammatory bowel disease.
Dose and route of administration
The dose is 0.5 ml by deep intramuscular injection. The deltoid is the 
recommended site of administration. The anterolateral thigh may also be 
used.
Alcohol swabs are best avoided as alcohol can inactivate the MMR 
vaccine.  If alcohol is used to clean the skin it must be allowed to 
evaporate completely before the injection is given.
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When other injectable vaccines are being given concurrently with MMR, 
different sites should be used.
MMR may be given at the same time as DTaP, IPV, MenC, Hib and 
Hep B in situations where the latter are overdue.
Indications
1.  All children at 12-15 months of age, with a second dose at 4-5 years 
of age. For older children who have not received 2 doses, MMR 
vaccine should be given as soon as possible, and a second dose one 
month later. Allowing 3 months between doses is likely to maximise 
the response rate in children aged under 18 months.. If children aged 
under 18 months are given the second dose less than 3months after 
the first dose, they need a third dose to ensure full protection. This can 
be given at 4-5 years. MMR vaccine can be given to those who have a 
history of measles, mumps or rubella infection.
2.  Children coming from low-income countries have probably received 
measles vaccine but may not have received rubella or mumps vaccine. 
Therefore, unless there is a reliable history of vaccine administration, 
these children should be regarded as unimmunised, and given 2 doses 
of MMR one month apart.
3.  All seronegative women of child bearing age who need to be  
protected against rubella should be offered 1 dose of MMR  vaccine 
(see below for health care workers). Satisfactory evidence of protection 
would include documentation of having received at least one dose of 
rubella containing vaccine or a positive antibody test (IgG level >10IU/
mL) for rubella.
4.  Health-Care Workers (HCWs) in the following situations (see Chapter 
18). Protection is important both for themselves and in the context of 
their ability to transmit rubella to vulnerable groups.
 •  Those who do not have evidence either of rubella infection or of 
having received 2 doses of MMR vaccine should be given 2 doses of 
MMR, separated by at least 1 month.
 •  If an outbreak occurs in an institution or an area served by an 
institution, HCWs without evidence of immunity to rubella, or without 
documented evidence of having received two doses of MMR, should 
be given 1 dose of MMR.
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Antibody response to the rubella component of the MMR vaccine
does not develop quickly enough to provide effective prophylaxis
after exposure to suspected rubella. However, the vaccine can provide
protection against future exposure infection. Therefore, contact with
suspected rubella provides a good opportunity to offer MMR to
previously unvaccinated individuals. If the individual is already incubating
rubella, MMR vaccination will not exacerbate the symptoms.
Human normal immunoglobulin is not routinely used for post-exposure
protection from rubella since there is no evidence that it is effective. It is
not recommended for the post-exposure protection of pregnant women
exposed to rubella. 
Changed September 2011
Contraindications
1. Anaphylaxis following a previous dose of MMR or one of its 
constituents (e.g. Neomycin, Gelatin)
2. Significantly immunocompromised persons, such as those with 
untreated malignant disease and immunodeficiency states other 
than HIV infection, and those receiving immunosuppressive 
therapy, high-dose x-ray therapy and current high-dose systemic 
corticosteroids (see Chapter 2)
3. Pregnancy. Furthermore, pregnancy should be avoided for 1 
month after MMR
There is no evidence to recommend or support the use of single 
vaccines against measles, mumps or rubella in place of the 
combination MMR vaccine.
The following are NOT contraindications to MMR vaccine
1. Allergy to egg, even anaphylaxis following egg. If there is a 
genuine concern regarding serious allergy, a paediatrician may 
be consulted and the vaccine given in hospital although this is 
not medically necessary. Currently-used measles and mumps 
vaccines do not contain significant amounts of egg cross-reacting 
proteins and recent data suggest that anaphylactic reactions to 
MMR are not associated with hypersensitivity to egg antigens but 
to other vaccine components (Gelatin or Neomycin)
2. Breast-feeding
3. HIV-positive patients who are not severely immunocompromised
4. Personal or family history of convulsions. Advice regarding the 
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possibility and treatment of pyrexia should be given
5. Immunodeficiency in a family member or household contact
6. Uncertainty as to whether a person has had 2 previous MMR 
vaccines
7. Administration of anti-RhD immunoglobulin. As anti-RhD 
immunoglobulin does not interfere significantly with the 
antibody response to MMR (varicella on p. 145) vaccine, the two 
injections may be given simultaneously (in different syringes, at 
different sites), or at any time in relation to each other.
Precautions
1. Acute severe febrile illness, defer until recovery
2. Injection with another live vaccine within the previous 4 weeks
3. Recent administration of blood or blood products (see above)
4. Patients who developed thrombocytopenia within 6 weeks of 
their first dose of MMR should undergo serological testing to 
decide whether a second dose is necessary. The second dose 
is recommended if the patient is not fully immune to the 3 
component viruses.
Adverse reactions
Soreness and erythema may occur at the injection site (3-8%). Fever (6%), 
rash (7%), headache, vomiting and salivary gland swelling may occur. A 
febrile convulsion occurs in 1 in 1,000 children.
‘Mini-measles’ may occur 6-10 days after immunisation and consists of 
mild pyrexia and an erythematous rash. ‘Mini-mumps’ with salivary gland 
swelling may rarely occur during the third week after immunisation. Very 
rarely, anaphylaxis, erythema multiforme, thrombocytopoenia, and nerve 
deafness have been reported.
The rubella component may occasionally produce a rash, mild arthralgia, 
and lymph-node swelling 2-4 weeks post-vaccination, particularly in post-
pubertal females (up to 25% of recipients). The incidence is lower than 
after natural disease. 
There is no evidence of congenital rubella syndrome or increase in other 
teratogenic effects in women inadvertently given rubella vaccine before 
or during early pregnancy, but pregnancy remains a contraindication.
Adverse reactions are considerably less common (under 1%) after a 
second dose of MMR.
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Introduction
Tetanus is an acute neurological disease characterised by muscular 
rigidity with superimposed contractions. It is caused by the neurotoxin 
produced by Clostridium tetani which grows anaerobically in a 
contaminated wound. Effective protection is provided in 90-95% of 
children who are fully vaccinated. Protection declines with time; up 
to 50% of 20-year-olds and up to 70% of 70-year-olds who have not 
received boosters may be unprotected.
Epidemiology
Tetanus spores are present in the soil, and in the gut and faeces of cattle, 
sheep, horses, chicken. In agricultural areas a significant number of 
adult humans may harbour the organism in their gut. The spores may be 
introduced into the body during injury, often through a puncture wound 
but also through burns or trivial wounds. Spores may also be found in 
contaminated heroin. 
Worldwide, over 1 million cases occur each year. Between 1988 and 
2004, 10 cases of tetanus were reported in Ireland with 2 deaths. Twenty 
cases occurred among injecting drug users in the UK in 2003-2004. 
The incubation period is between 4 and 21 days, commonly around 10 
days. The shorter the incubation period, the greater the likelihood of 
death. Spores germinate in anaerobic conditions, producing toxins that 
spread via blood and lymphatics. Tetanus is not transmissible from person 
to person. Those most at risk of developing tetanus are young children 
and people over 60, many of whom have never had active immunisation.
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Effects of tetanus
Local tetanus is manifested by muscle spasms in areas contiguous to the 
wound. The spasms may continue for several weeks. Local tetanus may 
precede generalised tetanus but is usually much milder, about 1% of 
cases being fatal.
Generalised tetanus is the most common type of tetanus. It usually starts 
with spasms of the jaw and neck muscles, and proceeds distally. Spasms 
may be frequent, last for minutes, and persist for 3-4 weeks. Complete 
recovery may take months. Complications include laryngospasm, 
fractures of the long bones, secondary infections, aspiration pneumonia, 
and hypertension due to autonomic nervous system dysfunction. 
Pulmonary embolism is a problem in drug users and the elderly. Mortality 
rates in recent years are 10-90%, being highest in infants, the elderly, and 
those who are unvaccinated.
Tetanus vaccine
This is a toxoid, prepared by inactivating tetanus toxin with formaldehyde 
and adsorbing it onto aluminium. This acts as an adjuvant, to increase 
immunogenicity.  Bordetella Pertussis also acts as an effective adjuvant.
Tetanus vaccine is not available as a single vaccine. The currently licensed 
tetanus vaccines are all combined vaccines. An up-to-date list of licensed 
vaccines is contained in Appendix 1, or can be accessed on the IMB 
website, www.imb.ie.
Toxoids should be stored at 2-8oC.  
Dose and route of administration
The suspension may sediment during storage and should be shaken prior 
to administration. The dose is 0.5 ml, given by intramuscular injection 
into the anterolateral thigh or the deltoid area.
Indications
Immunisation of infants and children under 10 yrs
Primary immunisation
This consists of 3 doses at 2, 4 and 6 months of age.
Booster doses
A booster dose should be given at 4-5 years of age, as DTaP/IPV, ideally 
at least 3 years after the third primary dose. The booster dose of DTaP/
IPV at 4-5 years should be given even though a child may already have 
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received 4 doses of these vaccines. The risk of Arthus reactions with 
currently-used vaccines is very small.  
A second booster as is given between the ages of 11 and 14. The aim 
is that each child should be given a minimum of 5 doses of tetanus and 
diphtheria toxoids. Whenever possible at least 5 years should be left 
between the first and second boosters.
If the primary schedule has been delayed, the first booster may be given 
at age 4-5 years, at least 6 months after the third primary dose.
Td is now recommended as a replacement for tetanus-only boosters for 
those aged over 10 years. For immunised persons who have received 5 
doses of tetanus toxoid, booster doses may be unnecessary as they may 
cause considerable local reactions.
If pertussis vaccine is refused by parents, the only available diphtheria 
and tetanus vaccines are Td and Td/IPV, which contain insufficient tetanus 
and diphtheria toxoid for primary immunisation. They are not intended 
for use as part of the primary vaccine schedule, may not give a 
sufficient immune response if so used, and are not licensed for such 
use.
Immunisation of persons aged 10 years or over (unimmunised or 
partly immunised)
Primary immunisation
This consists of 3 doses of tetanus toxoid with intervals of at least 1 
month between doses. 
Booster doses
A booster dose of tetanus toxoid should be given 5 years after the 
primary course and again 10 years later.
International travel
Td/IPV should be considered, as it may be difficult to obtain safe and 
effective booster doses in some countries.
HIV positivity
HIV-positive individuals can be immunised against tetanus unless they 
had anaphylaxis following a previous dose.
Adverse reactions
Local: Pain, redness, and swelling around the injection site can occur and 
persist for several days. These reactions are less likely when a 25 mm 
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needle is used, but are more common after the fourth and subsequent 
doses. Exaggerated local (Arthus-like) reactions occasionally occur. They 
begin 2-8 hours after vaccination and are more common in adults. They 
consist of extensive painful swelling which may involve the entire upper 
pear of the arm. They almost always resolve completely.
General: Headache, malaise, myalgia and fever are uncommon. Rash and 
lymphadenopathy occasionally occur. Anaphylaxis is extremely rare.
Contraindications  
Anaphylaxis to a previous dose of the vaccine or to one of its 
constituents.
Precautions 
Acute severe febrile illness; defer until recovery. 
Arthus-type reaction to a previous dose; further tetanus vaccine should 
be deferred for 10 years.
Prophylaxis for tetanus-prone wounds
The following wounds are considered tetanus-prone:
• Wounds contaminated with soil, faeces, saliva or foreign bodies
• Puncture wounds, avulsions, burns or crush injuries
• Wounds or burns requiring surgical treatment which is delayed for 
more than 6 hours
• Compound fractures
Note: Occasionally, apparently trivial injuries can result in tetanus.
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Table 15.1 Risk assessment of wounds for use of tetanus immunoglobulin 
(TIG)(1)
Age Immunisation 
status
Clean wound Tetanus prone 
wound 
<4 years <3 doses or 
unknown
3 or more doses
DTaP/IPV+/-
Hib(2) 
Nil
TIG, DTaP/IPV +/- 
Hib(3)
Nil 
Consider TIG(1)
>4 to 9 
years
<3 doses or 
unknown
        
3 doses only, >5 
years since last 
dose
3 or more doses, 
<5 years since 
last tetanus 
toxoid
4 or more doses, 
>5 years since 
last dose
DTaP/IPV
DTaP/IPV
Nil
Nil
TIG plus DTaP/IPV
DTaP/IPV
Consider TIG(1)
Nil 
Consider TIG(1)
DTaP/IPV, consider 
TIG(1)
10 years 
and over
<3 doses or 
unknown
3 or more doses 
>10 years since 
last dose
3 or more doses, 
<10 years since 
last dose
Td
Td
Nil
TIG plus Td/IPV
Td, consider TIG(1)
Consider TIG(1)
(1) Consider TIG if wound contaminated with stable manure, or extensive devitalised tissue.
Give TIG if HIV positive, irrespective of vaccine status.
(2) If last tetanus containing vaccine <1 month previously, defer for 1 month.
(3)  If child is >1 year, the follow-up vaccine(s) will be DTaP/IPV or DTaP/IPV/Hib (only one 
dose of Hib is required >1 year). 
TIG  Tetanus Immunoglobulin.
DTaP/IPV/Hib Diphtheria, Tetanus and acellular Pertussis vaccine/Inactivated Polio 
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Virus vaccine/ Haemophilius influenzae b vaccine
DTaP/IPV   Diphtheria, Tetanus and acellular Pertussis vaccine/Inactivated Polio 
Virus vaccine
Td/IPV  Tetanus, low-dose diphtheria/ Inactivated Polio Virus vaccine
Tdap  Tetanus, low-dose diphtheria and low-dose acellular pertussis vaccine
IMPORTANT:
If both TIG plus a vaccine are to be given, administer at separate sites.
Refer to GP for follow-up vaccines.
Batch numbers and expiry dates must be recorded for all vaccines 
given. 
This information MUST be communicated to the patient’s GP so that: 
• Duplication of vaccination does not occur.  
• Full records may be passed onto the relevant agencies in order 
that a full nationwide database is kept of batch numbers and 
expiry dates of vaccines given to children.
Specific anti-tetanus immunoglobulin
Indications
1 Those with tetanus-prone wounds who have not received at least 3 
doses of tetanus toxoid and their last dose within 10 years (see Table 
15.1 above)
2 Patients with impaired immunity (see Chapter 2) who suffer a tetanus-
prone wound – may in addition require anti-tetanus immunoglobulin
3 Patients who have suffered a high-risk wound, regardless of vaccine 
history
Dose and route of administration
Prevention
250 IU intramuscularly into the anterolateral thigh.
The single dose of TIG is doubled to 500 IU (2ml) when any of the 
following situations exist:
• The injury occurred more than 24 hours previously.
• The patient weighs more than 90 kg.
• The wound is heavily contaminated.
• The wound is infected or involves a fracture.
Treatment
150 IU/kg given in multiple sites. Specific anti-tetanus immunoglobulin is 
available in 1 ml ampoules containing 250 IU.
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Introduction
Human tuberculosis is caused by infection with bacteria of the 
Mycobacterium tuberculosis complex (M. tuberculosis, M. bovis, M. 
africanum, M. microti or M. canetii, M. caprae, M. pinnipedii). The 
organism may infect any part of the body. However, the majority of cases 
involve the respiratory system.  
The World Health Organization (WHO) declared TB a global health 
emergency in 1993. In 2006 WHO launched the Global Plan to Stop TB 
2006-2015 in collaboration with public and private partners. This plan 
is a comprehensive assessment of the action and resources needed for 
implementation and to make an impact on the global TB burden. It aims 
at global elimination of TB by 2050. 
Epidemiology
The incidence of tuberculosis in Ireland has declined from a recorded 
rate of 230 cases per 100,000 in 1952 to a rate of 10.6 per 100,000 in 
2005. The number of notified cases declined each year from 1991 to 
1997 but increased in 1998 and 1999. The number of cases fell to 9.7 per 
100,000 in 2001 with a total of 450 cases. Since 2001 the rate has slowly 
increased to the current rate of 10.6 per 100,000 (432 cases). Multidrug 
-resistant (MDR) isolates remain very uncommon, with 1-3 reported per 
year. Extensively drug-resistant (XDR) isolates remain very uncommon 
worldwide, with only 1 case reported in Ireland in 2005. 
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Transmission
The infection is usually acquired by the respiratory route through 
breathing in infected droplets from a person with infectious pulmonary 
TB. Such transmission is more likely when the index case has sputum, 
which is smear positive for the bacteria on microscopy, and often occurs 
after prolonged close contact such as living in the same household as the 
case. 
Effects of tuberculosis
A notified case of tuberculosis refers to clinically active disease due to 
infection with M. tuberculosis complex. Tuberculosis disease is classified 
as pulmonary, extrapulmonary or both. In Ireland, approximately 70% of 
all TB cases are pulmonary cases. Non-respiratory forms of TB are more 
common in those with impaired immunity.  
The symptoms of TB are varied and depend on the site of infection. 
General symptoms may include fever, lassitude, loss of appetite, weight 
loss and night sweats. Pulmonary TB typically causes a persistent 
productive cough, which may be accompanied by blood-streaked sputum 
or more rarely frank haemoptysis.  
The initial TB infection may be eliminated or remain latent or progress 
to active TB disease. Latent TB infection (LTBI) occurs where a person 
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Figure 16.1 Number and crude incidence rates (per 100,000 total population) 
of tuberculosis notifications in Ireland, 1991-2005. Source: HPSC
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has no symptoms and no evidence of TB disease but the TB bacteria 
remain in the body. LTBI may reactivate in later life in approximately 
5% of persons particularly if an individual’s immune system becomes 
weakened, e.g. by disease (HIV), due to certain medical treatments 
such as cancer chemotherapy, corticosteroids, TNF-α antagonists, or 
in old age. Currently a diagnosis of LTBI is most commonly based on a 
positive tuberculin skin test (Mantoux test). Interferon gamma release 
assays (IGRA) may be used (where they are available) as an adjunct to the 
tuberculin skin test in the diagnosis of LTBI.1
BCG vaccine
Bacille Calmette Guerin (BCG) vaccine contains a live attenuated strain 
derived from Mycobacterium bovis. BCG Vaccine Statens Serum Institut 
(SSI) is the only available licensed BCG vaccine in Ireland. It contains 
the Danish strain 1331. It does not contain thiomersal or any other 
preservatives. 
The efficacy of BCG in preventing tuberculosis has varied in reported 
studies over the years, but is probably most consistently effective 
against tuberculous meningitis and miliary TB, with protection lasting 
approximately 15 years. Two meta-analyses of published clinical trials 
and case control studies have shown the vaccine to be 70-80% effective 
against the most severe forms of disease such as TB meningitis in 
children. International and Irish studies have also indicated a protective 
efficacy of the vaccine against childhood tuberculosis. 
BCG is less effective in preventing respiratory disease, which is the more 
common form in adults and more important for the transmission of the 
disease. There are few data on the protection afforded by BCG vaccine 
when it is given to adults (aged 16 years and older) and virtually no data 
for persons aged over 35 years.  
BCG is not usually recommended for people over 16 years of age unless 
the risk of exposure is great, e.g. new entrants from areas where the 
annual rates of tuberculosis are high and those at occupational risk, in 
which case it is given up to and including age 35 years, except in the case 
of health-care workers when it is given at any age. 
Indications for BCG vaccine continue to be re-evaluated by the National 
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TB Advisory Committee. At present it is recommended that universal 
neonatal BCG be continued.  
Dose and route of administration
BCG vaccine may be given concurrently with another live vaccine, but if 
it is not given at the same time an interval of at least 4 weeks should be 
allowed between such vaccines. It can also be given at the same time 
as killed vaccines, e.g. DTaP/IPV/Hib or MenC. When BCG is given to 
infants there is no need to delay the primary immunisations. No further 
immunisation should be given in the arm used for BCG immunisation for 
at least 3 months because of the risk of regional lymphadenitis. 
Infants under 12 months of age
The recommended dose is 0.05 ml, by intradermal injection of the 
reconstituted vaccine at one site over the middle of the deltoid muscle.
Adults and children 12 months and over
The recommended dose is 0.1 ml, by intradermal injection, of the 
reconstituted vaccine and given at one site over the middle of the deltoid 
muscle. 
Although the protection afforded by BCG vaccine may wane with time, 
there is no evidence that repeat vaccination offers significant protection 
and repeat BCG is not recommended. If re-immunisation with BCG is 
being considered expert advice should be sought.
Indications
The vaccine is indicated for prophylactic immunisation in Mantoux (or 
interferon-gamma) negative individuals.  
Groups in whom BCG vaccine is indicated
a. Newborn babies 
b. Unvaccinated children aged 1-15 years (i.e. those with no 
documented evidence of BCG or without a characteristic scar)  
• Children aged 3 months to less than 6 years who are not in 
an at-risk environment2 do not need a Mantoux test prior to 
receiving BCG vaccine
• Children in at-risk environments should have a Mantoux test 
prior to BCG
c. Unvaccinated Mantoux negative immigrants with a history of 
ever living in a high incidence country (Appendix 2) and their 
children who are previously unvaccinated (that is without adequate 
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documentation or a characteristic scar) and aged younger than 16 
years OR aged 16-35 years who ever lived in a sub-Saharan African 
country or country with a TB incidence of 500 per 100,000
d. Unvaccinated Mantoux negative contacts aged 35 years and under, 
of cases with active respiratory tuberculosis. Children under 5 years 
of age in contact with smear positive tuberculosis should be referred 
to a contact tracing clinic for investigation and then immunised with 
BCG as indicated
e. Members of special at-risk groups such as the Traveller community 
– due to the logistical difficulties of providing alternative control 
measures and follow-up of contacts
f. Unvaccinated Mantoux negative persons under 16 years of age 
intending to live with local people in high-incidence countries for 
more than 1 month (Appendix 2)
g. All health-care workers who are previously unvaccinated (i.e. without 
adequate documentation or a characteristic scar) and will have 
contact with patients or clinical materials and are Mantoux (or 
interferon-gamma, if available) negative should be offered BCG 
vaccination irrespective of age.  Health-care workers include the 
following:
• Those who will have contact with patients or clinical materials
• Laboratory staff who will have contact with patients, clinical 
materials or derived isolates
h. Those more likely than the general population to come into contact 
with someone with infectious sputum positive TB. Unvaccinated  
Mantoux negative persons aged 35 years and under in the following 
occupations should be offered BCG vaccination.
• Veterinary laboratory staff who handle animal species known to 
be susceptible to TB and abattoir workers who handle animal 
species, carcasses and products known to be susceptible to 
tuberculosis. Agricultural officers and veterinary inspectors may 
require BCG vaccination based on individual risk assessment 
• Prison staff working directly with prisoners.
• Staff of facilities for the elderly
• Staff of hostels for homeless people and facilities 
accommodating refugees and asylum seekers.
Contraindications
BCG vaccine should not be given to:
1  Neonates in a household where an active TB case is suspected 
orconfirmed
2  BCG vaccination is contraindicated for up to 6 months in infants born 
to mothers who received immunomodulating drugs in the second 
and/or third trimesters of pregnancy. Immunomodulators include 
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TNF-alpha inhibitors such as  monoclonal antibodies (eg. infliximab, 
etc) and  fusion proteins (eg enbrel); calcineurin inhibitors (eg 
cyclosporin); cytotoxics (eg azathiaprin, methotrexate); and steroids. 
A decision regarding giving BCG to a breast-feeding infant whose 
mother is receiving immunomodulators can be made on a case-by-
case basis.
3 Those suffering from blood dyscrasias, lymphoma, or malignant 
neoplasms involving bone marrow or the lymphoreticular system, or 
with gamma globulin deficiency or abnormality
4 Those with a family history of primary immunodeficiency, e.g. 
inherited severe combined immunodeficiency (SCID), Chronic 
Granulomatous Disease (CGD) etc. until evaluation is complete
5 Those with pyrexia ≥ 380C
6 Those with generalised infected dermatosis. The effect of BCG 
vaccine may be exaggerated in these patients, and a more 
generalised infection is possible. If the person has eczema, an 
immunisation site should be chosen that is free from skin lesions. 
Eczema is not a contraindication
7 Those who are pregnant. Breast feeding does not constitute a 
contraindication to BCG vaccine
8 Those with positive tuberculin tests (or gamma interferon tests) 
9 Those who have had a confirmed anaphylactic reaction to a 
component of the vaccine.
Changed September 2011
HIV 
BCG should not be given to children known to be HIV positive. However 
lack of knowledge of maternal HIV status is not a reason to defer routine 
BCG inoculation in healthy newborns.
Low-birth weight infants
A number of studies of the safety and efficacy of BCG given to low-birth 
weight and/or preterm infants have been published. Some limitations 
of these studies are that they involved small numbers, were carried out 
in different ethnic groups, and used different BGG strains. Taking these 
limitations into account, the studies suggest that:
•  BCG elicits an immune response in preterm infants from 28 weeks 
gestation.
• The response increases with increasing gestational age.
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•  Preterm babies can be vaccinated effectively with BCG at 34–35 weeks 
gestation.
•  Low birth weight newborns (<2500g) show a good immune response to 
BCG. 
BCG vaccine can be given to low-birth weight infants before discharge 
from neonatal facilities when they have reached 34-35 weeks gestation, 
irrespective of their weight.
Changed September 2011
Adverse reactions
Local: Side-effects include local induration, pain and occasionally 
ulceration, enlargement of a regional lymph node greater than 1 cm, 
abscess formation, lupoid reaction and inflammatory and suppurative 
adenitis.3  
General: Headache, fever, and generalised lymphadenopathy 
can occur on rare occasions (in less than one in 1,500 vaccinated). 
Anaphylactic reaction and disseminated BCG complications (such as 
osteitis, osteomyelitis or disseminated BCG infection) are also very rare. 
Disseminated BCG infection occurs in approximately 2 per 1 million 
persons.
Interactions
Administration of blood or plasma transfusions, hepatitis B vaccine, 
hepatitis B immunoglobulin and normal immunoglobulin are thought not 
to reduce the effectiveness of BCG vaccine. A baby who has received 
blood or plasma transfusions can be subsequently immunised with 
BCG, after the observation period for transfusion reactions has ended 
(24 hours). A baby who has received hepatitis B vaccine, hepatitis B 
immunoglobulin or normal human immunoglobulin can be subsequently 
immunised with BCG without delay.
Administration of BCG vaccination
Detailed instructions including illustrations are available in Chapter 2.
Note: In all cases, BCG must be administered strictly intradermally. 
Immunisation reaction and care of the immunisation site
The expected reaction to a successful BCG vaccination seen in 90-95% 
of recipients is induration at the injection site followed by a local lesion, 
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which starts as a papule 2 or more weeks after vaccination. It may 
ulcerate and then slowly subside over several weeks or months to heal 
leaving a small flat scar. It may also include enlargement of a regional 
lymph node to less than 1 cm.
It is not necessary to protect the site from becoming wet during washing 
and bathing. The ulcer should be encouraged to dry and abrasion (for 
example by tight clothes) avoided. Should any oozing occur a temporary 
dry dressing may be used until a scab forms. It is essential that air is not 
excluded. If absolutely necessary (e.g. to allow swimming), an impervious 
dressing may be applied but only for a short period as it may delay 
healing and cause a larger scar. 
Further observation after routine vaccination with BCG is not necessary, 
other than as part of monitoring of the quality of the programme, nor is 
further tuberculin testing recommended. 
Severe injection site reactions, large discharging ulcers, abscesses and 
keloid scarring are most commonly caused by faulty injection technique, 
excessive dosage or vaccinating individuals who are tuberculin positive. 
It is essential that all health-care professionals be properly trained in 
all aspects of the process involved in tuberculin skin tests and BCG 
vaccination.  
Management of adverse reactions 
Local adverse reactions to BCG vaccine occur in 1-2% of immunisations. 
Severe local reactions (ulceration greater than 10 mm, caseous lesions, 
abscesses or drainage at the injection site) or regional suppurative 
lymphadenitis with draining sinuses following BCG vaccination should be 
discussed with a respiratory physician or paediatrician.
Most experts do not recommend treatment of draining skin lesions or 
chronic suppurative lymphadenitis caused by BCG vaccine because 
spontaneous resolution occurs in most cases. Large needle aspiration of 
suppurative lymph nodes may hasten resolution. There is little evidence 
to support the use of either locally instilled anti-mycobacterial agents or 
systemic treatment of patients with severe persistent lesions. 
Disseminated BCG infection should be referred to a respiratory or 
infectious disease consultant for specialist advice and will normally 
require systemic anti-tuberculous treatment and mandate a detailed 
immunological investigation. 
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Tuberculin testing prior to BCG immunisation
BCG should not be administered to an individual with a positive 
tuberculin test. It is unnecessary and may cause a more severe local 
reaction. Those with strongly positive tests should be referred to a 
respiratory physician for assessment of the need for further investigation 
and treatment. 
A tuberculin skin test (Mantoux test) is necessary prior to BCG 
vaccination for:
• Children aged 3 months to under 6 years in at-risk environments2
• Persons aged 6 years and older
• Infants and children under 6 years of age with a history of ever having 
lived or had a prolonged stay (more than 1 month) in a country of 
high endemnicity (Appendix 2)
• Those who have had close contact with a person with known TB
• When there is a history of TB in a household contact in the last 5 
years.
BCG can be given up to 3 months following a negative tuberculin test.
The Mantoux test is used as a screening tool for tuberculosis infection or 
disease and as an aid to diagnosis. The local skin reaction to tuberculin 
purified protein derivative (PPD) injected into the skin is used to assess an 
individual’s sensitivity to the tuberculin protein. The greater the reaction, 
the more likely it is that an individual is infected or has active TB disease.
The standard test for use in Ireland is the Mantoux 2TU/0.1 ml tuberculin 
PPD.
Administration of the Mantoux test 
Detailed instructions are available in Chapter 2.
Care should be taken to store PPD Mantoux tests and BCG vaccine 
in separate areas of the fridge to ensure that the correct product is 
administered (see section on cold chain for storage of PPD and BCG).
Mantoux testing can be undertaken at the same time as inactivated 
vaccines are administered. Live viral vaccines can suppress the tuberculin 
response and so testing should not be undertaken within 4 weeks of 
having received a live viral vaccine such as MMR.  
Reading the Mantoux test
The results should be read within 48-72 hours of receiving the test but a 
valid reading can usually be obtained up to 96 hours later. The transverse 
diameter of the area of induration but not the erythema at the injection 
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site is measured with a ruler and the result recorded using millimetres. As 
several factors affect interpretation of the test, the size of the induration 
should be recorded and NOT just as a positive or negative result, see 
Table 16.1.  
There is some variability in the time at which the test develops its 
maximum response. The majority of tuberculin sensitive subjects will be 
positive at the recommended time of reading.
Note:  
• A delay in reading the Mantoux test if the result is positive i.e. > 6 
mm does not affect the validity of the results.  
• A strongly positive Mantoux test resulting from inadvertent 
subcutaneous administration does not affect the validity of the 
reading. 
Table 16.1  Interpretation of the Mantoux test 
Diameter of induration Interpretation Action
Less than 6 mm Negative Previously unvaccinated 
individuals may 
be given BCG 
provided there are no 
contraindications 
6 mm or greater but 
less than 15 mm
Hypersensitive to 
tuberculin protein. May 
be due to previous 
TB infection, BCG or 
exposure to atypical 
mycobacteria
Should not be given 
BCG* 
≥15 mm Strongly hypersensitive 
to tuberculin protein 
Suggestive of TB 
infection or disease
Refer for further 
investigation and 
supervision which may 
include preventive 
chemotherapy 
* When Mantoux tests are being performed as part of an immunisation programme, no 
further action is required for people with a reaction in this range (6-<15 mm). In other 
contexts (e.g. new immigrant screening, contact tracing programmes) where the subject 
has not been previously vaccinated with BCG and taking account of the precise size of 
the reaction and the circumstances of the case, referral to a respiratory physician may be 
indicated for further investigation. 
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Factors affecting the result of the tuberculin test
The reaction to tuberculin protein may be suppressed by the following:
1 Infectious mononucleosis
2 Viral infections in general including upper respiratory tract infections
3 Live viral vaccines (tuberculin testing should not be undertaken within 
4 weeks of having received a live viral vaccine)
4 Sarcoidosis
5 Corticosteroid therapy
6 Immunosuppression due to disease or treatment including HIV 
infection 
Subjects who have a negative test but who may have had an upper 
respiratory tract or other viral infection at the time of testing or at the 
time of reading the test should be re-tested 2-3 weeks after clinical 
recovery before being given BCG. This second test should be done on 
the other arm; repeat testing at one site may alter the reactivity either by 
hypo- or more often hyper-sensitising the skin and a changed response 
may only reflect local changes in skin sensitivity. 
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Introduction
Infection with the varicella-zoster virus (VZV) causes two distinct clinical 
syndromes, chickenpox and shingles (zoster). Primary infection results 
in varicella, an acute exanthematous disease of childhood. The virus 
becomes latent in the cells of the dorsal root or cranial nerve ganglia 
and may reactivate after a latent period, which may be several decades. 
Reactivation results in the clinical syndrome of zoster.
Epidemiology
In Ireland, the incidence of varicella is seasonal, reaching a peak from 
January to April. The incubation period is from 14 to 16 days (range 
10-21). This may be prolonged up to 28 days in immunocompromised 
patients and in individuals who have received specific varicella-zoster 
immunoglobulin (VZIG). VZV enters through the respiratory tract and 
conjunctiva. Transmission is by inhalation of respiratory droplets, by direct 
contact with vesicular fluid, or less commonly by contact with fomites. In 
Ireland ICGP/HPSC sentinel data from 2000-2005 demonstrated that 54% 
of chicken pox cases occur in children under 5 years of age while 17% of 
cases occur over age 15 years.
Cases of chickenpox are highly infectious from 2 days before the 
appearance of the rash until all of the lesions have crusted, typically a 
total of 7 days. This period may be prolonged in immunosuppressed
individuals. In the family setting the secondary attack rate ranges from 
60-90% for susceptible hosts.
Zoster is transmissible to non-immune contacts as chickenpox, but is less 
infectious than chickenpox. Transmission is by direct or indirect contact 
including inhalation from non-intact vesicles. The period of infectivity, 
typically 5 days, is from the appearance of the lesions until all lesions 
have crusted. In some clinical circumstances, the viral load and/or viral 
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shedding may be increased with increased risk of transmission. Examples 
are disseminated zoster, exposed lesions (e.g. ophthalmic zoster) or 
immunosuppressed patients with localised zoster on any part of the 
body. In the Irish ICGP/HPSC sentinel data 60% of zoster cases occurred 
in those over 45 years of age, and 9% in those aged under 15 years.
Effects of varicella
Varicella is typically a benign infection of childhood characterised by 
a generalised, pruritic vesicular rash. Complications of varicella are 
uncommon in childhood and include superinfection usually with the 
Group A streptococcus, skin scarring, encephalitis, pneumonia, hepatitis 
and coagulopathy. The risk of complications varies with age and is higher 
in infants under 1 year and in persons over 15 years of age. In the USA, 
the fatality rate of varicella is approximately 1 per 100,000 cases among 
children aged 1-14 years; this increases to 25.2 per 100,000 cases in 
adults aged 30-49 years.
Maternal infection in pregnancy carries a greater risk of severe varicella 
pneumonia in the mother especially late in the second trimester and early 
in the third trimester. Risks to the foetus and neonate are related to the 
time of infection in the mother.
In the first 20 weeks of pregnancy maternal infection can result in the 
congenital (foetal) varicella syndrome, which includes limb hypoplasia, 
microcephaly, cataracts, growth retardation and skin scarring. The 
mortality rate is high. The incidence has been estimated to be less than 
1% in the first 12 weeks and around 2% between 13 and 20 weeks of 
pregnancy. A prospective study published in 1994 found no cases of 
congenital varicella syndrome among the 477 pregnancies in which 
maternal varicella occurred after 20 weeks gestation.
In the second or third trimester of pregnancy, infection can cause 
herpes zoster in an otherwise healthy infant. Occasional case reports of 
foetal damage comprising choriorentinal damage, microcephaly and skin 
scarring following maternal varicella between 20 and 28 weeks gestation 
have been published. The risk is likely to be substantially lower than that 
of the typical congenital varicella syndrome that occurs after maternal 
varicella in the first 20 weeks’ gestation.
In contrast, maternal infection in the period from 7 days before to 7 
days after delivery is associated with risk of neonatal infection, the 
highest risk has been associated with maternal infection in the 5 days 
before to 2 days after delivery. 
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Other groups at increased risk of severe complications or disseminated 
infection include immunocompromised patients, especially those who 
have leukaemia or other disorders in which there is depressed cell-
mediated immunity, and transplant recipients. 
Effects of zoster
Zoster is usually a unilateral vesicular eruption in the distribution of a 
single dermatome. Severe pain in the affected area and/or parasthesia 
is common and may occur prior to the onset of the rash. Post-herpetic 
neuralgia may be severe and is more common in the elderly. Zoster 
is typically found in conditions in which cell-mediated immunity is 
suppressed such as immunosuppressive therapy or HIV infection. Zoster 
is rare in childhood but can follow intrauterine exposure, congenital or 
neonatal varicella. Zoster is transmissible to susceptible individuals as 
chickenpox. There is no evidence that maternal zoster poses a risk to the 
foetus or neonate.
Passive immunisation: Varicella-zoster immunoglobulin (VZIG)
Two products which are licensed in Europe (but not in Ireland) can be 
obtained if required for post exposure prophylaxis, One is an  intravenous 
preparation of varicella-zoster immunoglobulin (IV VZIG), Varitect® CP 
and the other product, Human varicella–zoster immunoglobulin (VZIG) 
specific is produced by Bio Products Laboratory (BPL) and is administered 
via the intramuscular (IM) route.  Either product may be used for post 
exposure prophylaxis but the IM product is generally easier to administer 
in older children or adults rather than in neonates due to volume. 
These products are prepared from pooled plasma of donors with a history 
of recent chickenpox or herpes zoster, or from those who on screening 
are found to have high titres of V-Z antibody. These products contain 
specific antibodies (mainly IgG) against varicella-zoster virus. They must 
be stored at 2-8ºC and protected from light. Both products should be 
used immediately when ampoules or bottles have been opened and any 
unused solution discarded.
The timing of administration of the VZIG product depends on the product 
used. Ideally both products should be given as soon as possible after 
exposure, ideally within 96 hours of exposure, but the intramuscular 
product is licensed for use up to 10 days maximum after exposure (or 7 
days in individuals with immuncompromising conditions).
The administration of VZIG does not always prevent infection. However, it 
will typically attenuate the illness. Severe varicella may still occur despite 
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VZIG prophylaxis in high-risk groups including immunosuppressed 
individuals, adults and neonates.
Indications
Recommendations for VZIG prophylaxis
VZIG prophylaxis is recommended for individuals who fulfil all of the 
following three criteria:
a  Significant exposure (see below) to: 
(i) Chickenpox
or
(ii)  Disseminated zoster or extensive exposed lesions in 
immunocompetent individuals
or
(iii)  Localised or disseminated zoster in 
immunosuppressed patients.
PLUS
b   A clinical condition which increases the risk of severe varicella 
(see below).
PLUS
c  No antibodies to varicella-zoster virus (see below).
a. Explanation of significant exposure
As a guideline, significant exposure includes the following:
• Household contact
•  Contact in the same room* for a significant period of time (usually 1 
hour or more†)
•  Face-to-face contact such as when having a conversation (usually 5 
minutes or more)
* An example of ‘same room’ is a classroom or 2-4 bedded hospital bay. This does not 
usually include a large hospital ward. However, because airborne transmission at a distance 
has occasionally been reported in large open wards, in this instance the necessity of giving 
VZIG to all susceptible high-risk contacts should be considered on a case-to-case basis, 
particularly in paediatric wards where the degree of contact may be difficult to define.
† Experts differ in opinion about the duration of face to face contact that warrants VZIG. 
However, the contact should be non-transient. Some experts suggest a contact of 5 
minutes or more and other define contact as 1 hour or more. 
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VZIG should normally be restricted to patients exposed to a case of 
chickenpox or disseminated zoster between 48 hours before onset of 
rash until crusting of lesions. In the case of exposure to localised open
zoster (e.g. ophthalmic zoster) the relevant time period for exposure is 
day of onset of rash until crusting of lesions.
Zoster in an unexposed localised site (e.g. thoracolumbar area) in an 
immunocompetent patient has a low risk of transmission and contacts do 
not require VZIG therapy.
b.  Description of clinical conditions that increase the risk of severe 
varicella
(1) Neonates 
•  Infants whose mothers develop chickenpox (but not zoster) around 
the time of delivery are at increased risk of severe varicella. The 
risk is greatest for neonates whose mothers develop varicella 5 days 
before delivery or 2 days after delivery, but VZIG may be beneficial 
for infants of mothers who develop varicella 7 days before or 7 
days after deliveryApproximately half of these infants may develop 
varicella despite immunoprophylaxis, but the disease is usually 
modified. All infants in this group should be carefully monitored; 
hospitalisation and i.v. acyclovir treatment may occasionally be 
required.
•  VZIG is not usually recommended for full-term healthy infants 
exposed post-natally to varicella, including infants of mothers who 
develop varicella more than 7 days after delivery 
•  In the event of significant exposure in a neonatal intensive care unit 
(NICU), or special care baby unit (SCBU), 
o VZIG is recommended for infants of non-immune 
mothers. 
o Infants born before 28 weeks or whose birth weight is 
less than 1,000 g may not possess VZ antibody despite a 
positive maternal history or titre and should receive VZIG 
in the event of significant exposure.
By slow 
intramuscular 
injection
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Is mother the index case 
and has she got 
chickenpox or zoster? 
(If mother has zoster, 
no action required) 
Full term infant and mother 
has history of chickenpox,
Does the nature of the contact 
meet the criteria listed on page 
174
NB. VZIG not needed if last 
exposure >48 hours before 
onset of chickenpox rash or for
zoster before appearance of 
vesicles
When was rash onset in 
relation to delivery? 
 (see section b.1)  
VZIG not indicated if rash 
onset >5 days before or >2 
days after delivery. 
Otherwise, give VZIG 
I f fu ll te rm infa nt a nd
ma ter na l his tor y not
pos itive, is mother or 
infants’ VZ antibody status 
known ?
I f not known , check 
maternal or infant 
antibodies. Give VZIG only 
if antibody negative and 
VZIG can be given within 
96 hours of initial exposure 
I f known a nd nega tive,
VZIG indicated only if it can
be given within 96 hours of 
initial exposure 
I f known a nd pos i tive,
VZIG not indicated .
I f pr em/L B W, what was 
gestation and birth weight 
and is infant still in SCBU? 
If still in SCBU, VZIG 
indicated even if contact 
>2 days after birth (if infant 
VZ antibody negative) 
NB. VZIG can be given if 
<28/40 or <1 kg at birth 
without antibody testing. 
However, serological 
testing is recommended  
Was the contact in the first 
two days of life? If no and 
infant is full term 
VZIG not indicated 
No 
Yes
VZIG is not indicated
Figure 17.1  VZIG algorithm for neonates (see modification)
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(2) Pregnant women
It is generally recommended that non-immune women who have been 
significantly exposed to varicella at any stage of pregnancy should be 
offered VZIG as soon as possible and ideally within 96 hours of the 
contact. VZIG BPL product for IM administration can be administered up 
to within 10 days post exposure. 
The primary aim of VZIG immunoprophylaxis is to modify the illness in the 
mother, but severe maternal varicella may still occur despite prophylaxis. 
There is little evidence that VZIG will prevent the congenital varicella 
syndrome following significant exposure of a non-immune mother in 
the first 20 weeks. Management of varicella in pregnancy should be 
discussed urgently with an obstetrician/microbiologist/ID consultant and 
consideration given to the use of acyclovir.
Figure 17.2 VZIG algorithm for pregnant women
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VZ antibody status
Does index case have chickenpox or zoster?
            See section a Significant exposure  
Was contact during infectious period?  
NB VZIG not given if last exposure >48 hours before onset of chickenpox 
rash, or  zoster vesicles 
If unknown, test urgently if <96 hours 
of exposure. If >96 hrs, VZIG 
prophylaxis ineffective  
If  negative, give 
VZIG if < 96 hours of  
exposure 
If positive, VZIG 
not indicated. 
Has the pregnant woman a history of chickenpox? 
If yes, VZIG not indicated
If no 
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(3) Immunosuppressed patients
Immunosuppressed patients in whom VZIG is recommended include: 
•  Patients being treated with chemotherapy or generalized 
radiotherapy, or within 6 months of completing such treatments
•  Patients who have received an organ transplant and are currently 
receiving immunosuppressive treatment
•  Patients who have received a bone marrow transplant until at least 
12 months after finishing all immunosuppressive treatment, or longer 
where the patient has developed graft-versus-host disease. Further 
advice can be found in current guidance produced by the European 
Group for Blood and Marrow Transplantation (www.ebmt.org )
•  Children who within the previous 3 months have received 
prednisolone, orally or rectally, at a daily dose (or its equivalent) 
of 2 mg/kg/day for at least one week, or 1 mg/kg/day for one 
month. For adults, an equivalent dose is harder to define but 
immunosuppression may be present in those who have received a 
dose of around 40 mg prednisolone per day for more than one week 
in the previous 3 months
•  Patients on lower doses of steroids, given in combination with 
cytotoxic drugs
•  Patients with evidence of impaired cell mediated immunity, e.g. 
severe primary immunodeficiency or those with symptomatic HIV 
infection. There is no evidence of any increased risk of severe 
varicella in asymptomatic HIV-positive individuals with normal CD4 
counts; hence VZIG is not indicated in this group
•  Patients with immunoglobulin deficiencies who are receiving 
replacement therapy with intravenous normal immunoglobulin do 
not require VZIG.
Whenever possible, immunosuppressed contacts should be 
tested irrespective of their history of chickenpox. However,VZIG 
administration should not be delayed past 7 days ideally after initial 
contact while and antibody test is done. Under these circumstances 
VZIG should be given on the basis of a negative history of chickenpox. 
If the patient has a history of chickenpox wait for the antibody results. 
Those with a positive history in whom VZ is not detected by a sensitive 
assay should be given VZIG.
c.  Description of conditions where there are no antibodies to varicella-
zoster virus
Normal immunocompetent contacts with a definite history of chickenpox 
are immune; serology or immunoprophylaxis are not necessary and they 
can be reassured.
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The majority of adults and a substantial proportion of children 
without a definite history of chickenpox are VZ antibody positive. In 
all individuals without a definite history or of unknown status who are 
being considered for VZIG, a serum sample should be tested for VZ 
antibody; only those without antibody require immunoprophylaxis. 
However, immunosuppressed contacts should be tested for VZ antibody 
regardless of history of chickenpox. When antibody is not detected, VZIG 
is indicated. To arrange urgent testing for VZ antibody local laboratories 
should be contacted. Testing will rarely be required outside normal 
working hours.
VZ antibody detected in patients who have been transfused, or who 
have received intravenous immunoglobulin in the previous 3 months, 
may have been passively acquired. Although VZIG is not indicated if 
antibody from other blood products is detectable, re-testing in the event 
of a subsequent exposure is required, as the patient may have become 
antibody negative.
Does condition meet criteria 
listed at section b.3 (i.e. nature 
of immunosuppression)
Was the contact during the 
infectious period? 
 (see section a) 
VZIG is not issued to 
‘contacts of contacts’ 
Does index case have 
chickenpox or zoster? (see 
section a) 
VZ antibody status (see 
section c) 
If unknown, test
urgently i f <96 hours of
exposure.
If >96hrs, VZIG
prophylaxis ineffective
If negative, give VZIG if < 96 
hours of exposure 
If posit ive: VZIG 
not indicated 
VZIG not normally given if  
exposure >48 hours before  onset
of chickenpox rash or zoster 
i l
Figure 17.3  VZIG algorithm for immunocompromised patients exposed to 
varicella
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VZIG products for post exposure prophylaxis
1. Intramuscular VZIG (Bio Products Laboratory, BPL)
This product is licensed in Europe for post exposure prophylaxis of 
varicella (previously defined)
This product is dispensed in vials of: 250mg (minimum 100 i.u./
ml) supplied by BPL and ideally should be given within 96 hours of 
exposure but can be given within 10 days of exposure.
 Recommended dose for prevention of chickenpox: 
Dosage is > 15 I.U/kg body weight
Alternative dose levels for treatment are as follows
0 – 5 Years    250mg (1 vial)
6 – 10 Years   500mg (2 vials)
11 – 14 Years   750mg (3 vials)
15 years and older   1000mg (4 vials)
 The correct volume of solution to give a dose of 250 mg is overprinted 
on the label.
 Give second dose if further exposure occurs and three weeks have 
lapsed since first dose.
Administration
VZIG IM product should be administered via the intramuscular route. 
The usual recommended sites:
•  for adults are the buttock, thigh or deltoid; 
•  for infants, the lateral aspect of the thigh is preferable. 
If a large volume is required (> 2 ml for children or > 5 ml for adults) is 
required, it is recommended to administer this in divided doses at different 
sites. 
If Intramuscular administration is contra-indicated (bleeding disorders) the 
injection can be administered subcutaneously. However it should be noted 
that there are not efficacy data to support administration by this route. 
Note: For small infants in NICU, the intravenous VZIG product (outlined 
below) may be the preferred option due to volume required and small 
muscle mass in these infants.  
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Procurement
The VZIG BPL product can be obtained from BPL directly. Contact 
details of BPL can be found at http://www.bpl.co.uk/worldwide-
contacts/contact-us/
Or  Tel: +44 (0) 20 8957 2200 and Email: info@bpl.co.uk
Please see product information for more detail. 
2. Intravenous VZIG (Varitect® CP supplied by Intrapharma) 
This product is licensed in Europe for post exposure prophylaxis of 
varicella (previously defined)
  Varitect® CP is a ready for-use solution for intravenous administration 
provided in glass containers: Vial with 5 ml (125 IU), vial with 20 ml 
(500 IU)
Recommended dose for prevention of chickenpox: 
1 ml (25 IU) per kg body weight. 
In repeated exposure, e. g. household contact, higher doses are preferable. 
For post- exposure prophylaxis, Varitect® CP should be administered as 
soon as possible and not later than 96 hours after exposure. 
Administration
During the infusion the rate of 20 drops per minutes (corresponding 
to 1 ml per minute) must not be exceeded. (see product insert)
The solution must be inspected for particulate matter and 
discolouration prior to administration; cloudy or discoloured solutions 
or those that have deposits must not be used. Varitect® CP should 
be brought to room or body temperature before administration.
Special warnings and special precautions for use
Certain severe adverse drug reactions may be related to the rate 
of infusion. The recommended infusion rate outlined in the product 
insert must be closely followed. Patients must be closely monitored 
and carefully observed for any symptoms throughout the infusion 
period. In case of adverse reactions, either the rate of administration 
must be reduced or the infusion stopped until symptoms disappear. 
Patients should be monitored for the first hour post infusion. Please 
see product insert for more information and read carefully before 
administration.
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Patients with gammaglobulin deficiencies who are receiving 
replacement therapy with intravenous normal immunoglobulin, do not 
require VZIG
Procurement
Varitect® CP can be obtained by contacting Intrapharma. Contact details 
are available at http://www.united-drug.ie/intrapharma.php, Telephone: 
+353 (1) 452 0388
Please see product information for more detail. 
Adverse reactions to VZIG
Nausea, chills, fever, headache, vomiting, allergic reactions, arthralgia 
and mild back pain may occasionally occur. The efficacy of live attenuated 
virus vaccines may be impaired for at least 6 weeks and possibly up to 3 
months.
Active immunisation: Varicella Vaccine
Varicella zoster vaccine is a live attenuated viral vaccine, derived from the 
Oka strain of VZV.
Indications 
Recommendations for use of the vaccine
Two doses at least 4 weeks apart are required in both children and adults 
in the following risk groups:
 •  Non-immune health-care workers. HCWs without a definite 
history of chickenpox, proof of immunity or vaccination status, 
particularly those working with haematology, oncology, 
obstetrical, general paediatric or neonatal patients should be 
routinely screened for VZ antibody. 
A history of chickenpox is a less reliable predictor of immunity 
in individuals born and raised overseas, and therefore routine 
testing should be considered in this group of HCWs. In addition, 
HCWs from outside Ireland and Western Europe are less likely to 
be immune. 
Vaccination should be offered to non-immune staff. 
 •  Laboratory staff who may be exposed to varicella virus in the 
course of their work
 •  Healthy susceptible close household contacts of 
immunocompromised patients
 •  Children with asymptomatic or mildly symptomatic HIV infection 
with age specific CD4+ T-lymphocyte percentage more than 25% 
should be considered for varicella vaccination. Two doses with a 
3-month interval are required
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 •  Under specialist hospital supervision and protocols certain 
categories of immunocompromised patients may be 
vaccinated, e.g. cases of lymphocytic leukaemia in remission 
and organ transplant recipients
 •  Children in residential units for physical disability
 •  All women of childbearing age without a history of varicella 
infection should have their immunity checked. Women with 
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Definite history of VZ virus 
infection and Irish born?
Yes
Consider immune 
Evaluate for VZ virus 
vaccine 
Consider immune VZ virus antibody test 
?Contraindication 
(Immunocompromised, 
pregnant etc ) 
Negative 
Positive 
No 
Informed consent for vaccination, 
advice to avoid salicylates for six 
weeks, pregnancy for three months, 
and to consult occupational health 
department if post-vaccine rash 
appears 
Two doses 4-8 weeks apart 
Localised rash – cover lesions 
and allow to work (those working 
in close contact with high-risk 
patients should be reviewed on a 
case-by-case basis) 
Generalised rash – exclude 
from patient contact until 
lesions crusted 
Outcome 
No VZ virus compatible rash 
HCW may continue working 
VZIG prophylaxis if 
significant exposure to VZ 
virus 
Figure 17.4  Procedure for vaccinating health-care workers
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negative serology should be vaccinated prior to pregnancy, 
if no contraindications exist. Pregnancy should be avoided 
for 3 months following the last dose of varicella vaccine. 
Alternatively, on completion of their pregnancy women who do 
not have evidence of varicella immunity should receive the first 
dose of varicella vaccine before discharge from the health-care 
facility. The second dose should be administered 4-8 weeks 
later. 
Contraindications
 •  Anaphylactic reaction to a preceding dose or any of the 
constituents including neomycin or gelatin.
 •  Immunosuppression due to leukaemia, lymphoma, generalized 
malignancy, immunodeficiency disease or immunosuppressive 
therapy should not be vaccinated (see above for exceptions 
under hospital supervision).
 •  Pregnancy. Pregnancy should be avoided for 3 months 
following the last dose of varicella vaccine. Inadvertent 
vaccination during pregnancy should be reported to the 
immunisation division in HPSC where surveillance of these 
events is being established. 
Precautions
 •  Recent (less than 11 months) receipt of antibody containing 
blood product (specific interval depends on product See 
Chapter 1).
 •  Acute severe febrile illness, defer until recovery. 
 •  Vaccine recipients should avoid salicylates for 6 weeks after 
vaccination (because of the association between aspirin use 
and Reye syndrome following chickenpox although this has not 
been reported following the vaccine)
 •  Persons known to have active untreated tuberculosis, although 
there is no evidence that either varicella or VZV exacerbates 
tuberculosis.
Persons whose immunosuppressive therapy with steroids has been 
discontinued for a month (3 months for chemotherapy) can be 
vaccinated.
The following are NOT contraindications
 •  Pregnancy of recipient’s mother or other close or household 
contact
 •  Immunodeficient family member or household contact*
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 •  Treatment with low dose (less than 2 mg/kg/day) alternate-day, 
topical, replacement, or aerosolised steroid preparations
 •  Asymptomatic or mildly symptomatic HIV infection
 •  Humoral immunodeficiency (e.g. agammaglobulinemia)
 •  Breast feeding. A study has shown no evidence of transmission 
of vaccine virus in breast milk. Non-immune breast-feeding 
mothers should be given varicella vaccine.
* If a vaccinee experiences a presumed vaccine-related rash 7-25 days 
after vaccination, avoid direct contact with immunocompromised persons 
for the duration of the rash, if possible.
Assessing immunity post vaccination is not recommended. 
Testing for varicella immunity following two doses of vaccine is not 
recommended because 99% of persons have adequate response 
following the second dose Moreover, available commercial assays are not 
sensitive enough to detect antibody following vaccination in all instances.
Presentation and storage
Varicella vaccine is available as lyophilised preparations for reconstitution 
with a diluent. VZV is less stable than other live virus vaccines and the 
storage temperature requirements are critical. The unreconstituted 
vaccine and its diluent should be stored in the original packaging at 
+2ºC to +8ºC and protected from light. After reconstitution the vaccine 
should be used immediately. Discard any vaccine unused after 30 
minutes. Varicella vaccines do not contain thiomersal or any other 
preservatives.
The vaccine should be administered by Intramuscular (I.M.) or deep 
subcutaneous injection (SC). 
Immunogenicity and vaccine efficacy
After one dose of vaccine, 97% of children 12 months to 12 years of 
age develop detectable antibody titres. Vaccine efficacy is estimated to 
be 70-90% against infection, and 90-100% against moderate or severe 
disease.
As 10-30% of children who have received 1 dose of the vaccine are not 
fully protected, 2 doses are now advised for all ages. Vaccine efficacy is 
lower (~75%) in those aged 13 years and older. Immunity appears to be 
long lasting, probably permanent in the majority of vaccinees. However, 
approximately 1% of vaccinees per year have developed breakthrough 
infections. Breakthrough infection is significantly milder, with fewer 
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lesions many of which are maculopapular rather than vesicular. The 
incidence of breakthrough infections is less in those receiving 2 doses
Post-exposure prophylaxis
Data from the USA and Japan indicate that varicella vaccine is effective 
in preventing illness or modifying the severity of illness if used within 
3 days, and possibly up to 5 days of exposure. Post-exposure vaccine 
prophylaxis is indicated for those listed in the risk groups for vaccination, 
but who have not yet been vaccinated or had the disease (subject to the 
listed precautions and contraindications).
Adverse reactions
Local reactions (pain redness or swelling) occur in 7-30% of vaccinees. 
Fever over 39°C occurs in 15% of children and 10% of adolescents and 
adults.
A localised or generalised maculopapular or papulovesicular rash may 
develop. Most varicelliform rashes that occur within 2 weeks after 
vaccination are due to wild type varicella-zoster virus with median onset 
8 days after vaccination (range 1-24 days), while rashes caused by vaccine 
strain occur at a median of 21 days after vaccination (range 5-42 days). 
About 50% of vaccinated leukaemic patients develop a rash after the first 
dose and some may need antiviral therapy.
Transmission of vaccine virus from a vaccinated person can occur but the 
risk is very low and primarily occurs in the presence of a post-vaccination 
rash.
Zoster in vaccinated children has rarely been reported, and is usually a 
mild illness without complications.
Management of hospital exposure
Non-immune staff who have had a significant exposure to VZV (see 
above) should be excluded from contact with high-risk patients from 8-21 
days after exposure.
HCWs with localised herpes zoster on a part of the body that can be 
covered with a bandage and/or clothing may be allowed to continue 
working unless they are in contact with high-risk patients, in which case 
an individual risk assessment should be carried out.
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 Immunisation and Health 
Information for Health-Care 
Workers and Other ‘At Risk’ 
Occupations
Workers in many occupations may be exposed to infectious agents. A 
complete risk assessment should be carried out to determine which, 
if any, vaccinations are recommended for workers. This is required 
under the Health and Safety at Work Biological Agents Regulations. It 
should ideally take place before employment. Routine review of general 
immunisation status may also be appropriate. Persons whose work 
involves international travel should consider the recommendations given 
in the chapter on travel vaccinations.  
Immunisation is one of the most effective health-care interventions. 
Nonetheless, it must be seen as just one part of a wider policy to prevent 
transmission of infection in health-care workers and their patients. 
Immunisation should never be regarded as a substitute for good infection 
control practices, such as hand washing and universal precautions for the 
prevention of transmission of blood-borne viruses.
Decisions about vaccination(s) recommended should be based on the 
duties of the individual rather than on job title alone. These guidelines 
may change as the prevalence of disease changes.
Categories of workers
Category A
Frontline health-care workers (both clinical and non-clinical), whose work 
may expose them to blood-borne virus infections and other infectious 
188
diseases, e.g. 
•   Medical, nursing and paramedical staff
•   Medical and nursing students
•   Dentists and dental staff
•   Hospital porters and cleaners
•   Ambulance personnel
•   Other health-care personnel deemed vulnerable following risk 
assessment
(This may include all persons working ‘on-site’ whether paid or 
unpaid)
Hepatitis A
• Hepatitis A immunisation may be occasionally advisable in some 
of the above categories, e.g. paediatric hospital staff, workers 
who culture hepatitis A, or during local outbreaks of hepatitis A.
Hepatitis B
• All workers in this category should be offered hepatitis B 
vaccination if not previously vaccinated.
• All workers in this category should have anti-HBs levels checked 
if previously vaccinated against hepatitis B and response not 
known (see hepatitis B chapter for adequate response levels).
• Please refer to hepatitis B chapter for new recommendations re 
anti-HBc testing in frontline health-care workers.
BCG (Bacillus Calmette Guerin)
• Please refer to tuberculosis chapter.
• Health-care workers should have pre-employment base-line 
Mantoux tuberculin testing performed if there is no BCG scar 
present, or no documented evidence of having received BCG 
vaccination. 
• If there is an inadequate Mantoux response (defined as skin 
induration less than 5 mm in diameter) then the health-care 
worker should be referred to their public health clinic or 
occupational health department, where BCG should be offered.
• Any health-care worker who has been in close contact with a 
case of smear-positive tuberculosis should be assessed by an 
occupational health department.
Varicella 
• Health-care workers without a definite history of chickenpox, 
proof of immunity or vaccination status, particularly those 
working with haematology, oncology, obstetrical, general 
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paediatric or neonatal patients should be routinely screened for 
VZ antibody. A history of chickenpox is a less reliable predictor of 
immunity in individuals born and raised overseas, and therefore 
routine testing should be considered in this group of HCWs.  In 
addition HCWs from outside Ireland and Western Europe are 
less likely to be immune. Vaccination should be offered to non-
immune staff. 
• Laboratory staff who may be exposed to varicella virus in the 
course of their work should be offered vaccination. 
• Post-vaccination serological testing is not recommended. Where 
exposure occurs in a susceptible HCW, advice should be sought 
from Occupational Health on further management and possible 
exclusion from the workplace.
Influenza
• Health-care workers should be offered vaccination against 
influenza on an annual basis each autumn. 
Measles, mumps, rubella
• Health-care workers should have serological proof of immunity 
or evidence of having received 2 doses of MMR. Those who are 
non-immune should receive 2 doses of MMR. Post-vaccination 
testing is not recommended. 
• Where exposure occurs in a susceptible HCW, advice should be 
sought from Occupational Health on further management and 
possible exclusion from the workplace.
Category B1
Non-healthcare workers who share the occupational risk of exposure to 
blood borne viral infection:
• Members of security and rescue services
• Members of An Garda Síochána
• Members of the fire brigade
• Members of the armed forces
• Employees of security companies
• Staff of institutions for persons with learning difficulties
• Any other workers who may be exposed to ‘blood to blood’ 
injuries.
Hepatitis B
• All workers in this category should be offered hepatitis B 
vaccination if not previously vaccinated (see hepatitis B 
chapter for immunisation schedule).
• All workers in this category should have anti-Hbs levels 
Chapter 18  Immunisation and Health Information for Health-Care Workers 
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checked if previously vaccinated against hepatitis B and 
response not known (see hepatitis B chapter for adequate 
response levels).
Category B2
Prison Officers
Hepatitis A
• Immunisation against hepatitis A may be considered if there 
is an ongoing outbreak in a prison.
Hepatitis B
• All workers in this category should be offered hepatitis B 
vaccination if not previously vaccinated (see hepatitis B 
chapter for immunisation schedule).
BCG
• Prison Officers aged 35 years and under should have 
pre-employment base-line Mantoux tuberculin testing 
performed if there is no BCG scar present, or no 
documented evidence of having received BCG vaccination. 
• If there is an inadequate Mantoux response, BCG 
vaccination should be offered.
Category C
Workers in contact with raw faecal material, e.g. 
• Sewage workers
• Crèche workers.
Hepatitis A
• All workers in this category may be checked for hepatitis A 
immunity (see Chapter 5).
• Workers in this category who are not immune to hepatitis 
A may be offered hepatitis A vaccination (see Chapter 5 for 
immunisation schedule).
• Crèche workers may be immunised against hepatitis A, 
especially if there is evidence of an ongoing outbreak of 
hepatitis A.
Category D
Scientists dealing with human body fluids, e.g.
• Medical laboratory technicians
• Research scientists.
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Hepatitis A
• All workers in this category who culture hepatitis A virus 
should be checked for hepatitis A immunity, and if not 
immune, should be offered hepatitis A vaccine (see Chapter 
5 for immunisation schedule).
Hepatitis B
• All workers in this category should be offered hepatitis B 
vaccination if not previously vaccinated (see Chapter 6 for 
immunisation schedule).
• All workers in this category should have anti-HBs levels 
checked if previously vaccinated against hepatitis B and 
response not known (see Chapter 6 for adequate response 
levels).
Polio
• Workers in this category who culture enterovirus should give 
a history of polio vaccination and may need to be offered 
immunisation.
Diphtheria
• Workers in this category who handle material that 
may contain pathogenic corynebacteria may require 
immunisation. This includes most laboratory staff (see 
Chapter 3 for immunisation schedule).
BCG
• Immunisation may be required in certain instances. Workers 
in this category who culture mycobacteria may require 
immunisation.
Other organisms
• Medical laboratory staff working in higher risk settings (e.g. 
reference laboratories or infectious disease units) or those 
conducting research into specific organisms should be 
considered for immunisation against these organisms (e.g. 
Japanese B encephalitis, cholera, meningococal ACW135Y, 
typhoid, influenza, varicella, rabies).
Category E
Personnel who work with animals and have exposure to animal tissues, 
e.g. veterinary staff, abattoir workers, zoological workers, veterinary 
inspectors, agricultural officers and poultry workers.
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BCG
• This may be recommended to those thought to be at 
particular risk, (see Chapter 16, for immunisation schedule).
Rabies
• This may be recommended to those thought to be at 
particular risk, (see Chapter 20, for immunisation schedule).
Tetanus
• This may be recommended to those thought to be at 
particular risk, (see Chapter 15, for immunisation schedule).
Influenza
• Poultry workers, veterinary inspectors, agricultural workers, 
park rangers and those with likely contact with water fowl (as 
this puts them at risk of co-infection with avian influenza).
Occupational blood exposures
Occupational blood exposures (e.g. through needle stick or sharp 
injuries) may occur in the health-care sector. Some of these may leave a 
person at risk of getting hepatitis B, hepatitis C or HIV. Such exposures 
should be assessed by a competent person, e.g. Occupational Medicine 
Consultant or Infectious Diseases Consultant, or a member of their team.
In the first instance, the wound should be washed and all appropriate first 
aid given. Health-care workers should attend their occupational health 
department or A&E depending on local arrangements. A risk assessment 
will then be carried out. If appropriate, the Occupational Medicine 
Consultant or Infectious Diseases Consultant should be contacted. Such 
risk assessment includes details of the source patient’s risk status (if 
known). A blood sample from the source patient should be taken (with 
consent) and tested for viruses.
If the exposed person has not been adequately vaccinated against 
hepatitis B, then hepatitis B prophylaxis should be considered. Specific 
hepatitis B immunoglobulin is available for passive protection and may 
be used in addition to hepatitis B vaccination to confer passive/active 
immunity after exposure. If they have had a previous needle stick injury, 
or recent hepatitis B vaccination, it may not be necessary to give hepatitis 
B immunoglobulin as the results of any previous hepatitis B test should 
be available within 72 hours.  
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If the occupational blood exposure was from a source believed to be HIV 
positive, then post-exposure prophylaxis with antiviral therapy should 
also be considered. This should be undertaken urgently, ideally within 
1-4 hours. As the drug regime for such antiviral prophylaxis changes 
regularly, it is not possible to go into the details of such therapeutic 
protocols in these guidelines. The local Occupational Medicine 
Consultant/ Infectious Disease Consultant, or a member of their team, 
can provide up-to-date details on this.
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 Immunisations and Health 
Information for Travel
This chapter has the following sections:
• Introduction
• Vaccines for global travellers
• Yellow fever 
• Meningococcal Infection
• Cholera 
• Typhoid
• Japanese B encephalitis 
• Tick-borne encephalitis 
• Rabies 
• Diphtheria 
• Poliomyelitis 
• Hepatitis A
• Influenza
• Tuberculosis
• Hepatitis B
• Other immunisations
 • Travel health general information
• Diarrhoea
• Malaria
• AIDS
• Prolonged travel
• Visiting friends and relations
 • Bibliography
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The increase in international travel has continued to grow over the 
past 20 years and current projections suggest that this pattern will 
be maintained for the foreseeable future. Data released by the World 
Tourism Organisation in 2002 showed international tourist arrivals 
amounted to 693 million despite economic downturns and terrorist 
attacks. The figures of 150 million arrivals in 1970 and 500 million in 
1993 illustrate how rapidly the numbers in international passengers are 
growing. 
Changes in travel patterns that have become apparent include a trend 
for visiting ever more remote destinations. Many young people travel 
to several countries or continents for months at a time either as part 
of their summer holiday or as a gap year. International corporations 
place travellers in diverse destinations for short visits on international 
assignments. Travel for medical care is a relatively new phenomenon 
and is likely to increase over the coming years. Other specialised groups 
are those seeking to adopt children abroad and immigrants who wish to 
return to their country of origin in order to visit family and friends.
Many people are unaware that exotic destinations include potential 
exposure to infections that are rare in their home environment and 
other infections such as malaria that they will never have encountered 
previously. The resurgence of malaria in many parts of the world, with 
an increasing pattern of drug resistance, has led to an increase in the 
number of cases of malaria presenting in non-endemic areas. The 
emergence of new infections such as SARS and the spread of dengue 
fever and West Nile Virus place an ever-increasing responsibility on the 
doctor to remain up-to-date with current practice. The advent of new 
chemoprophylatic agents and of new vaccines also presents exciting 
challenges in dealing with the traveller.
A pre- travel consultation needs to address what immunisations are 
recommended, their potential side-effects and suitability for each 
traveller. Knowledge of relative risks to particular destinations is essential, 
as is an assessment of the patient’s overall medical health and current 
medications. Additional recommendations and advice for those with 
pre-existing chronic illness should be included. Patients who are very 
young, those who are pregnant and the elderly also warrant special 
considerations in many areas of the usual consultation. 
The determinates of advice and immunisations to travellers depend on:
• Duration of visit
Chapter 19  Immunisations and Health Information for Travel
196
Im
m
unisatio
ns and
 
H
ealth Info
rm
atio
n 
fo
r Travel
• Destination
• Purpose of visit
• Standards of accommodations and food hygiene
• Behavioural or lifestyle patterns of the traveller
Many major urban centres and well-developed tourist destinations pose 
small risks to the short-term tourist or business traveller. Travel to areas 
where water supplies are difficult, the general standard of hygiene is 
poor and medical services are difficult to access or non-existent can 
pose serious risks to travellers. Any special occupation or activity should 
also be taken into account, e.g. contact with fresh water in areas where 
schistosomiasis is endemic. 
While immunisations represent an important part of the travel 
consultation it should be emphasised that advice on risk avoidance, 
chemoprophylaxis and in some cases methods of self-treatment all 
constitute an important role in the travel medicine consultation. Ideally 
short-term travellers should present for advice 4-6 weeks before 
travel; those travellers who are travelling for long periods or going 
to very remote regions may require 6-12 weeks for the full series of 
immunisations. 
Travellers should be aware that many conditions may present after they 
have returned from their trip abroad. In general patients who encounter 
problems within 1 year of returning should inform a doctor that they have 
been abroad. Check-ups for disease should be considered in those who 
have suffered from any serious problem abroad, i.e. any medical problem 
that has not been self-limiting, potential exposure to a known medical 
risk or development of problems within a year of return.
It is also of note that tour operators, travel agents and airline and 
shipping companies have a responsibility to advise travellers to consult 
a travel medicine clinic as soon as possible after booking a trip to any 
destination where significant health risks may be encountered. 
There are also responsibilities that any traveller needs to accept 
before travel, including seeking advice in good time, compliance 
with recommended vaccines and other medications and general 
health measures. They should also consider carrying a medical kit and 
obtain adequate health insurance cover. Regulations regarding entry 
requirements such as the need for yellow fever certificates can be 
obtained from organisations such as WHO whose website address is 
given at the end of the chapter. 
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Immunisations should be arranged at least several weeks before 
travel, where possible.
Vaccination is a highly effective way of preventing disease. However, not 
all vaccinations offer 100% protection against disease and all additional 
recommendations in preventing disease should be followed. In general 
travel vaccinations are both safe and effective. As most vaccines take 
some time to become fully effective they should be administered at least 
2 weeks before travel, although the late-presenting traveller may still 
benefit from having vaccinations even at the last minute. 
Multiple vaccines can be administered at different sites on the same 
day. However, certain vaccines commonly cause local reactions that may 
be accentuated if a number of these vaccines are given simultaneously. 
If possible these should be given on separate occasions unless time 
constraints dictate otherwise. This is important in aluminium-containing 
vaccines such as hepatitis A, hepatitis B, tetanus, diphtheria toxoids, IPV, 
and conjugate meningococcal C vaccines. Various combined vaccinations 
are now available and these offer travellers considerable advantage by 
reducing the number of injections involved and improving compliance.  
Vaccines for global travellers 
1 Those that are used routinely particularly in children
2 Those that may be advised before travel 
3 Those that are mandatory
Many childhood vaccinations require periodic boosting to maintain 
immunity throughout life. Pre-travel precautions should include booster 
doses of routine vaccines if the regular schedule has not been followed 
or where travel occurs to countries where boosters, e.g. tetanus, may 
not be readily available should the need arise. Older travellers may never 
have received primary courses of routine vaccines. Immunisation history 
should be checked to confirm adequate protection, including need for 
appropriate booster doses. It is recommended that each traveller 
should be up to date with his/her routine vaccine schedule including 
vaccines against influenza and pneumococcal vaccines for travellers 
who are in the appropriate age group or those who have indications 
for vaccines due to underlying medical conditions. Other vaccines 
will be advised depending on the area visited, the type of travel, any 
special identified risks, and on age, health and vaccination history of each 
individual. Please note that some vaccines can appear in more than one 
group.
Chapter 19  Immunisations and Health Information for Travel
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Table 19.1 Vaccines for travellers
Category Vaccine
1. Routine vaccination – check status 
and update
DTaP/IPV or Td/IPV for adults
Hepatitis B
Hib
MMR
Influenza
Pneumococcal
2. Recommended vaccines 
depending on itinerary, type and 
duration of travel
Cholera
Hepatitis A
Hepatitis B
Japanese encephalitis
Meningococcal ACWY
Rabies
Tick-borne encephalitis
BCG
Typhoid fever
Yellow fever 
3. Mandatory vaccination Yellow fever 
Men A,C,W,Y (for Hajj, Umra)
Table: WHO, International Travel and Health 2006
Yellow fever vaccine should not be given to infants less than 9 
months of age unless the risk of yellow fever is very high, as the 
vaccine may cause encephalitis.
Yellow fever (notifiable)
Yellow fever is an acute haemorrhagic fever spread by mosquitoes 
that occurs in Tropical South America and in many countries in sub-
Saharan Africa. Generally presenting as an acute fever with jaundice and 
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acquiring disease increases in patients who travel to jungle areas but also 
in urban centres reporting outbreaks. Areas where yellow fever occurs far 
exceed those officially reported. 
The risk of infection can be reduced by taking precautions against 
mosquito bites. The species that transmits yellow fever also bites during 
day time. Vaccination is recommended for all travellers (for exceptions 
see below) who visit countries or areas within countries where there is 
a risk of yellow fever transmission. For in-country travel, vaccination is 
recommended outside urban areas of the endemic zone (see current 
WHO maps) even if these countries have not officially reported the 
disease. Vaccination for personal protection is not mandatory.
Mandatory vaccination against yellow fever is carried out to prevent the 
importation of yellow fever virus in countries where the potential for 
yellow fever exists because the vectors and primate hosts to support 
transmission are already present. In such cases vaccination against 
yellow fever may be an entry requirement for all travellers arriving from 
countries where there is a risk of yellow fever transmission. It does not 
generally apply to passengers from European countries unless the host 
country states that all travellers must have yellow fever as an entry 
requirement. 
If yellow fever is contraindicated for medical reasons (see below) a 
certificate of exemption may be provided. 
A yellow fever certificate only becomes valid after10 days and is valid for 
10 years from that date. 
Vaccine 
Yellow fever is a live viral vaccine. The dose is 0.5 ml subcutaneously, for 
both children and adults. One dose provides 10 years protection.
Tolerance of the vaccine is generally good; 2-5% of recipients have 
mild reactions including myalgia and headache. Up to 20% may report 
influenza like symptoms. Rarely encephalitis can occur at any age but has 
a higher incidence in infants under the age of 9 months. Infants less than 
6 months should never receive yellow fever vaccine.
Contraindications to the vaccine include egg protein allergy, a confirmed 
serious reaction to a previous dose of any vaccine component, congenital 
or acquired cellular immunodeficiency, and symptomatic HIV infection. 
In cases where patients are under specialist care for immunodeficiency, 
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consultation with the patient’s doctor may clarify matters for the travel 
advisor. Pregnant women should be advised not to travel where exposure 
to yellow fever may occur. There is a theoretical risk of harm to the foetus 
if the vaccine is given in pregnancy but that risk must be weighed against 
the serious risk of the mother travelling unvaccinated to a high risk zone.  
Recently there have been reports of a small number of serious adverse 
reactions, including deaths, following yellow fever vaccine. This syndrome 
has been described as yellow fever vaccine associated viscerotropic 
disease (YEL-AVD); post-vaccinial encephalitis has been renamed as 
yellow fever associated neurotropic disease (YEL-AND). Most cases 
occurred in elderly people being vaccinated for the first time for yellow 
fever and there was an association with a history of thymectomy or 
disorders of the thymus. The risk to individuals travelling to areas where 
transmission is occurring is far higher than the risk of vaccination but it is 
important that yellow fever vaccination is not prescribed for individuals 
who are not at risk of exposure to infection. 
Meningococcal infection (notifiable)
Meningococcal vaccine (see Chapter 9).
Indications
1. Travel to high-risk areas, particularly for those visitors who live 
or travel ‘rough’ such as hitchhikers or ‘trekkers’. These areas 
include the meningitis belt of Africa (Southern sub-Saharan parts 
of Senegal, Mali, Niger, Chad and Sudan; all of Gambia, Togo and 
Benin; Northern parts of Sierra Leone, Liberia, Ivory Coast, Nigeria, 
Cameroon, Central African Republic, Uganda and Kenya) where 
epidemics of Group A infections occur in the dry season (December-
February)
2. Travel to areas where epidemics of meningococcal disease are 
occurring
3. Long-term and rural travellers to countries where outbreaks can 
occur. In the past these outbreaks have usually been due to Group 
A disease, especially in areas of Africa as above. Outbreaks have 
occurred in Saudi Arabia due to meningococcal A and to W135 in 
association with the Hajj and have led to mandatory requirements for 
meningococcal vaccine before entry to Saudi Arabia. W135  has also 
been reported from Burkina Faso. ACWY quadrivalent vaccine is the 
recommended vaccine for travellers.
Vaccine
The ACWY vaccine is a purified heat-stable lyophilised capsular 
Chapter 19  Immunisations and Health Information for Travel
201
Im
m
un
is
at
io
ns
 a
nd
 
H
ea
lt
h 
In
fo
rm
at
io
n 
fo
r 
Tr
av
el polysaccharide from meningococci of the respective groups. Efficacy 
levels of 85-100% have been documented in older children and young 
adults but it is not as effective in children under the age of 2 years. The 
meningococcal C conjugate vaccine (MenC) is not suitable for travel to 
areas where group A types are dominant. There is no available vaccine 
against type B strains. 
Adverse reactions
Local: Injection site reactions occur in approximately 10% of recipients 
and last for about 24-48 hours.
General: Generalised reactions are rare but pyrexia occurs in up to 2% of 
vaccines.
ACWY vaccine does not elicit a protective immune response to 
meningococcal serotype C antigen in children under the age of 2 years. 
Response to A, W and Y antigens may be achieved in children under the 
age of 2 years but are likely to be short-lived.
In adults and children over the age of 5 years immunity will persist for up 
to 5 years. Children who are vaccinated under the age of 5 years should 
receive boosters at 2-3 years. The mandatory booster interval for those 
travelling to Saudi Arabia is 3 years. 
Cholera (notifiable)
Cholera is an acute diarrhoeal disease caused by an enterotoxin of Vibrio 
cholera which has infected the small bowel. The illness is characterised 
by the sudden onset of profuse watery stools and occasionally vomiting. 
Dehydration, metabolic acidosis and circulatory collapse may follow 
rapidly.
Two main serogroups occur: 01 and 0139. Cholera occurs mainly in 
countries where there is inadequate sanitation and where clean drinking 
water is difficult to obtain. The risk for most travellers is very low even in 
travellers where cholera epidemics occur. Simple precautions are usually 
sufficient to prevent cholera in most travellers. Workers in disaster areas 
and in refugee camps are at the highest risk. Cholera is easy to treat; the 
vast majority of patients will recover if adequate hydration is supplied. 
Vaccination is only advised for those at increased risk of the disease, 
particularly emergency relief and health workers in poor conditions. 
Vaccine
Parenteral cholera vaccine is no longer recommended by WHO. 
Modern oral cholera vaccines have now been produced and are now 
the only recommended vaccines. The killed oral vaccine contains a heat-
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inactivated V. Cholerae strain of both the Classic and el Tor biotypes 
but is not effective against 0139 strains. It gives some cross-protection 
vaccine against some strains of enterotoxigenic E. coli by preventing a 
sub-unit from attaching to intestinal mucosal sites. The vaccine is two 
doses at 1-6 weekly intervals. It should be kept in a refrigerator and food 
should be avoided for an hour before and after a dose is taken. The level 
of protection is much higher than that of previous vaccines (85-90%) 
in the first 6 months, with antibodies persisting up to 3 years after the 
original vaccination.
Only evidence of a previous allergic reaction precludes administration of 
cholera vaccine (killed). Post-vaccine reactions are generally mild and of 
short duration. 
Contraindication
Previous anaphylactic reaction to any component of the vaccine.
An EU licensed oral cholera vaccine has been added to the IMB list of 
vaccines that are authorised and marketed for use in Ireland.
Typhoid (notifiable)
Typhoid fever is a systemic infection caused by Salmonella typhi. 
Only humans carry salmonella typhi. Most of the approximately 2,000 
serotypes in the genus salmonella cause only local infection of the 
gastro-intestinal tract (gastro-enteritis or ‘food poisoning’). S. typhi, S. 
paratyphi A, B and C and occasionally other salmonella species may 
invade systemically to produce a serious illness with prolonged pyrexia 
and prostration. The likelihood of becoming a chronic carrier increases 
with age.
Typhoid/paratyphoid fevers are acquired mainly through food or drink 
contaminated with the excreta of a human case or carrier. It is therefore 
predominantly a disease of countries with poor sanitation and poor 
standards of personal and food hygiene. All travellers to endemic areas 
are at potential risk of typhoid fever; the risk of typhoid fever is lowest in 
tourist and business centres and rises as travellers enter more rural areas 
where standards of accommodation and food hygiene are not high. As 
typhoid vaccine is only partially effective, travellers should be advised 
to take precautions against eating or drinking potentially contaminated 
food and drink. Typhoid is particularly prevalent in the Indian sub-
continent.
Vaccine – parenteral
Vi polysaccharide vaccine: parenteral capsular polysaccharide typhoid 
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el vaccine is available. Each 0.5 ml dose contains 25 mcg of the Vi 
polysaccharide antigen of S. typhi preserved with phenol. A single dose 
gives 70-80% protection for at least 3 years.
 
Typhoid vaccine should be stored at 2-8oC.
Dose and route of administration
Adults
• Vi polysaccharide vaccine: a single intramuscular or subcutaneous 
dose (0.5 ml) is given. Reimmunisation with a single dose every 3 
years is recommended for those who remain at risk of infection.
Children 
• Vi polysaccharide vaccine: the risk for children developing typhoid 
under one year is low. Children under 2 years may show a suboptimal 
response to polysaccharide antigen vaccines. Use of the vaccine in 
this age group should therefore be governed by the likely risk of 
exposure to infection. Children over the age of 2 years may receive 
the normal adult dose.
Indications
Typhoid immunisation is required for:
• Laboratory workers handling specimens which may contain typhoid 
organisms
• Travellers to countries in Africa, Asia, Central and South America and 
South East Europe, and to other areas where hygiene is likely to be 
poor. Vaccination is generally less important in areas where typhoid 
is not highly endemic and where visits are confined to urban centres 
with good accommodation
• Typhoid immunisation is not recommended for contacts of a known 
typhoid carrier or for controlling common-source outbreaks.
Contraindications 
Previous anaphylactic reaction to any component of the vaccine.
Precautions
1 Acute febrile illness; defer until recovery.
2 As with other vaccines, typhoid vaccine should only be given to a 
pregnant woman if a clear indication exists.
Adverse reactions 
Vi polysaccharide vaccine: Local reactions are reported to be mild and 
transient and systemic reactions are less common than with the older 
whole cell vaccine.
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Japanese B encephalitis (notifiable)
This is predominantly a rural disease causing a potentially fatal 
encephalitis that is endemic in a large expanding swathe from northern 
Australia to India and Nepal. Epidemics are associated with the monsoon 
season. The majority of people who contract Japanese encephalitis 
virus will remain asymptomatic or suffer from a short acute viral illness. 
In 1 in 200 people the disease causes encephalitis that has a mortality 
rate of about 30%; many survivors have long-lasting severe neurological 
sequelae. The chance of permanent neurological disease increases with 
increasing age. The case fatality rate can reach 50%.
This Culex mosquito-borne viral disease is a zoonosis infecting pigs and 
wading birds, and humans are infected incidentally. The mosquito is a 
night feeder, biting especially in the cooler hours of dusk and dawn. Rice 
paddies are important breeding sites. 
The risk of contracting the disease is estimated at 1:5,000 per month of 
travel in highly endemic areas. The risk to short-term tourists is low. The 
vaccine should be offered to expatriates who plan to reside in endemic 
areas and travellers spending more than 30 days in such areas or those 
whose type of activity places them at risk. If indicated, further detailed 
information should be sought from specialised centres or the WHO 
website.
Vaccine
The current vaccine is available on a named patient basis only. The 
vaccine is a solution of inactivated Nakayama-NH strain of the virus 
incubated with mouse brain. This produces a highly efficacious vaccine. 
The vaccine is administered at 0, 7 and 28 days using 1.0 ml of vaccine 
subcutaneously. Shorter, 2-dose schedules (day 0 and 14) can be used 
but efficacy is usually reduced in these cases to about 80%. 
Localised pain and erythema occur in about 20% of recipients, with 
fever and pruritis occurring in 10%. Due to a number of cases of 
hypersensitivity reactions in the past it is advisable to keep patients for 
at least 30 minutes post-vaccine and advise them of potential late-onset 
allergic reactions up to 10 days post-vaccination. Patients should not 
travel abroad for at least 10 days after the last vaccination. 
Tick-borne encephalitis (notifiable)
This viral disease occurs sporadically through parts of eastern and central 
Europe and the Asian part of the former USSR. Disease transmission 
primarily occurs during the spring and summer months in those exposed 
to tick bites. Travellers planning to camp or trek through forests or 
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el to walk along nature trails should consider having vaccination before 
travelling as currently no therapy exists for this disease. If indicated, 
further detailed information should be sought from specialised centres or 
the WHO website.
This flavivirus belongs to the same family as Japanese encephalitis, 
dengue and yellow fever viruses. The virus is transmitted by ticks that 
feed on wild and domestic animals that constitute the natural reservoirs 
for TBV. Once infected, the tick can then transmit the virus to humans. 
They are mainly to be found in spring and summer. The ticks wait for their 
prey on the underside of vegetation and attach themselves to passing 
animals or humans. After attachment the tick may not feed for up to 12 
hours. Early removal of ticks can, therefore, prevent disease. The tick 
should be removed with tweezers, care being taken not to leave the 
head or mouth parts attached to the skin.  
The disease is also transmitted by unpasteurised goat’s milk or goat’s 
milk products. It occurs in many countries in Central Europe and has 
spread to areas in Scandinavia and Switzerland. In Russia and across 
the former USSR it is known as Russian spring-summer fever. There 
is an initial viraemic phase, with a minority of those affected going 
on to develop encephalitis in about 20-30% affected. Similarly post-
encephalitic sequelae are common and the disease has a mortality rate of 
1%.
Vaccine
The vaccine is a suspension of purified inactivated TBV propagated on 
chick embryo cells. Three doses of 0.5 ml are given, the first two at an 
interval of 1 month with a booster at 12 months. A booster is given every 
3 years for those who are exposed to the disease regularly. A shorter 
course of a 14-day interval can be used for rapid protection. The vaccine 
is currently unlicensed but is available in adult and junior forms.
Occasional local reactions may occur such as erythema and induration 
at the site of injection. In a small number of cases fever occurs and 
may persist.  Contraindications include sensitivity to thiomersal, 
hypersensitivity to egg protein and severe reaction to a preceding dose. 
Rabies (notifiable) (see Chapter 20)
Rabies, a viral disease transmitted by bites licks or scratches from 
infected mammals, is a very important cause of viral encephalomyelitis 
in many parts of the world. Travellers can be bitten in parts of the world 
where access to treatment is difficult and sometimes unavailable. For a 
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full discussion of rabies pre- and post-exposure vaccines see Chapter 20.
Diphtheria (notifiable) (see Chapter 3)
It should be re-emphasised that children aged 10 years and over and 
adults should not be given the higher strength childhood vaccine due 
to the possibility of anaphylactic reaction. An up-to-date list of licensed 
vaccines is contained in Appendix 1, or can be accessed on the IMB 
website, www.imb.ie.
Poliomyelitis (notifiable) (see Chapter 13)
Transmission of poliomyelitis in many regions of the world has been 
significantly lessened during the past 20 years and so the risk of infection 
for the international traveller is small. In most cases vaccination is no 
longer recommended for those visiting any region in the Americas and it 
is likely that the recommendations for SE Asia will also change during the 
next few years. Most disease risk currently occurs through the Indian and 
African Subcontinents.
Hepatitis A (notifiable)
Gammaglobulin provides passive immunity against Hepatitis A and 
has been used for this purpose since the early 1940s. Declining levels 
of hepatitis A antibodies in donor patients and the production of an 
effective vaccine mean that it is no longer used for routine protection 
against hepatitis A in travellers. If its use is indicated gammaglobulin is 
sometimes available. Current internationally accepted advice suggests 
that active vaccination against Hepatitis A (even at short notice before 
potential exposure) provides adequate protection. Travellers presenting 
within 10 days of travel should be advised of the potential risk of vaccine 
failure and the need to exercise extra precautions during this initial 
period.
Influenza (notifiable) (see Chapter 7)
All travellers are at some risk of acquiring a seasonal influenza during 
an outbreak. Tourists are at increased risk because they often travel 
in crowded conditions and visit very crowded locations. All groups at 
special risk due to age or chronic illness are at increased risk as per the 
chapter on influenza. Health-care workers are also at high risk. 
Vaccine 
Each year influenza vaccines change according to the change in their 
antigenic pattern. The vaccine contains 3 strains, with the composition 
changing each year to protect against the strains prevalent in any one 
season. There may be, in any given year, a significant difference between 
strains during the influenza seasons of the northern and southern 
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el hemispheres, which occur at different times of the year (November to 
March in the north and April to September in the south). Therefore 
influenza vaccine administered in one hemisphere may only offer partial 
protection to travellers to a different hemisphere. At-risk travellers who 
are going to another hemisphere just before or early on in the influenza 
season should arrange to have influenza vaccine as soon as possible after 
arriving at their destination. 
Tuberculosis (notifiable)
See Chapter 16 for a full discussion on TB and the recommendations for 
BCG.
Tuberculosis occurs worldwide and the risk of infection varies from 
country to country (see map available on WHO website). BCG should be 
considered in the following groups of travellers. (Note: Mantoux testing 
should have been performed within the previous 3 months if BCG is to 
be recommended.)
1. Unvaccinated Mantoux negative persons intending to live or work 
with local people in high-incidence countries for more than 1 month. 
Vaccine may also be considered for shorter-stay travellers who are 
likely to be at increased risk. 
2. Health-care workers who are Mantoux negative and have no history 
of vaccination and no scar to indicate previous vaccination and who 
have contact with patients or infectious material. 
The degree of protection afforded to those over 16 years is not well 
documented but for the above groups it is considered to offer some 
protection. Individuals who are already vaccinated do not need repeat 
vaccination. 
For travel purposes, the vaccine should be given at least 6 weeks before 
departure. Please note that live vaccines should be separated by at least 
4 weeks and further vaccination in the arm in which BCG is given is not 
recommended for at least 3 months. 
Travellers should avoid unpasteurised dairy products. If in doubt boil milk 
before drinking it. 
For information on contraindications to BCG vaccine refer to Chapter 16.
Hepatitis B (notifiable)
Hepatitis B vaccine can be given as an accelerated course if the time to 
departure is short. The dose is 1.0 ml of vaccine given intramuscularly on 
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days 0, 7 and 21 or 28. A booster dose should be given 12 months after 
an accelerated schedule. Accelerated doses of the combined hepatitis A 
and B vaccine have also been shown to be effective. Other accelerated 
schedules are indicated in the main text. 
Other Immunisations
Advice about other immunisations will always be tempered by the length 
of time to be spent abroad, the location, and if camping/trekking is 
intended. If more than 1 live vaccine is required, they should either be 
given at the same time in different sites, or at an interval of four weeks. 
(Check relevant Chapters within this book.)
Travel health: general information
It is important to remember that the commonest illnesses acquired 
abroad are preventable by measures other than vaccines.
Diarrhoea
Traveller’s diarrhoea is one of the commonest problems in people 
travelling abroad. It is estimated that between 20-50% of travellers are 
affected by this self-limiting condition. The average duration of an attack 
is 2-5 days. Diarrhoea that continues for longer than 2 weeks is deemed 
to be persistent traveller’s diarrhoea and is more likely to have an 
underlying parasitic cause. The main cause of acute traveller’s diarrhoea 
is bacterial, although viruses may also be implicated. Organisms causing 
dysentery can present in well-fed travellers without blood appearing 
in the stool. The main causative bacterium tends to differ between 
the areas visited, and variation in the organisms most likely to cause 
diarrhoea can be seasonal.  
All travellers should be made aware to avoid untreated water, avoid 
ice in their drinks and stick to hot, fresh, well-cooked food preferably 
eaten in well-maintained restaurants. Statistics do show that travellers 
rarely adhere to this regime. Apart from advice, most travel advisors 
will prescribe anti-motility agents and an appropriate anti-microbial 
for travellers as emergency self-treatment. The use of antibiotics as 
prophylaxis for diarrhoea is reserved for special cases where chronic 
disease may make the risk of diarrhoea considerably more serious for 
such individuals.
Malaria (notifiable)
Malaria is a common and life-threatening disease in many tropical and 
sub-tropical areas of the world. In general the number of malaria cases is 
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el increasing due to the increasing drug resistance of the parasite itself, the 
increasing resistance of mosquitoes to insecticides and the breakdown of 
public health measures against malaria in many parts of the world due to 
social and civil disruption. 
Malaria is caused by a protozoan plasmodium. Four varieties are 
recognised of which P. falciparum is the most serious form. Malaria 
can be rapidly fatal and is especially serious in pregnant women and 
children under the age of 5 years. Small children and pregnant women 
are advised not to travel to areas where falciparum malaria occurs unless 
travel is essential. 
There is ample evidence that strict adherence to mosquito bite 
precautions and taking appropriate malarial prophylaxis can considerably 
reduce the risk of acquiring malaria. All travellers to regions where 
malaria occurs should be informed of the level of risk involved and the 
types of malaria that occur. Appropriate chemoprophylaxis should be 
prescribed. Patients should be educated on how to take their medication 
and advised of any potential side-effects. It is also important to stress 
that travellers should take precautions against mosquito bites such as 
the use of repellents and of impregnated bed-nets. Anti-mosquito-bite 
protection regimes have been shown to provide a significantly cumulative 
protective effect with chemoprophylaxis.
No anti-malarial regime is 100% effective and travellers should be 
informed of the need to investigate any unexplained ’flu-like illness 
occurring more than 7 days after entering a malarious area and for up to 
a year after return from that area.
For long-term travellers to areas where medical care may be inaccessible, 
emergency stand-by medication may be appropriate.  
It should also be noted that many arthropod viruses are also mosquito-
borne and appropriate advice about mosquito avoidance is very 
pertinent in these diseases, some of whom have no available vaccine, 
e.g. dengue fever. 
Acquired Immune Deficiency Syndrome (AIDS)
Travellers should be told that there are no AIDS-free areas of the world 
and advised of the dangers of unprotected casual sex. They should also 
be advised to be accident-wise because of the risk of AIDS transmission 
in many countries through blood transfusion. Tattoos, acupuncture, 
unsterile needles and body piercing can place travellers at risk from 
blood-borne viruses including HIV, hepatitis B and C. Sexually-transmitted 
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diseases are also an area where considerable risks are taken by travellers. 
All travellers should be made aware of the dangers of many diseases 
including bacterial and viral conditions, caused by having unprotected 
casual sexual intercourse and that the use of condoms while offering 
some protection is not always reliable. 
Prolonged travel
Those planning to live overseas for prolonged periods of time should 
attend for medical advice regarding immunisations and general health-
care advice in sufficient time before their departure. Generally periods 
up to 3 months may be required and this should be considered when 
booking their itinerary.
A dental check before travelling is recommended and it may be wise to 
carry sterile syringes/needles in case an injection is necessary.
Visiting friends and relations
This category of traveller is a new entity for Irish practitioners. Generally 
these patients will be visiting family and friends in their country of origin 
and in many cases they will be in rural regions where the risk of disease 
is high. If visiting highly endemic countries, they may also be resistant 
to the suggestion that malaria prophylaxis and vaccination cover will be 
required. 
It should be remembered that natural immunity against a number of 
diseases drops rapidly once an individual is not continuously exposed. 
Thus following a stay in Ireland of over 6 months it should be assumed 
that an individual will have lost all natural protection against malaria 
and diarrhoeal diseases. Generally malaria prophylaxis and vaccination 
cover for this group should be the same as that suggested for any 
other traveller. Statistics show that this group is much less likely to seek 
advice and is many times more likely to present with malaria post-travel. 
Evidence also shows they are more likely to suffer from other preventable 
diseases such as typhoid.
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Further Information
The World Health Organization produces a yearly guide  International 
Travel and Health, Vaccination Requirements and Health Advice for 
the International Traveller. Supplies are available through local medical 
bookstores or directly from WHO in Geneva (Tel +4122 791 2476 e-mail 
publications@who.ch). The WHO guidelines are available online and can 
be downloaded.
Useful websites
• Irish Travel Medicine Society  www.istm.ie 
•  Centre Disease Control,  www.cdc.gov
 Atlanta Georgia,  
 USA
• WHO     www.who.int 
 Geneva
 Switzerland
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Rabies
 NOTIFIABLE
Introduction
Rabies is an acute progressive viral infection, which, if left untreated 
leads to an almost invariably fatal encephalomyelitis, death resulting 
from respiratory paralysis. Members of the lyssavirus genus cause rabies. 
Rabies has traditionally been associated with the Genotype 1 form 
(classical or sylvatic rabies); another six genotypes are known to produce 
disease. 
In recent years, rabies has become recognised as an emerging zoonosis 
originating in bats; rabies-related bat lyssaviruses implicated in human 
disease include European Bat Lyssaviruses (EBLV) and Australian Bat 
Lyssavirus (ABLV). These variants present in humans in ways that are 
clinically indistinguishable from classical rabies.
Epidemiology
The WHO records between 40,000 and 70,000 cases of human rabies 
annually, most in less-developed countries. All continents except 
Antarctica report animal cases, although individual countries are reported 
to be rabies-free. Any warm-blooded animal may be infected but 
amongst domestic animals, dogs and cats are most commonly infected. 
Globally, over 90% of all human infections result from dog bites. The 
main source of human rabies in developing countries is from stray or feral 
dogs and cats and in developed countries the risk arises mainly from wild 
animal sources. In endemic areas, children are at particular risk.  
In the United States, amongst wild animals, skunks, racoons and bats 
R
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account for 85% of animal cases of classical rabies; the incidence has 
been rising there since the 1950s. In Latin America, vampire bats carry 
classical rabies. Elsewhere, monkey bites have been known to transmit 
the virus. The development of international travel, and the capacity for 
greater numbers of people to travel to more exotic and remote locations, 
puts many more people at risk now than was the case in the past.  
It should be emphasised that any bite, lick or scratch from any warm-
blooded animal in an endemic area must be considered as a high risk 
and further specialised advice should be sought as soon as possible. In 
Europe, foxes have been the primary host but there has been extensive 
infection among dogs and cats. Vaccination of foxes (and certain 
domestic species) has led to the dramatic decline in vulpine rabies in 
Western Europe in the last 20 years, although foxes remain a significant 
source of rabies in Eastern Europe and Turkey.
Certain countries that are declared rabies-free have rabies-related viruses 
(bat lyssaviruses) in their bat populations, e.g. Australia and the UK. In 
the UK, rabies-related viruses have only been detected in Daubenton’s 
bats but not in the commonest UK bat species, the Pipistrelle. 
The issue of EBLV has become a concern recently; an ongoing survey 
in the UK has demonstrated that four bats have been identified as 
having been infected with EBLV. In addition, in 2002 an unvaccinated 
bat handler in Dundee in Scotland died of EBLV, having been bitten by 
a bat. Only 3 other cases of EBLV infection (all fatal) have been reported 
in the past 30 years in Europe. In order to assess the risk of EBLV in 
Ireland, the Department of Agriculture and Food is undertaking a survey 
of Daubenton’s bats for EBLV. This survey was initiated in 2002 and is 
ongoing.
Transmission
Infection is usually transmitted by the bite (or scratch) of a rabid animal. 
The virus may also be passed when infected saliva comes in contact 
with broken or grazed skin, with mucous membranes and with the 
cornea. In addition, laboratory workers manipulating the virus or clinical 
specimens containing the virus are at potential risk of occupational 
contact or inoculation. Aerosol transmission is considered possible 
(possibly accounting for certain lab-acquired cases; this method may 
also be important in rabies-infected bat caverns). Human-to-human 
transmission is rare and the only documented cases involve corneal and 
solid organ transplantation.
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Effects of rabies
The incubation period of rabies is generally between 2 and 12 weeks but 
may range from 9 days to 2 years or even longer. The wide variation in 
incubation is thought to depend, in part, on the site of inoculation, the 
severity of the wound, and the amount of virus introduced. The factors 
that tend to reduce the incubation period include inoculation occurring 
closer to well-innervated parts of the body (including primary nerve 
bundles and the brain) and deeper and more extensive wounds (which 
will tend to allow an increased viral load into the wound). The duration 
tends to be shorter in children than adults.
Rabies has the highest case-fatality ratio of any infectious disease. 
Untreated, symptomatic disease is almost invariably fatal; the majority of 
the half dozen or so documented cases of survival from rabies had had 
some form of pre- or post-exposure treatment.  
Initial virus replication takes place in the tissues at the point of entry, 
persisting for between 48 and 72 hours. It progresses along the axonal 
sheaths in peripheral nerves towards the central nervous system. Viral 
spread then occurs to the peripheral nerves, largely out of reach of 
circulating antibody; there is no antibody response until the onset of 
clinical symptoms.  
The symptoms of rabies are highly variable. Early symptoms are non-
specific and include pain and paraesthesiae at the inoculation site. Low-
grade fever, malaise, anorexia, headache, nausea and vomiting and even 
sore throat are all commonly reported. Depending on the parts of the 
CNS affected, the patient may be excitable, irritable with more classical 
hypoglossal spasm associated with water (hydrophobia) or blowing in the 
face (aerophobia) or more obtunded with an ascending paralysis. Rising 
intracranial pressure leads to the decreased level of consciousness and 
the development of focal convulsions. Central and peripheral nervous 
impairment will lead to progressive respiratory distress. A wide variety of 
cardiac dysrhythmias can occur. 
Other causes of viral encephalitis, Guillain-Barré syndrome, tetanus, 
poliomyelitis and the toxic effects of drugs and poisons are among the 
differential diagnoses.
A. PRE-EXPOSURE PROPHYLAXIS
Rabies vaccines 
Rabies vaccine is used for pre-exposure protection of those at risk. One 
type of rabies vaccine, human diploid cell rabies vaccine (HDCV), is a 
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freeze-dried suspension of Wistar rabies virus strain PM/W1 38 1503-3M 
cultured on human diploid cells and inactivated by beta-propiolactone. 
The potency of the reconstituted vaccine is not less than 2.5 IU per 1 ml 
dose. The freeze-dried vaccine should be stored at 2-8ºC. It should be 
used immediately after reconstitution with the diluent supplied and any 
unused vaccine discarded after 1 hour. It may be given by intramuscular 
injection, usually in the deltoid region or anterolateral region of the thigh 
(never in the buttocks). The manufacturer’s recommendations should 
be consulted prior to administration. The vaccine contains traces of 
neomycin and human albumin.
An alternative vaccine that may be used is purified chick embryo cell 
vaccine. This contains inactivated rabies virus (Flury LEP). The potency 
of 1 ml is greater than or equal to 2.5 IU. The vaccine should be kept 
refrigerated. The recommended dose is 1 ml intramuscularly. The vaccine 
should be given in the deltoid or antero-lateral part of the thigh. Intra 
gluteal injection is not recommended. Patients with a history of severe 
hypersensitivity to eggs or egg products should not receive this vaccine 
for pre-exposure prophylaxis. This vaccine may also contain trace 
residues of polygeline, amphotericin B, chlorotetracycline or neomycin.  
Ideally a pre-exposure course should be completed using one type of 
cell culture vaccine throughout the primary course, but if one type of cell 
culture vaccine is unavailable then another may be substituted.
Indications
Pre-exposure prophylaxis should be offered to those in the following 
categories:
• Laboratory workers handling or potentially handling the virus
• Those, who by the nature of their work are likely to be in direct 
contact with imported animals:
o Staff at animal quarantine centres
o Staff at zoos
o Staff at research and acclimatisation centres where 
primates and other imported animals are housed
o ‘At-risk’ staff at sea and airports, e.g. Dept of Agriculture 
and Food Inspection Staff
o Authorised carrying agents for imported animals
• Selected National Parks and Wildlife Staff who may handle bats, 
based on risk assessment
• Dog wardens and other relevant staff in the Local Authorities
• Workers in enzootic areas abroad at special risk (e.g. veterinary staff, 
zoologists)
• People who regularly handle bats
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• Health-care workers who have, or are about to, come into close 
contact with a patient (or their clinical specimens) with probable or 
confirmed rabies
• Those living or travelling in endemic areas who may be exposed to 
the risk of being infected or are undertaking journeys in remote parts 
where medical treatment may not be immediately available
• Staying in highly endemic areas for more than 4 weeks (particularly in 
the case of children).
Dose and route of administration
For primary pre-exposure protection, three 1.0 ml doses of HDCV should 
be given, one each on days 0, 7, 21 OR 28 by intramuscular injection in 
the deltoid region or anterolateral region of the thigh. The same dose 
is used for adults and children. All travellers to areas of risk should be 
informed by their medical advisors to seek immediate medical aid if 
an animal bite or scratch is sustained. They should be given advice on 
wound toilet – see Standard Operating Procedure for Risk Assessment 
and Management of Non-Indigenous Rabies Exposure available at www.
hpsc.ie.  
Contraindications
Anaphylactic reaction to a preceding dose or any of the constituents.  
Precautions
Pre-exposure vaccine should only be given to pregnant women if the risk 
of exposure to rabies is high.
Adverse reactions
Local: HDCV may cause local reactions such as redness, swelling or pain 
at the site of injection within 24-48 hours of administration.
General:  Systemic reactions such as headaches, fever, muscle aches, 
vomiting and urticarial rashes have been reported. Anaphylactic 
shock has been reported from the USA and Guillain-Barré Syndrome 
from Norway, although no causal relationship between Guillain-Barré 
syndrome and rabies vaccine has been established. Reactions to the 
vaccine may become more severe with repeated doses.
The initial primary dose pre-exposure course produces protective 
antibody in virtually 100% of recipients and makes routine post-
immunisation serological testing unnecessary. 
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Rabies vaccine will induce long-lasting memory giving rise to an 
accelerated immune response when a booster dose of vaccine is 
administered.  
• Periodic booster injections are therefore not recommended 
for general travellers.  
• In the event of a significant animal exposure, persons who 
have previously been immunised should receive 2 further 
doses of rabies vaccine. 
B. CONTINUED OCCUPATIONAL EXPOSURE
The following groups are managed as outlined below:
For those people who have continuous occupational exposure and 
where exposure is likely to go unnoticed, e.g. rabies research laboratory 
workers and rabies vaccine production workers, serological testing 
should be carried out at 6-monthly intervals and boosters administered 
when the antibody level goes below a predetermined level – less than 0.5 
IU/ml.
For those who have frequent episodic exposure, e.g. rabies diagnostic 
workers, veterinary surgeons and staff, wildlife rangers who are 
conducting bat research, serology should be carried out every 2 years 
and boosters administered as necessary. 
For those who are at greater risk than the population but have only 
potential episodic exposure and can report exposures, e.g. dog bites. 
In the absence of an exposure, these staff do not require further 
booster doses/ serological testing once primary immunisation has been 
completed.
The current best advice is that boosters should not be administered more 
frequently than every 2-3 years to minimise the possibility of localised 
reactions to the vaccine. 
Serological testing is otherwise only advised for those who have had a 
severe reaction to a previous dose of vaccine to determine the necessity 
of a booster dose.
Further information on rabies vaccine and post-exposure treatment is 
available from the Irish Medicines Board, Cherry Orchard Hospital, Health 
Protection Surveillance Centre and from the Health Service Executive. 
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C. POST-EXPOSURE TREATMENT
Travellers who have been exposed to the possibility of rabies while 
abroad should seek immediate medical attention. On return to Ireland 
they should contact their General Practitioner or specialised vaccination 
centre or infectious diseases department to receive further advice. 
Similarly, anyone having received a bat bite in Ireland or the UK should 
seek immediate medical attention.  
Treatment, including wound toilet, must not be delayed, and should be 
started as soon as possible while enquiries are made about the local 
epidemiology of rabies in the country concerned (see above) and, where 
possible, the ownership and condition of the biting animal and the 
vaccination status of the animal should be determined.
The immediate steps to be taken are as follows:
1 Wound toilet: As soon as possible after the incident, the wound 
or site of exposure (e.g. mucous membrane) should be thoroughly 
cleaned with water under a running tap for at least 10 minutes. The 
wound should be initially washed thoroughly (with soap or detergent 
and water) and then rinsed completely. It is important not to mix 
disinfectant with soap during washing, as detergents can negate the 
effects of disinfectant. A suitable disinfectant (e.g. povidone-iodine 
solution or 70% alcohol) should be applied and the wound covered 
with a simple dressing. Tetanus prophylaxis and measures to control 
bacterial infection should also be administered as indicated. Suturing 
should be delayed where at all possible (taking into account cosmetic 
factors and the potential for bacterial infections).
2 Risk assessment:  Each case of possible exposure requires a careful 
and thorough risk assessment along the lines laid out below:
• Country of exposure (or the country of origin of the animal):  
Depending on the country of exposure, the patient will be 
considered to be at ‘No Risk’, ‘Low Risk’ or ‘High Risk’.  (Up-to-
date information on rabies by country can be found in World 
Health Organization, Rabies Bulletin Europe: www.who-rabies-
bulletin.org/ or Centre for Disease Control and Prevention, USA: 
www.cdc.gov/ncidod/dvrd/rabies/epidemiology/epidemiology.
htm). 
• The type, severity and site of the wound: Highest risk wounds 
involve piercing and breaking of the skin or involvement of 
mucous membranes.
• Circumstances of bite: Unprovoked bites are more worrying and 
carry a much higher risk than provoked bites.
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• The species, behaviour and appearance of the animal: Crazed 
or frantic animals pose a very significant risk. Bat rabies may 
be suspected if the bat is sick, grounded without injury or if an 
uninjured bat is found dead. Apparently healthy bats may have 
rabies. That said the risk of bat rabies in Ireland is likely to be 
very small. Table 20.1 shows the assessment of post exposure 
treatment requirements from significant bat bites sustained in 
Ireland and UK.
• Vaccination status of the animal (if known): Regularly 
vaccinated animals are much less likely to have rabies.
• Immune status of the individual involved: Fatal rabies 
encephalomyelitis is extremely unlikely in a fully immunised 
individual and is virtually certain to be prevented by an effective 
course of post-exposure treatment, if given sufficiently early.
Table 20.1 Assessment of post-exposure treatment requirements from 
significant bat bites (Ireland and UK)
Rabies risk Unimmunised
/incompletely immunised 
individual1
Fully immunised 
individual
Insignificant
Contact, but no lesions; 
indirect contact;
No contact.
None None
Minor significance
Licks of the skin;
Scratches or abrasions; 
Minor bites (covered 
areas of arms, trunk, and 
legs)
Five doses (each 1.0 ml) 
rabies vaccine on days 0,
3, 7, 14 and 30
Two doses (each 1.0 
ml) rabies vaccine on 
day 0 and day 3
Major significance
Licks of mucosa;
Major bites (multiple or 
on face, head, finger or 
neck)
Five doses (each 1.0 ml) 
rabies vaccine on days 0,
3, 7, 14 and 30, plus
HRIG on day 0 only
Two doses (each 1.0 
ml) rabies vaccine on 
day 0 and day 3
1Persons who have not received a full course of pre- or post-exposure tissue-culture rabies 
vaccine
3 Post-exposure immunisation and immunoglobulin. Specialist 
advice should be sought when post-exposure immunisation and 
immunoglobulin seems indicated. All immunosupressed subjects 
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should be given HRIG following exposure. Table 20.2 provides 
guidance on the administration of HDCV and HRIG depending on the 
level of risk as dictated by the country of exposure.
Table 20.2 Post-exposure treatment requirement by country of exposure 
(for overseas exposure or by exposure to overseas animal)
Rabies risk Unimmunised
/incompletely immunised 
individual1
Fully immunised 
individual
No risk None None
Low risk Five doses (each 1.0 ml) rabies 
vaccine on days 0,
3, 7, 14 and 30
Two doses (each 1.0 ml) 
rabies vaccine on day 0 
and day 3
High risk Five doses (each 1.0 ml) rabies 
vaccine on days 0,
3, 7, 14 and 30, plus
HRIG on day 0 only
Two doses (each 1.0 ml) 
rabies vaccine on day 0 
and day 3
1Persons who have not received a full course of pre- or post-exposure tissue-culture rabies 
vaccine
Rabies-specific immunoglobulin
Human rabies immunoglobulin (HRIG) is obtained from the plasma of 
immunised human donors. It is used after exposure to rabies to give 
rapid protection until rabies vaccine, which should be given at the same 
time, becomes effective. After thorough wound cleansing, HRIG should 
be infiltrated into the depth of the wound and around the wound as 
much as anatomically feasible. Any remainder should be injected at 
an intramuscular site distant from that of the vaccine inoculation, e.g. 
anterior thigh (not gluteal region). The dosage is calculated based on 
body weight (20 IU/kg body weight).  
Adverse reactions
HRIG may cause local reactions and low-grade fever but no serious 
adverse reactions have been reported.
Vaccine and HRIG suppliers
Post-exposure prophylaxis with the HDCV is currently available free of 
charge through the National Fever Hospital in Cherry Orchard. A supply 
of Human Rabies Immunoglobulin (HRIG) will also be maintained at this 
centre. Contact Dr. O’Dea, Tel. (01) 620 6000
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HRIG is also available from CDSC HPA, 61 Colindale Avenue, London 
NW9 5EQ, Tel. (00 44) 181 2006868. 
It is essential that post-exposure treatment is started as soon as possible 
after exposure. Moreover, treatment should be considered, irrespective 
of the period between exposure and presentation unless the individual 
is previously vaccinated and rabies antibodies can be detected. The 
decision to administer HRIG should be based on a risk assessment and 
specialist advice should be sought.
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Introduction
Human papillomavirus (HPV) is a double stranded DNA virus that 
infects squamous epithelia including the skin and mucous membranes 
of the upper respiratory and anogenital tracts. HPV targets basal cells 
in the stratified squamous epithelium and metaplastic cells at the 
squamocolumnar junction of the cervix and can, over time, lead to 
cervical cancer. Infection of the glandular epithelium of the endocervix 
can lead to adenocarcinoma. There are more than 100 different types of 
HPV. Some types are responsible for common warts (verrucae). Around 
40 types can infect the genital tract. Genital infection is associated with 
genital warts and various cancers such as cancer of the cervix, vulva, 
vagina, anus, and penis. HPV infection is also associated with various 
oropharyngeal cancers in men and women. The types that cause genital 
warts (low-risk types e.g. HPV 6 and 11) are not  those associated with 
cancer (high-risk types e.g. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66). 
Epidemiology
Genital HPV infection is the most common sexually transmitted 
disease worldwide. Transmission occurs during vaginal, oral or anal 
sexual intercourse or genital contact with an infected person. Non-
1
6a
 Human papillomavirus
 NOTIFIABLE
H
um
an
 
p
ap
ill
o
m
av
ir
us
sexual routes of HPV transmission include vertical transmission from 
mother to newborn baby. The clinical spectrum of disease ranges from 
asymptomatic infection, to benign warts, to invasive cancer. 
Genital warts are highly contagious; two-thirds of people who have 
sexual contact with an infected partner will develop warts. Risk factors 
associated with genital HPV infection include younger age at sexual 
initiation, number of sexual partners, and the sexual history of the partner 
(number of previous sexual partners). In the United States, it is estimated 
that approximately 1% of sexually active adults have visible genital warts 
and that at least 15% have subclinical infection, as determined by HPV 
DNA assay. The highest rates of HPV infection occur in the 18-28 year 
age group. An estimated 80% of sexually active women become infected 
with at least one type of HPV by age 50 years. 
Most genital HPV infections are asymptomatic and transient. However, 
although 70% of new genital HPV infections clear within one year, and 
91% within two years, high-risk types are more persistent than low-risk 
types. Persistent infection over a number of years may lead to grade 2 
or 3 cervical intraepithelial neoplasia (CIN) and cervical cancer. In one 
study approximately 27% of women with an initial HPV 16 or 18 infection 
progressed to CIN2/3 within 36 months. Persistent infection by high-risk 
types is detectable in more than 99% of cervical cancers. Types 16 and 
18 are responsible for over 70% of cervical cancers. Types 6 and 11 are 
associated with over 90% of genital warts.
The prevalence of cervical HPV infection varies worldwide. The 
International Agency for Research on Cancer (IARC) population-based 
studies found that overall HPV DNA prevalence varied 20-fold from 
1.4% (95% CI 0.5-2.2) in Spain to 25.6% (95% CI 22.4-28.8) in Nigeria. 
The most common type was 16, followed by type 42, 58, 31, 18, 56, 
81, 35, 33, and 45. HPV 16 was twice as common as any other high-risk 
type in all regions except sub-Saharan Africa where HPV 35 was equally 
common. Infection by multiple types was common. 
Ireland
Ano-genital warts are notifiable in Ireland. They accounted for 35% 
of all sexually transmitted infection notifications in 2006. The trend 
in notifications is similar in males and females (Figure 1). The largest 
proportion of cases occurs in young adults in the 20-29 year age group. 
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Figure 1 Ano-genital wart notifications in Ireland by gender, 1995-2006.
Source: HPSC
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A recent study of 996 cervical cytology samples in an Irish urban female, 
opportunistically screened population, found an overall HPV prevalence 
of 19.8%, varying from 31% in women under 25, to 23% in women aged 
25-35 and 11% in women over 35 years of age. HPV 16 at 20% and HPV 
18 at 12% were the commonest high-risk types detected. 
Effects of human papillomavirus
HPV is responsible for 5.2% of the cancer burden worldwide. Cervical 
cancer is the second most common cancer in women worldwide with an 
estimated 493,000 new cases in 2002 and 274,000 deaths. Most cases 
occur in countries without effective screening programmes.
In Ireland, on average 180 women develop cervical cancer each year with 
73 deaths from cervical cancer. The average age at diagnosis is 46 years 
and of death is 56 years. Recent trends in the incidence of squamous 
cell carcinoma, adenocarcinoma, CIN3 and adeno-squamous carcinoma 
in Ireland are shown in Figure 2. The incidence of CIN3 has increased 
significantly from 1999 to 2006 while the incidence of carcinoma has 
remained unchanged. 
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Figure 2 Rate of invasive and in situ cervical cancer per 100,000 
population in Ireland, 1994-2006.
Source: Irish Cancer Registry
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Individuals can reduce their risk of getting genital HPV infection by 
changes in sexual behaviour including abstinence from any sexual activity 
or lifelong monogamy. Reducing the number of sexual partners and the 
frequency of new partners will also reduce the risk. Condom use reduces 
but does not eliminate the risk of sexual transmission of HPV. 
Cervical screening can detect pre-cancerous lesions and cervical cancer 
at an early stage when treatment can be successful. In countries where 
there is an organised cervical cancer screening programme there has 
been a marked reduction in the incidence of invasive cervical cancer. 
Human papillomavirus vaccines
Currently available HPV vaccines contain virus-like particles (VLPs) 
produced from the major capsid protein L1 of each HPV type using 
recombinant DNA technology. These vaccines are not live vaccines, 
contain no viral DNA and are not infectious or oncogenic. An up-to-date 
list of vaccines that are licensed and marketed in Ireland is contained in 
Appendix 1, or can be accessed on the IMB website at www.imb.ie. Full 
prescribing information relating to the HPV vaccines is available at www.
medicines.ie.
Two HPV vaccines are licensed for use in Ireland, a bivalent vaccine 
containing VLPs for two HPV types (16 and 18) and a quadrivalent vaccine 
containing VLPs for four HPV types (6, 11, 16 and 18). The VLPs used in 
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the bivalent vaccine are adjuvanted by ASO4 containing 3-O-desacyl-4’- 
monophosphoryl lipid A (MPL) adsorbed on aluminium hydroxide. The 
VLPs used in the quadrivalent vaccine are adsorbed on amorphous 
aluminium hydroxyphosphate sulphate adjuvant.
Immunogenicity and vaccine efficacy
Both HPV vaccines are highly effective at preventing infection of 
susceptible women with the HPV types covered by the vaccines. 
Both vaccines were also found to be over 99% effective in preventing 
pre-cancerous lesions associated with HPV types 16 and 18 in young 
women. Efficacy of the quadrivalent vaccine against HPV 6, 11, 16 or 
18–related genital warts was 99%. Vaccination provides less benefit to 
females if they have already been infected with one or more of the HPV 
vaccine types. Protection lasts for at least five years and is likely to be 
long-lasting. The need for a booster has not yet been determined for 
either vaccine. Partial cross-protection has been demonstrated for both 
vaccines against infection with several non-vaccine oncogenic HPV types, 
including HPV 45 and 31 the commonest non-vaccine oncogenic types. 
The vaccines will reduce but not eliminate the risk of cervical cancer 
since at present they target only two oncogenic HPV types (16 and 18) 
which account for 70% of cervical cancer risk. Therefore, cervical cancer 
screening programmes will continue to be important even in vaccinated 
populations.
Dose and route of administration 
There is no evidence that the HPV bivalent and quadrivalent vaccines are 
interchangeable. If an individual has started a course of one vaccine then 
the vaccination series should be completed with that vaccine. 
The bivalent vaccine is licensed for females aged 10-25 years for the 
prevention of premalignant cervical lesions (CIN2/3) and cervical 
cancer causally related to HPV types 16 and 18. Three doses (0.5ml) are 
recommended to be given at 0, 1 and 6 months by IM injection in the 
deltoid region. If flexibility in the vaccination schedule is necessary, the 
second dose can be administered between one month and 2.5 months 
after the first dose and the third dose between 5 and 12 months after the 
first dose. 
The quadrivalent vaccine is licensed for females aged 9-26 years for the 
prevention of premalignant genital lesions (cervical, vulvar and vaginal), 
cervical cancer and external genital warts causally related to HPV types 
6, 11, 16 and 18. Three doses (0.5ml) are recommended to be given at 
0, 2 and 6 months by IM injection in the deltoid region. If an alternative 
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vaccination schedule is necessary,  the second dose should be given at 
least one month after the first dose and the third dose at least three 
months after the second dose with all three doses given within one year.
The vaccines are currently not licensed for women over 26 years of age 
or for males.
HPV vaccines should be stored at 2°C to 8°C in the original packaging
and protected from light. If the vaccine has been frozen, it should not be
used.
The same HPV vaccine should be used for the 3-dose vaccination 
series. However, if the previously administered HPV vaccine is unknown 
or unavailable, either vaccine can be used to complete the series 
to provide protection against HPV 16 and 18.  Less than 3 doses of 
quadrivalent vaccine might provide less protection against HPV 6 and 11 
than a complete 3-dose course of quadrivalent vaccine. Due to lack of 
information, no recommendation regarding the administration of vaccine 
to a person previously fully vaccinated with bivalent vaccine can be given. 
The reactogenicity of more than 3 doses HPV vaccine is unknown.
Changed September 2011
Indications
Recommendations for HPV immunisation:
•  All girls 12 years of age should receive the vaccine
•  It may be given to girls aged 9-12 years in accordance with the vaccine 
licence and at the discretion of the physician
•  Females aged 13-26 years who would not have had the opportunity to 
receive the vaccine at age 12 may also be given the vaccine.
Ideally, the vaccine should be administered before potential exposure to 
HPV through sexual contact. However, as it is not possible to determine 
which females have been exposed to any or all of the HPV types 
contained in the vaccines, women in the appropriate age group with a 
history of sexual contact may also benefit from the vaccine. Those who 
are sexually active should be advised that the vaccine has not been 
shown to have a therapeutic effect on existing HPV infection or cervical 
lesions. 
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Contraindications
Anaphylactic reaction to a preceding dose or any of the constituents.
Precautions
Acute severe febrile illness; defer until recovery. The response may be 
impaired in those who are immunocompromised. Syncope has been 
reported among adolescents who received HPV or other vaccines. 
Recipients should be seated during vaccine administration. Where 
possible, patients should remain in the vicinity of the place of vaccination 
for up to 15 minutes.
Pregnancy and breastfeeding
HPV vaccine is not at present recommended during pregnancy, although 
there is no known risk associated with using recombinant viral vaccines 
during pregnancy. If a woman becomes pregnant during the vaccination 
series, remaining doses should be delayed until after completion of the 
pregnancy. 
The quadrivalent vaccine can be given to breastfeeding mothers. The 
effect on breastfed infants of giving the bivalent vaccine to the mother 
has not been evaluated, although there is no known risk associated with 
using recombinant viral vaccines whilst breastfeeding. 
Use of HPV vaccine with other vaccines
The vaccines can be given at the same visit as other vaccines 
recommended for persons of this age group (e.g. Tdap, MMR, hepatitis 
B, IPV), preferably in a different limb. 
Adverse reactions
Local: Localised pain, swelling and erythema are very common at the 
injection site.
General: Fever (≥ 38°), myalgia, fatigue and headache have been 
commonly reported. Fainting can uncommonly occur.
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Appendix 1. List of licensed vaccines provided by the Irish Medicines 
Board which are authorised and marketed in Ireland.
Appendix 2. Table of countries with TB Notification Rates ≥40/100,000 
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Appendix 1  List of licensed vaccines provided by the Irish 
Medicines Board which are authorised and marketed in 
Ireland.
VACCINES AUTHORISED AND MARKETED IN IRELAND 
 Feb 2008
Marketing 
Authorisation Holder
Product Name and Authorisation 
number
Common Name
Baxter Healthcare 
Limited
Ticovac 0.5ml  (PA 935/1/3) Tick Borne Encephalitis 
Vaccine (inactivated )   
 Ticovac 0.25ml Junior (PA 935/1/2)   Tick Borne Encephalitis 
Vaccine (inactivated)  
 NeisVac-C  (PA 167/107/001)        Meningococcal Group 
C  Polysaccharide 
Conjugate Vaccine 
(adsorbed)
GlaxoSmithKline 
Ltd.
Engerix B Adult  (PA 1077/23/2) Recombinant Hepatitis 
B (adsorbed)   
 Engerix B Paediatric (PA1077/23/1) Recombinant Hepatitis 
B (adsorbed)   
 Fendrix (EU/1/04/299/1-3) Hepatitis B vaccine 
(adjuvanated, 
adsorbed)
 Fluarix (PA 1077/25/1) Influenza vaccine (split 
virion, inactivated), 
Seasonal  
 Havrix Junior Monodose  (PA 
1077/26/1)
Hepatitis A Vaccine 
(inactivated, adsorbed)
 Havrix Adult Monodose   (PA 
1077/26/2)
Hepatitis A Vaccine 
(inactivated, adsorbed)
 Hepatyrix (PA 1077/99/1) Hepatitis A Vaccine 
(inactivated, adsorbed) 
and Typhoid 
Polysaccharide vaccine
 Hiberix  (PA 1077/27/1) Haemophilus 
Influenzae type B 
conjugate Vaccine 
 IPV Infanrix  (PA 1077/108/1) Diptheria, Tetanus, 
Acellular Pertussis 
and Poliomyelitis 
(inactivated) Vaccine 
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 Infanrix IPV Hib  (PA 1077/29/2) Diptheria, Tetanus,  
Acellular Pertussis,   
Poliomyelitis 
(inactivated)  and 
Haemophilus 
Influenzae type B 
conjugated Vaccine 
(adsorbed) 
 Priorix   (PA 1077/36/1) Measles / Mumps/
Rubella live Vaccine
 Poliomyelitis Vaccine (Oral) 
Ph. Eur., Live. (Monodose) (PA 
1077/35/1)
Poliomyelitis Vaccine 
(Oral, live)
 Twinrix Paediatric  
(EU/1/97/029/009)
Hepatitis A and 
Hepatitis B Surface 
Antigen vaccine
 Twinrix Adult (EU 1/96/20/7) Hepatitis A and 
Hepatitis B Surface 
Antigen Vaccine
 Typherix (PA 1077/38/1) Typhoid polysaccharide 
vaccine
 Rotarix (EU/1/05/330/001) Oral Rotavirus Vaccine 
(Live)
 Cervarix (EU/1/07/419/004) Human Papillomavirus 
vaccine [Types 16, 
18] (Recombinant, 
adjuvanted, adsorbed). 
Novartis Vaccines 
and Diatgnostics 
GmbH & Co.KG
Begrivac- Influenza Vaccine  (PA 
877/1/1)
Influenza Vaccine (split 
virion, inactivated) 
(seasonal)
Rabipur  (PA 877/3/1) Rabies Virus Inactivated
Novartis Vaccines 
and Diagnostics S.r.l.
Menjugate Kit  (PA 919/4/2) Meningococcal group 
C oligosaccharide 
conjugate vaccine
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VACCINES AUTHORISED AND MARKETED IN IRELAND 
 Feb 2008
Marketing 
Authorisation Holder
Product Name and Authorisation 
number
Common Name
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Sanofi Pasteur MSD 
Ltd     
Gardasil (EU/1/06/357/015) Human Papillomavirus 
Vaccine [Type 
6,11,16,18]
 
HBVAXPRO 5 (EU/1/01/183/024) Hepatitis B  
(recombinant) Vaccine
 HBVAXPRO 10 (EU/1/01/183/028) Hepatitis B  
(recombinant) Vaccine
 HBVAXPRO 40 (EU/1/01/183/015) Hepatitis B  
(recombinant) Vaccine
 Rabies Vaccine  (PA 544/14/1)  Rabies Vaccine 
(inactivated)
 Pneumovax II Vial  (PA 544/21/3) Pneumococcal 
polysaccharide vaccine
 Avaxim (PA 544/29/1) Hepatitis A 
(inactivated, adsorbed) 
 Stamaril  (PA 544/31/1) Yellow  Fever  Vaccine 
(live)   
 Pentavac   (PA 544/32/1) Diphtheria, tetanus, 
acellular, pertussis,  
inactivated 
poliomyelitis and 
haemophilus type b 
conjugate vaccine 
(adsorbed)
 Tetravac  ( PA 544/33/1) Diphtheria, tetanus, 
acellular, pertussis,  
and inactivated 
poliomyelitis vaccine
 Typhim Vi (PA 544/7/1) Typhoid polysaccharide 
Vaccine 
 Inactivated Influenza Vaccine (split 
virion)BP (PA 544/34/1)
Influenza Vaccine (split 
virion, inactivated) 
(seasonal)
 Revaxis (PA 544/35/1) Diphtheria,  tetanus 
and poliomyelitis(inacti
vated) vaccine
 Varivax  (PA 544/38/1) Varicella Vaccine(live)
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VACCINES AUTHORISED AND MARKETED IN IRELAND 
 Feb 2008
Marketing 
Authorisation Holder
Product Name and Authorisation 
number
Common Name
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VACCINES AUTHORISED AND MARKETED IN IRELAND 
 Feb 2008
Marketing 
Authorisation Holder
Product Name and Authorisation 
number
Common Name
 Viatim  (PA 544/37/1) Typhoid polysaccharide 
and Hepatitis A 
(inactivated) Vaccine
SBL Vaccine Ab Dukoral (EU/1/03/263/001-003) Oral Cholera vaccine
Solvay Healthcare Influvac Sub-unit PA 108/17/4 Influvac Sub-unit, 
suspension for injection 
(Influenza vaccine, 
surface antigen, 
inactivated) 
Statens Serum 
Institute 
BCG Vaccine  (PA 798/2/1) BCG Vaccine
 diTeBooster  (PA 798/3/1) Diphtheria and Tetanus 
vaccine (adsorbed)
Wyeth Lederle 
Vaccines SA   
 
JOHN WYETH  & 
BROTHER 
Prevenar pre-filled syringe 0.5ml 
singles pack with separate needle 
(EU/1/00/167/006)
Pneumoccal 
polysaccharide 
Conjugate Vaccine 
(adsorbed)
Meningitec suspension for injection 
in prefilled syringe PA 22/78/2     
Meningococcal Group 
C  polysaccharide 
Conjugate Vaccine 
(adsorbed) 
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Appendix 2 Table of countries with TB Notification Rates ≥40/100,000 
Population, 2005 (WHO figures).
Western Pacific Region
Country Rate/100,000 population
Brunei 44
Cambodia 253
China 68
China, Hong Kong SAR 81
China, Macao SAR 77
Kiribati 334
Lao PDR 64
Malaysia 61
Marshall Islands 179
Micronesia 89
Mongolia 174
Nauru 81
Northern Mariana Islands 71
Palau 50
Papua New Guinea 231
Philippines 165
Rep. of Korea 80
Solomom Islands 83
Tuvalu 115
Viet Nam 113
Wallis & Futuna 45
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South-East Asia 
Country Rate/100,000 population
Bangladesh 87
Bhutan 47
DPR Korea 190
India 105
Indonesia 114
Myanmar 212
Nepal 123
Sri Lanka 45
Thailand 90
Timor-Leste 398
Europe 
Country Rate/100,000 population
Armenia 73
Azerbaijan 72
Belarus 54
Bosnia & Herzegovina 54
Bulgaria 42
Georgia 101
Kazakhstan 174
Kyrgyzstan 120
Latvia 61
Lithuania 62
Rep. of Moldova 122
Romania 120
Russian Federation 89
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Tajikstan 84
Turkmenistan 66
Ukraine 85
Uzbekistan 81
Eastern Mediterranean
Country Rate/100,000 population
Afganistan 73
Djibouti 392
Morocco 83
Pakistan 87
Qatar 40
Somalia 157
Sudan 76
Yemen 43
The Americas
Country Rate/100,000 population
Bolivia 106
Brazil 43
Dominican Rep. 56
Guyana 85
Haiti 168
Honduras 46
Panama 51
Peru 119
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Africa
Country Rate/100,000 population
Algeria 65
Angola 233
Botswana 570
Burundi 87
Cameroon 132
Cape Verde 58
Central African Rep. 79
Chad 65
Congo 246
Cote d’Ivore 108
DR Congo 169
Eritrea 81
Ethiopia 160
Gabon 182
Gambia 134
Ghana 55
Guinea 73
Guinea-Bissau 112
Kenya 300
Lesotho 602
Liberia 105
Madagascar 102
Malawi 198
Mauritania 70
Mozambique 168
Namibia 735
Niger 56
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Nigeria 48
Rwanda 80
Sao Tome & Principe 87
Senegal 84
Sierra Leone 122
South Africa 570
Swaziland 781
Togo 41
Uganda 142
UR Tanzania 159
Zambia 425
Zimbabwe 388
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Routine childhood immunisation schedule
Age Immunisations Comment
Birth BCG 1 injection
2 months DTaP/Hib/IPV/Hep B + PCV 2 injections
4 months DTaP/Hib/IPV/Hep B + MenC 2 injections
6 months DTaP/Hib/IPV/Hep B + PCV + 
MenC
3 injections
12 months MMR + PCV 2 injections
13 months MenC + Hib 2 injections1
4 to 5 years DTaP/IPV + MMR 2 injections
11 to 14 years Tdap + BCG2 1 injection
1. If a combined MenC/Hib vaccine is available only one injection is required.
2   Only for those who are known to be tuberculin negative and have no previous BCG   
(see Chapter 16).
BCG  Bacille Calmette Guerin vaccine
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
Hib  Haemophilius influenzae b vaccine
IPV  Inactivated Polio Virus vaccine
Hep B  Hepatitis B vaccine
PCV  Pneumococcal Conjugate Vaccine
MenC  Meningococcal C vaccine
MMR  Measles, Mumps and Rubella vaccine
Tdap   Tetanus, low-dose diphtheria and low-dose acellular pertussis vaccine
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Introduction
Rotaviruses (RV) belong to the Reoviridae family of viruses. They are 
composed of 11 segments of double-stranded RNA enclosed in a 
three-layer protein capsid. The two outer capsid proteins are used to 
classify rotavirus strains into P (protease-sensitive) and G (glycoprotein) 
serotypes. There are at least seven antigenic groups, A-G.  Five serotypes 
of Group A (G1P, G2P, G3P, G4P and G9P) cause over 90% of clinical 
rotavirus disease in temperate climates.  A change in the major serotype 
typically occurs every two to three years.
Worldwide, rotaviruses are the commonest cause of community-acquired 
gastroenteritis in children, with a worldwide mortality of approximately 
500,000/year. Most deaths occur in developing countries; death from 
rotavirus infection is very rare in the developed world where there is 
ready access to oral and parenteral rehydration.  
Epidemiology
The virus is very infectious; up to ten million viral particles can be 
excreted per ml. of faeces, and only ten particles are required to cause 
infection. Spread is predominantly by person-to-person contact or from 
contaminated environmental surfaces, but infection can be transmitted 
by the respiratory route, and also through contaminated water and food. 
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Animal-to-human transmission appears to be rare. Viruses may survive 
on hands for more than four hours, on environmental surfaces for days 
to weeks, and in recreational or drinking water for weeks. The incubation 
period is from 1-4 days.  
The peak incidence of infection occurs between 4 and 36 months of 
age and in winter and spring. Virtually all children throughout the world 
are infected with RV by the time they are 5 years old, regardless of 
socioeconomic or environmental conditions. Infection is rare in those 
under 2 months of age, perhaps because of passively transferred 
maternal antibody; if infection does occur it is often asymptomatic or 
mild. Symptoms range from mild diarrhoea to severe gastroenteritis 
with dehydration, electrolyte imbalance and shock. Children may have 
multiple RV infections during the first years of life.Adults, especially 
the elderly, can develop rotavirus disease. Hospitalisation for rotavirus 
gastroenteritis is associated with low birth weight (a likely proxy for 
prematurity), daycare attendance, another child aged <2yrs in the 
household and maternal smoking. Breast feeding protects against 
hospitalisation.
Those who are immunocompromised because of congenital 
immunodeficiency or bone marrow or solid organ transplantation may 
experience severe or prolonged gastroenteritis. Severity of rotavirus 
disease in children infected with human immunodeficiency virus (HIV) may 
be similar to that occurring in those without HIV infection. 
A single natural infection gives >85% protection against subsequent 
severe rotavirus gastroenteritis, >75% protection against subsequent 
rotavirus gastroenteritis, and >35% protection against subsequent 
rotavirus infection. 
Different countries in Europe report widely different rates of disease and 
of admission to hospital because of RV disease. Hospitalisation rates of 
children <5 yrs of age vary from 3.8per 1,000/year in Denmark to 12.8 
in Ireland. The proportion hospitalised as a ratio of those medically 
assessed varied from 1 in 17 in Ireland to 1 in 80 in Spain
In Ireland, rotavirus became a notifiable disease in 2004 (under the 
category of Acute Infectious Gastroenteritis). Since then there has been 
a consistent and sustained rise in notifications. However, since almost all 
children are infected by their fifth birthday, there is very significant under- 
notification.
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In 2009 there were 1748 cases of rotavirus reported to the Health 
Protection Surveillance Centre. Most were aged <24 months. There were 
12 outbreaks of rotavirus notified during 2009 with 74 cases of associated 
illness. Of the 12 outbreaks, four occurred in crèches, four were family 
outbreaks in private homes, three were in hospitals and one was in a 
community hospital/long-stay unit. Since 2004, 8 outbreaks have been 
reported in hospitals.
Figure 1. Number of cases of Acute Infectious gastroenteritis (AIG) and 
rotavirus by year, 2004 to 2009 (Data courtesy of HPSC)
Figure 2. Number of Rotavirus Cases by age group 2009.
Effects of Rotavirus
The virus damages the mature enterocytes of the small intestinal villi, 
where it produces an enterotoxin which causes epithelial necrosis, 
atrophy and desquamation. This results in reduced absorption of 
carbohydrates, salt and water, and in secretary and osmotic diarrhoea. 
Excretion of virus in faeces precedes the onset of illness, and may 
continue for weeks after resolution of symptoms.
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There is a wide spectrum of symptoms, ranging from none through 
mild diarrhoea to severe gastroenteritis with dehydration, electrolyte 
imbalance and shock. Rarely, encephalitis and meningitis may occur. 
Severe illness is more likely in those aged 4-24 months.  Up to one third 
of children have a temperature of >39ºC. Vomiting usually lasts<48 hrs, 
but may persist for 8-10 days. Other gastrointestinal symptoms generally 
resolve in 3-7 days. Occasionally diarrhoea may last for up to 3 weeks.
Asymptomatic infections are common among neonates, older children 
and adults
Diagnosis
The most widely used diagnostic laboratory method is antigen detection 
in the stool by an enzyme immunoassay (EIA) directed at an antigen 
common to all group A rotaviruses, the principal cause of human disease. 
Rotavirus-specific IgG, IgA and neutralising antibodies can be measured 
in serum; at present this is only done in research settings.
Rotavirus Vaccines
Two vaccines are currently available.  
  Rotarix (RV1) is a live monovalent attenuated human type G1P1A 
virus vaccine. It is supplied as a powder and solvent with an oral 
applicator, providing an oral dose of 1ml. Successive doses give cross 
protection against different strains.  
  Rotateq (RV5) is a live pentavalent reassortant human-bovine virus 
vaccine, containing five reassortant strains developed from human 
and bovine strains, which stimulates production of type-specific 
antibodies against the commonest types of rotavirus. It is supplied as 
a liquid, given orally in a dose of 2mls.
Both vaccines should be stored between 2-8°C.
Both vaccines give at least 95% (C.I. 88-100%) protection against severe 
RV disease and over 70% protection against any RV disease.   
In 1998, a tetravalent rotavirus vaccine, RRV-TV (Rotashield) was
recommended for routine vaccination of U.S. infants at ages 2, 4, and 6
months. Evidence of significant association with intussusception emerged
in its first year of use and it was withdrawn
Post-marketing surveillance of both currently available rotavirus vaccines 
has detected a small increased risk of intussusception (about 1-2/100 000 
infants vaccinated) in some settings shortly after the first dose. This risk is 
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5-10 times lower than that observed with the previously licensed vaccine, 
and the benefits of rotavirus vaccination against severe diarrhoea and 
death from rotavirus infection far exceed the risk of intussusception. As a 
precaution, healthcare professionals should follow-up on any symptoms 
indicative of intussusception (severe abdominal pain, persistent vomiting, 
bloody stools, abdominal bloating and/or high fever). Parents/guardians 
should be advised promptly to report such symptoms.
Dose and route of administration
1.  Rotarix (RV1, live attenuated human vaccine).Two oral doses of 1ml 
doses are given at 2 and 4 months of age. No restrictions are placed 
on the infant’s feeding in relation to rotavirus vaccine. If an infant 
regurgitates or vomits during or after administration of vaccine that 
dose should not be repeated. The infant should receive any remaining 
dose 2 months later.
2.  Rotateq (RV5, live human-bovine reassortant vaccine). Three oral 
doses of 2mls are given at 2, 4 and 6 months of age. No restrictions 
are placed on the infant’s feeding in relation to rotavirus vaccine. If an 
infant regurgitates or vomits during or after administration of vaccine 
do not repeat that dose. The infant should receive remaining doses 
after the recommended interval.
Age and interval restrictions for administration 
The minimum age for dose 1 of any rotavirus vaccine is 6 weeks; the 
maximum age for dose 1 is 14 weeks and 6 days. There is insufficient 
data on the safety of a first dose of rotavirus vaccine in older infants. The 
minimum interval between doses is 4 weeks; no maximum interval is set, 
however no dose should be given after 32 weeks of age. 
No dose should be administered after 32 weeks of age (even if the 
course is incomplete) because of lack of safety and efficacy data in 
those older than 32 weeks.
If the first dose is given inadvertently at age 15 weeks or older, the 
rest of the rotavirus vaccination series should be completed before 32 
weeks of age, because the timing of the first dose  should not affect the 
safety or efficacy of any subsequent doses. Infants who get rotavirus 
gastroenteritis before receiving the full series of rotavirus vaccination 
should still be immunised, because the initial rotavirus infection might 
provide only partial protection against subsequent rotavirus disease.
Rotavirus vaccine can be given to infants with minor acute illness 
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including mild gastroenteritis or mild upper-respiratory tract infection, 
with or without a fever.
Indications
Rotavirus vaccines are indicated for the prevention of rotavirus 
gastroenteritis when given to infants aged between 6 and 32 weeks.
Rotavirus vaccination is not included as part of the routine childhood 
immunisation schedule. However parents may choose to have their 
healthy children immunised.
Vaccination of special groups:
a. Preterm Infants (<37 Weeks Gestation)
Preterm infants are at increased risk for hospitalisation from rotavirus 
gastroenteritis during the first one to two years of life. In clinical trials, 
rotavirus vaccine was generally well tolerated in preterm infants, although 
relatively small numbers have been evaluated. Thus, the benefits of 
rotavirus vaccination of preterm infants outweigh the risks of adverse 
events.
b. Immunocompromised persons
No safety or efficacy data are available for the administration of 
rotavirus vaccine to infants who are immunocompromised or potentially 
immunocompromised. Vaccine strains of rotavirus are considerably 
attenuated. Those with severe combined immunodeficiency should not 
be given either vaccine. If in doubt, consult an immunologist or Infectious 
Disease (ID) specialist.
c.Infants with a history of intussusception
Compared with infants who have never had intussusception, infants with 
a history of intussusception are at higher risk for a repeat episode of 
intussusception. No data are available on the administration of rotavirus 
vaccine to such infants. Neither vaccine should be given to an infant who 
has had an intussusception.
Simultaneous Administration with other vaccines
Rotavirus vaccine can be administered together with the following
vaccines: DTaP, Hib, IPV, Hepatitis B, Men C, PCV and BCG. It may be
administered at any time before, along with, or after administration of
any blood product, including antibody-containing products.
Interchangeability of Rotavirus Vaccines
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Whenever possible the same rotavirus vaccine should be used to 
complete the series. However, if the brand is not available or is 
unknown, continue or complete the series with the vaccine available, 
unless there is a contraindication. If any dose in the series was RV5 or the 
vaccine product is unknown for any dose in the series, a total of 3 doses 
of rotavirus vaccine should be administered.
Do not administer on or after 32 weeks, even if fewer than three 
doses have been administered. 
Contraindications
1.  Anaphylactic reaction to any of the vaccine constituents.
2.  Uncorrected congenital GIT malformation (e.g., Meckel’s diverticulum) 
that would predispose an infant to intussusception.
3.  Previous intussusception.
4.  Severe combined immunodeficiency(SCID).
Precautions
1.  Acute severe febrile illness – defer until recovery. Vaccination should 
not be delayed because of the presence of a mild acute illness with or 
without fever.
2.  Moderate or severe vomiting or diarrhoea – defer until recovery. 
However, infants with mild acute gastroenteritis can be vaccinated, 
particularly if the delay in vaccination might make the infant ineligible 
to receive the vaccine (e.g., aged >15 weeks before the vaccine series 
is started), even though the immunogenicity and efficacy of the vaccine 
could be reduced. 
3. Immunodeficiency (other than SCID). No safety or efficacy data are 
available for administration of rotavirus vaccine to infants who are 
immunocompromised or potentially immunocompromised. Vaccine 
strains of rotavirus are considerably attenuated. Consult with an 
immunologist or ID specialist.
4.  Infants with Spina Bifida or Bladder Extrophy. These infants are at 
high risk for acquiring latex allergy. Latex is contained in the Rotarix 
oral applicator whereas the RV5 dosing tube is latex-free. Such infants 
should be given Rotateq (RV5) instead of Rotarix (RV1) to minimize 
latex exposure in these children.
5.  There is a possibility that both vaccine viruses can be transmitted to 
non-vaccinated contacts. The potential for transmission of vaccine 
virus following vaccination should be weighed against the possibility of 
acquiring and transmitting natural rotavirus.
6.  Caution is advised when considering whether to administer RotaTeq to 
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individuals with close contacts who are immunocompromised such as:
 • Individuals with malignancies;
 • Individuals with primary immunodeficiency; or
 • Individuals receiving immunosuppressive therapy.
It is prudent for all members of the household to employ measures such
as good handwashing after changing a nappy or otherwise coming in to
contact with the faeces of the vaccinated child.
Adverse Reactions
Generally rotavirus vaccines are very well tolerated. Irritability, loss of 
appetite, diarrhoea, vomiting, rash and pyrexia may occur, but are no 
more common than when compared with placebo.
Post-marketing surveillance indicates the possibility of an increased risk 
of intussusception shortly after the first dose of both currently licensed 
rotavirus vaccines in some populations. If confirmed, the level of risk 
observed in these post-marketing studies is substantially lower than the 
risk of one case of intussusception in 5,000-10,000 vaccinees identified 
after Rotashield vaccination.
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